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Abstract 
Follicular lymphoma (FL) is the second most common form of non-Hodgkin 
lymphoma and at least a third of cases undergo aggressive transformation (t-FL), 
most frequently to diffuse large B-cell lymphoma. This study examined the role of 
germline and acquired genetic changes in FL and t-FL to determine prognostically 
significant events and chart the evolution of transformation. 
Assessment of germline polymorphic variation in over 200 FL cases demonstrated 
two SNPs in the HLA region of chromosome 6p (rs10484561 and rs6457327) 
associate with FL risk in the UK and identified that rs6457327 predicts both time to 
and risk of transformation independently of clinical variables, including the FLIPI. 
Mutation and expression studies of the single known gene in linkage disequilibrium 
with rs6457327 (C6orf15) suggest an alternative mechanism is responsible for this 
transformation association. 
DNA copy number and mutational analysis of FL and t-FL samples then revealed a 
high prevalence of TNFSRF14 and EZH2 mutations at transformation accompanied 
by frequent loss and gain of their genomic locations on chromosome 1p and 7q, 
respectively. In a search for co-operating genetic events, genome-wide profiling 
identified recurrent losses and gains ranging from 4 kb to 60 Mb with gain 2p16.1-
p15 (including REL) predictive of worse survival in FL that transforms. 
In >50% of transformed cases, FL DNA contained either copy number aberrations or 
mutations that were absent from subsequent t-FL. This suggested FL and t-FL might 
develop non-sequentially from a common cell of origin. To further explore the 
evolution of FL and t-FL, IGH-V somatic-hypermutation (SHM) analysis was 
performed in sequential FL / t-FL samples. t-FL clones were detected in FL samples 
taken many months prior to clinical presentation of transformation and, furthermore, 
the predicted SHM patterns of putative precursors were detected in both FL and t-FL 
samples indicating that a (long-lived) common progenitor cell could indeed give rise 
to both FL and subsequent t-FL by divergent clonal evolution. 
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Chapter 1    Introduction 
The hallmark of cancer is uncontrolled clonal proliferation of cells which occurs 
following genetic changes that disrupt normal cell cycle regulation. A single genetic 
“hit” is typically insufficient to cause cancer and this led to the two-hit hypothesis 
established by Knudson four decades ago (Knudson 1971). Subsequently, a sequence 
of cancer development characterised by the accumulation of multiple genetic events, 
including chromosomal changes and gene mutations, was proposed (Fearon and 
Vogelstein 1990). These models reflect the observation that “Cancer is, in essence, a 
genetic disease” (Vogelstein and Kinzler 2004), a statement which highlights the 
fundamental importance of the genetic events that contribute to tumour development 
and progression.  
Around one in three people develop cancer and one in four people die from it in the 
UK (Source: Office for National Statistics, 16 April 2010 available at website 
http://www.statistics.gov.uk/CCI/nugget.asp?ID=915; licensed under the Open 
Government Licence v.1.0). Cancer is therefore the most common form of genetic 
disease and insights into the underlying genetic mechanisms are an important aspect 
of understanding its behaviour. These have been made possible through the steady 
improvement in resolution of investigative techniques that have developed from the 
early identification of chromosomes by staining with giemsa giving characteristic 
signature patterns to each chromosome (so called “G banding”). This enabled the 
formation of a karyotype which could be examined for abnormalities. Subsequently, 
refinements to karyotyping have included the use of probes for specific regions (as in 
fluorescent in-situ hybridisation; FISH) to detect chromosomal rearrangements or, 
more recently, to compare target and control DNA by hybridisation to metaphase 
chromosomes (comparative genomic hybridisation; CGH) enabling more focal 
regions of copy number change to be determined. 
The advent of DNA micro-arrays containing many thousands (and now millions) of 
probes has subsequently enabled a reduction in the resolution of chromosomal study 
to less than 10 kb in size. Furthermore, the current era of genome-wide sequencing 
that has developed following the completion of the human genome project (Lander et 
al. 2001) permits pan-genomic inspection at the single base pair level. This is a 
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significant advance that should reveal much information about the genetics of cancer 
over the coming years. 
Haematological malignancies have been at the forefront of genetic studies in cancer, 
with leukaemias particularly suitable due to the presence of cells in the peripheral 
blood which are, therefore, easily accessed and can be applied to several 
investigative platforms. Indeed, both cytogenetic and molecular features of various 
leukaemias are now core aspects guiding their treatment.  
However, in the most common form of haematological malignancy, non-Hodgkin 
lymphoma (NHL), although chromosomal translocations are well characterised and 
aid diagnosis they do not typically influence subsequent management and 
considerably less is known as to the relevance of other genetic changes in disease. As 
many forms of NHL remain incurable and it has shown an increased incidence in 
recent decades, there is a pressing need for accurate prognostic and predictive models 
which can guide the development and application of therapy. Indeed, several clinical 
tools can group cases in to prognostic groups but these still do not influence routine 
patient management.   
Consequently, as has occurred in the leukaemias, characterising the critical genetic 
events in NHL can be expected to better risk stratify cases both for upfront 
management as well as treatment later in the course of disease. This is particularly 
important for a prevalent form of NHL, follicular lymphoma (FL), which shows a 
spectrum in both its natural history and clinical course, despite similar upfront 
clinical and histological parameters in the majority of cases.  
Studies in FL to date show that it is accompanied by frequent and diverse genetic 
changes but the specific events driving its progression and outcome are largely 
uncharacterised. The degree of genetic instability in FL may explain the range of 
clinical outcomes observed in this disease, however, the challenge is identifying the 
critical changes which could provide suitable therapeutic targets and help improve its 
outcome. In this regard, the examination of both heritable and acquired genetic 
variants in this thesis provides novel insights in to FL and its progression that help 
explain previous reports and provide an important model of FL evolution which 
should guide future studies.  
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1.1 Follicular lymphoma 
FL was first described over eighty years ago (Brill et al. 1925; Symmers 1927) and 
has most recently been defined as a “neoplasm composed of follicle centre ... B-cells 
... which usually has at least a partially follicular pattern” in the World Health 
Organisation (WHO) Classification of Tumours (Swerdlow 2008).  
1.1.1 Histopathology 
This current classification follows early efforts using histology alone (Gall and 
Mallory 1942) that distinguished FL from reactive hyperplasia and termed it a 
nodular lymphoma (Hicks et al. 1956). This was then refined by the incorporation of 
immunological cell type (Lukes and Collins 1974) and recognition that FL arose 
from the germinal centre (Lennert et al. 1975), a structure found in the follicles of 
secondary lymphoid organs as discussed by MacLennan (MacLennan 1994). 
Subsequent attempts to improve the clinical utility of NHL classification commenced 
with the working formulation ("The Non-Hodgkin's Lymphoma Pathologic 
Classification Project"  1982) before a large international collaboration proposed the 
Revised European-American classification of lymphoid neoplasms (REAL) (Harris 
et al. 1994). This and the earlier WHO classification (Jaffe et al. 2001) incorporated 
histological, immunological, genetic and clinical features of disease, an approach 
which forms the current diagnostic standard (Swerdlow 2008).   
As FL is a malignant expansion of the germinal centre B cells from lymphoid 
follicles, it includes both cell types normally found in these structures, namely 
centrocytes and centroblasts. Centrocytes are small cells often with cleaved nuclei 
and scant cytoplasm and form the bulk of the tumour. Centroblasts are larger and 
show prominent nucleoli. The varying proportions of centroblasts in FL tumour 
specimens, as initially proposed by Berard and colleagues (Glick et al. 1981; Mann 
and Berard 1983), has led to three different grades of tumour being described (Jaffe 
et al. 2001), summarised as follows:  
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Grade* Criteria 
1 ≤ 5 centroblasts per hpf 
2 6 - 15 centroblasts per hpf 
3 > 15 centroblasts per hpf 
3A Centrocytes present 
3B Solid sheets of centroblasts 
 
*Distinction between 1 and 2 no longer required as there are no important clinical differences between them. 
hpf indicates high power field of 0.159mm
2
 (which is the view obtained using a 40 objective lens) 
 
 
Tumour grading is important as grade 3 may progress more readily than grade 1 or 2 
(Bartlett et al. 1994). Furthermore, within grade 3 solid sheets of centroblasts 
distinguish a 3B subtype (Jaffe et al. 2001), which has molecular features analogous 
to the most common aggressive form of B-NHL, diffuse large B cell lymphoma 
(DLBCL) (Ott et al. 2002; Bosga-Bouwer et al. 2003; Karube et al. 2007) and 
frequently contains areas suggestive of DLBCL (Katzenberger et al. 2004). 
Consequently, FL grade 3B has been managed in a similar manner to de novo 
DLBCL. Indeed, the presence of any regions of DLBCL in association with FL now 
requires a formal diagnosis of DLBCL (with accompanying FL). Nevertheless, the 
majority of FL cases (at least 80%) present as grade 1 or 2 disease. Furthermore, 
grade 3B constitutes only around one quarter of the remaining cases (Hans et al. 
2003) and it seems probable that this proportion will reduce as cases are formally 
diagnosed as DLBCL in light of the recent WHO classification update. 
However, as identified by Relander and colleagues in a recent review (Relander et al. 
2010), there have been persistent challenges in accurately reproducing FL tumour 
grading between centres. Indeed, despite observed histopathological and molecular 
differences between grades 3A and 3B, one recent report suggests that outcomes of 
these two subtypes are comparable (Shustik et al. 2010). Consequently, the role of 
grade in determining FL prognosis and management remains unclear. 
Immuno-histochemical staining is an important aspect of diagnosis, particularly in 
the minority of cases which do not have a clear follicular architectural pattern on 
morphological examination, with FL cells expressing the B cell markers CD20, 
CD22, CD79a and immunoglobulin. The majority of cases express CD10 while CD5 
and cyclinD1 are not expressed which can, at least in part, help distinguish them 
from other B-NHL while the expression BCL2 (Lai et al. 1998) and BCL6 (Cattoretti 
et al. 1995) are characteristic, but not specific, findings in FL. 
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1.1.2 Presentation demographics 
FL is the most common indolent NHL and the second most common form of all 
NHL after DLBCL, as illustrated in Figure 1.1 ("The Non-Hodgkin's Lymphoma 
Classification Project"  1997; Swerdlow 2008). The median survival of around one 
decade reflects the relapsing-remitting nature that is typically observed over a disease 
course of a number of years (Johnson et al. 1995). As NHL constitutes 
approximately 4% of all cancers diagnosed annually in the UK (Source: Office for 
National Statistics “Cancer and mortality in the United Kingdom 2005-2007” 
Statistical Bulletin 24 August 2010; licensed under the Open Government Licence 
v.1.0.), FL forms only around 1% of new cancer but due to its prolonged clinical 
course has a comparatively high prevalence (approximately 20 to 25 cases per 
100000 population) which represents an important overall clinical burden.  
With a median age at presentation in the 6
th
 decade (Friedberg et al. 2009) FL is 
predominantly a disease of older adults, although paediatric cases are occasionally 
reported (Swerdlow 2004). It has a higher incidence in western countries (Anderson 
et al. 1998), has a slight male preponderance and occurs more commonly in whites 
(Groves et al. 2000). Importantly, Groves and colleagues also demonstrated, using 
data from the Surveillance, Epidemiology and End Results (SEER) program, that the 
incidence of FL increased significantly over the period 1978 to 1995 (Groves et al. 
2000) and a more recent study indicates a similar trend for FL may have continued in 
to this century, with a rate of increase in incidence of 1.8% per year from 1992 to 
2001 (Morton et al. 2006). Indeed, in a subsequent SEER analysis extended to 2007 
(available at website http://seer.cancer.gov/csr/1975_2007/), the incidence of all 
NHL continues to increase (Altekruse et al. 2009). 
1.1.3 Outcome 
The majority of patients will experience disease relapses and remissions over the 
course of a number of years, with remission duration after therapy tending to shorten 
after each disease recurrence (Johnson et al. 1995). In contrast, some patients may 
never require treatment and some can even experience spontaneous disease remission 
(Horning and Rosenberg 1984) whereas others succumb early to rapidly progressive  
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Figure 1.1  Subtypes of B-cell non-Hodgkin lymphoma 
Illustrated are differing lymphoma subtypes and the respective percentages they form of B-NHL. 
Adapted from the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 
(Swerdlow 2008). As T-NHL make up in the region of 10% of NHL, FL constitutes around one 
quarter of all NHL.  
DLBCL indicates diffuse large B cell lymphoma; MALT, mucosal associated lymphoid tissue; MCL, 
mantle cell lymphoma; CLL/SLL, chronic lymphocytic leukaemia/small lymphocytic lymphoma; 
PMBCL, primary mediastinal B cell lymphoma; HG-B NOS, high grade B cell lymphoma not 
otherwise specified; and MZL, marginal zone lymphoma. 
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disease that is resistant to therapy or develop aggressive transformation which has a 
dismal prognosis (Montoto et al. 2007b; Al-Tourah et al. 2008).    
1.1.4 Clinical aspects 
Painless lymphadenopathy is the typical presentation of FL and accompanying 
symptoms are uncommon. Other involved sites may include the bone marrow in 
around half of cases (Federico et al. 2000; Federico et al. 2009) and, less frequently, 
the spleen and tonsillar tissue. Disease may sometimes be detectable in peripheral 
blood but can present at any extra-nodal site, with isolated primary skin or intestinal 
involvement identifying specific variants with particularly good prognosis (Shia et 
al. 2002; Willemze et al. 2005). The majority of cases present with advanced disease, 
as Stage 3 or 4 when applying the Ann Arbor Classification (Gallagher et al. 1986; 
The Non-Hodgkin's Lymphoma Classification Project"  1997), which is associated 
with a worse prognosis compared to disease of limited extent (Stages 1 or 2) (Bastion 
et al. 1997; Solal-Celigny et al. 2004). Other indicators of high disease burden 
including a large (>5cm) peripheral lymph node, extensive bone marrow 
involvement and two or more extra-nodal sites of disease also associate with worse 
outcome (Romaguera et al. 1991). Age and male sex are further negative predictors 
of outcome (Leonard et al. 1991; Decaudin et al. 1999) as are elevated serum LDH, 
ESR and β2-microglobulin as well as anaemia and hypo-albuminaemia (Leonard et 
al. 1991; Bastion et al. 1997) while a higher absolute peripheral blood lymphocyte 
count may predict better overall survival (Siddiqui et al. 2006).  
As cases with apparently similar morphology at initial presentation can have 
markedly different disease courses, the identification of these outcome associations 
has led to the development of clinical prognostic indices that can risk stratify patient 
groups. These indices typically include several factors reflecting patient fitness, 
disease bulk and disease aggressiveness. Each factor contributes to an overall score 
which is used to risk stratify patients with FL into prognostic groups. Four large 
studies that have generated prognostic tools are summarised in Table 1.1. The first of 
these was the International Prognostic Index (IPI) which was initially developed for 
prognostication of aggressive NHL ("The International Non-Hodgkin's Lymphoma 
Prognostic Factors Project"  1993) and was subsequently shown to define risk groups 
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Table 1.1  Comparison of clinical prognostic indices in follicular lymphoma 
Study group IPI  ILI  FLIPI  FLIPI-2   
Prognostic 
factors
§
 
Age > 60  Age > 60  Age ≥ 60  Age > 60   
Stage 3 or 4  Sex Male  Stage 3 or 4  BMI present   
LDH (iu) > ULN  LDH (iu) > ULN  LDH (iu) > ULN   β2M > ULN   
PS  2 to 4  B sx Present  Hb (g/dl) < 12  Hb (g / dl) < 12   
Extranodal ≥ 2  Extra-nodal ≥ 2  LN sites ≥ 5  LN size (cm) > 6   
    ESR (mm/hr) ≥ 30         
              
  Cases 10 yr OS  Cases 10 yr OS  Cases 10 yr OS  Cases 5 yr OS 5 yr PFS  
Risk groups* Low (0 or 1) 36 75 Low (0 or 1) 64 65 Low (0 or 1) 36 71 Low (0) 18 98 79 
 Low-int (2) 32 47 Int (2) 23 54 Int (2) 37 51 Int (1 or 2) 62 88 51 
 High-int (3) 19 55 High (3 to 5) 13 11 High (3 to 5) 27 36 High (3 to 5) 20 77 20 
 High (4 or 5) 13 0           
              
Study type Retrospective single-centre Retrospective multi-centre Retrospective multi-centre Prospective multi-centre  
 
§The values for each factor that give a score of 1 in risk group stratification are indicated for the respective prognostic indices. The maximum score for each study was five 
(note: although six factors were included in the ILI study, no case scored more than five). 
*The risk group categories are indicated for each of the four clinical prognostic indices. The respective cumulative scores established from the prognostic factors are given in 
parentheses. There are four groups for the IPI and three each for the remaining three indices. Figures indicate the percentages of cases included in each risk group and the 
percentage survival (OS or PFS at five or ten years, as indicated). 
LDH indicates lactate dehydrogenase; iu, international units; PS performance status as per the Eastern Cooperative Oncology Group (ECOG) criteria (Oken et al. 1982); int, 
intermediate; ULN, upper limit of normal; sx, symptoms; extra-nodal, number of extra-nodal sites involved by disease; ESR, erythrocyte sedimentation rate; Hb, 
haemoglobin, LN sites, number of lymph node sites involved by disease; BMI, bone marrow involvement by disease; β2M, beta-2 microglobulin; LN size, longest diameter 
of the largest involved lymph node; and int, intermediate.  
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in FL (Lopez-Guillermo et al. 1994). However, only a relatively small proportion of 
FL cases (13%) are classified as high risk using this model, which has limited its 
clinical application. An FL specific prognostic index which identified three risk 
groups was developed over a decade ago by the Italian Lymphoma Intergroup (ILI) 
(Federico et al. 2000) with the poor risk group constituting 13% of cases. Following 
this, a large international multi-centre study (Solal-Celigny et al. 2004) developed 
the Follicular Lymphoma International Prognostic Index (FLIPI). This includes five 
clinical parameters and classifies cases in to low (36% of cases), intermediate (37%) 
and high (27%) risk groups with overall survival at ten years of 71%, 51%, and 36%, 
respectively. Recently, the FLIPI-2 has been reported which used prospectively 
acquired data to develop a model which predicted both overall survival and 
progression free survival (Federico et al. 2009). However, although all these 
prognostic tools robustly stratify patients in to survival risk groups and can be easily 
applied in the clinical setting, they have not yet led to risk adapted treatment. 
Moreover, there is heterogeneity of outcome within the risk groups themselves which 
limits their predictive power at the level of individual cases. So, while they are 
valuable adjuncts to prospective clinical studies, these clinical prognostic indices are 
yet to impact on routine patient management. 
1.1.5 Management 
The management of FL is diverse reflecting the heterogeneity of clinical behaviour 
that can be observed over the course of the illness. However, a particularly important 
determinant of initial management is the presenting disease stage.  
1.1.6 Limited stage disease 
Although the minority of cases present with limited (stage 1 or 2) disease, these cases 
may enter prolonged remission following local radiotherapy (Richards et al. 1989; 
MacManus and Hoppe 1996). This has led to the recommendation that local 
radiotherapy should be offered to patients with limited stage FL at diagnosis 
(Dreyling 2010). Intriguingly, some cases with stage 1 disease may experience long 
remissions following excision of the single disease site alone (Soubeyran et al. 
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1996), giving a “surgical remission”, but this approach is not considered standard of 
care. 
1.1.7 Advanced stage disease 
As the majority of FL cases have stage 3 or 4 disease at diagnosis they are not 
suitable for treatment with radiotherapy. At present there remains no recommended 
curative option for these cases but, following many years of uncertainty regarding 
how best to manage advanced stage FL, recent advances have brought at least some 
consensus as to initial treatment. The need for treatment is largely determined by the 
presence of B symptoms, organ compromise, haematopoietic impairment, bulky 
disease, ascites / pleural effusion or rapid lymphoma progression and, in the absence 
of these features, management by observation alone may be appropriate. Such a 
“watch and wait” approach has long been employed (Portlock and Rosenberg 1979; 
O'Brien et al. 1991), may not adversely influence subsequent disease events 
(Horning and Rosenberg 1984) and prospective randomised studies have 
demonstrated similar outcomes compared to upfront therapy (Young et al. 1988; 
Brice et al. 1997; Ardeshna et al. 2003). However, this approach is being challenged 
following the recent demonstration that single agent rituximab (an anti-CD20 
monoclonal antibody) given upfront at initial presentation may be beneficial in those 
patients who would otherwise be candidates for watch and wait (Ardeshna et al. 
2010). 
Following reports beginning more than three decades ago into the activity of both 
single agent (Lister et al. 1978) and combination chemotherapy (Portlock and 
Rosenberg 1976) regimes in FL, the advent of rituximab immunotherapy has 
significantly improved the treatment of patients with advanced stage disease. 
Rituximab itself has activity as a single agent in FL (McLaughlin et al. 1998) but it is 
in combination with chemotherapy that it has shown most promise. Following the 
first report of its use with cyclophosphamide, doxorubicin, vincristine and 
prednisolone (CHOP) in FL (Czuczman et al. 1999), four randomised studies have 
demonstrated significant survival benefits of rituximab when added to combination 
chemotherapy as initial treatment (Hiddemann et al. 2005; Marcus et al. 2005; 
Herold et al. 2007; Marcus et al. 2008; Salles et al. 2008) and a benefit on overall 
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survival is supported by a systematic meta-analysis (Schulz et al. 2007). This data 
has led to Rituximab given in combination with chemotherapy being recommended 
as first line treatment in advanced stage previously untreated FL that requires therapy 
("NICE Technology Appraisal Guidance 137"  2008). 
The optimal management of relapsed disease is less clear. However, rituximab has a 
role either in combination with chemotherapy (Forstpointner et al. 2006; van Oers et 
al. 2006; van Oers et al. 2010) or as a single agent (Ghielmini et al. 2004; Martinelli 
et al. 2010) and non-cross resistant chemotherapy is considered, particularly if the 
disease recurrence occurs early (< 6 months) following prior treatment.  
Augmentation of remission has been attempted by maintenance therapy with either 
chemotherapy (Steward et al. 1988) or interferon but these have been limited by 
significant risks of myelosuppression or poor tolerability, although interferon may 
improve both progression free and overall survival particularly in the pre-rituximab 
era (Rohatiner et al. 2007; Baldo et al. 2010). However, maintenance therapy with 
rituximab following induction of remission appears to be beneficial and well 
tolerated after both treatment with combination chemotherapy (Forstpointner et al. 
2006; van Oers et al. 2006; van Oers et al. 2010) or rituximab monotherapy 
(Hainsworth et al. 2002) following FL relapse as well as after rituximab 
monotherapy as first line therapy after diagnosis (Ghielmini et al. 2004; Martinelli et 
al. 2010). Furthermore, rituximab maintenance is beneficial in previously untreated 
patients with FL following combination chemotherapy induction (Hochster et al. 
2009). Importantly, a recent large international multi-centre study demonstrates that 
following remission induction with rituximab and combination chemotherapy for 
previously untreated advanced stage FL, subsequent rituximab maintenance is 
beneficial (Salles et al. 2011) suggesting this approach may become a standard of 
care.  
Options for patients with FL who may not be suitable candidates for combination 
chemotherapy include single agent chemotherapy (such as alkylating agents) or 
rituximab monotherapy which may achieve satisfactory disease control. Monoclonal 
anti-CD20 antibody conjugated with radio-isotopes are further therapies which have 
been approved for use either in relapsed disease (in the form of either 
90
Yttrium-
ibritumomab tiuxetan or 
131
Iodine-tositumomab) or as consolidation of remission 
Chapter 1 
28 
after first-line chemotherapy (
90
Yttrium-ibritumomab tiuxetan) and have the potential 
to provide long-term disease control following a single application (Kaminski et al. 
2001; Davies et al. 2004; Morschhauser et al. 2008). Other therapies also show 
promise in FL and the preliminary report on a randomised study of the use of 
bendamustine in combination with rituximab is encouraging. It indicates this regime 
has similar efficacy but a better side-effect profile than the widely used R-CHOP 
regime when employed as initial therapy in advanced stage disease (Rummel et al. 
2009) and may be particularly relevant to those patients less suited to more intensive 
approaches. 
1.1.8 Role of haematopoietic stem cell transplantation 
By contrast, a subset of patients may be candidates for intensive high-dose 
chemotherapy (HDT) augmented by autologous haematopoietic stem cell 
transplantation (auto-HSCT). This attempts to provide long-term disease remission 
but the increased toxicity of this approach is an important limiting factor. 
Consequently, it is typically reserved for a cohort of younger, fitter patients who 
have poor risk disease. However, as first line therapy, it cannot yet be recommended 
outside the context of clinical trials as no overall survival benefit has been 
demonstrated to date in randomised studies although an improvement in PFS with a 
plateau indicates that at least for some patients it may be beneficial (Deconinck et al. 
2005). However, prolonged follow-up confirms an excess of second malignancies 
following this approach when total body irradiation (TBI) is included in the 
conditioning regime (Gyan et al. 2009). At relapse, HDT with auto-SCT has been 
investigated in randomised studies and a benefit in overall survival compared to 
chemotherapy has been reported (Schouten et al. 2003). This study again utilised 
TBI conditioning and other studies with prolonged follow-up after auto-HSCT 
administered at FL relapse have reported an increase in second malignancies (at a 
rate of around 15%) associated with a similar approach (Montoto et al. 2007a; 
Rohatiner et al. 2007). Conditioning regimes that excluded TBI had a lower rate 
(3.5%) of secondary malignancies (Montoto et al. 2007a) but the role of this 
approach requires clarification in the era of rituximab immunotherapy.  
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Allogeneic HSCT (allo-HSCT) represents a potentially curative option in patients 
with advanced stage FL and its use has recently been reviewed by van Besien (van 
Besien 2009). It provides a graft versus lymphoma effect, eliminates the risk of graft 
contamination by lymphoma cells and is associated with lower rates of relapse. 
However, these effects have frequently not translated in to a survival benefit due to 
non-relapse related mortality (NRM) rates caused by the intensive, myelo-ablative 
conditioning and risk of graft-versus-host disease (GvHD). This has prompted 
investigation of reduced intensity conditioning (RIC) allo-HSCT, an approach which 
shows promise as indicated by recent studies in relapsed FL. One report, with a 
median of five years follow-up, provides estimated OS and PFS of 85% and 83% 
respectively (Khouri et al. 2008) and another study, using T cell depletion in an 
attempt to reduce the risk and severity of GvHD, demonstrates low NRM (15%) and 
an encouraging PFS (76%) at 4 years (Thomson et al. 2010).  
Few studies have compared the two transplant approaches, with one randomised 
study closing early due to sub-optimal recruitment (n = 30) (Tomblyn et al. 2010). A 
two-centre retrospective study compared HDT and auto-HSCT to RIC-allo-HSCT, 
over a median follow-up of 7 and 3 years respectively, using regimens that did not 
contain TBI (Ingram et al. 2008). The respective disease free (67% v 69%) and 
overall survival (56% v 58%) are similar for both approaches, reflecting a lower 
relapse rate but higher NRM of the allogeneic approach. In the auto-HSCT group 
after censoring at 5.5 years, there were five secondary malignancies recorded 
(representing 6% cases) and only one in the Allo-SCT group, perhaps reflecting the 
shorter follow-up. 
Encouragingly, the overall clinical outcome of FL is improving as demonstrated for 
cases managed at St Bartholomew’s Hospital over the last four decades Figure 1.2 
and this effect is probably a consequence of recent improvements in both treatment 
and supportive management of patients with this disease (Fisher et al. 2005; Liu et 
al. 2006). However, FL survival still lags behind that of the general population 
(Swenson et al. 2005) and an important issue in this regard is the current inability to 
reliably predict adverse events over the prolonged course of this disease.  
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Figure 1.2  Improving overall survival in FL 
OS for all patients with FL (n = 834) presenting to Barts and the London NHS trust over four decades 
(as indicated). Data (unpublished) were extracted in July 2010 from the clinical database previously 
maintained by the ICRF / CRUK Medical Oncology Unit (now Department of Haemato-Oncology) 
based at St Bartholomew’s Hospital. 
 
 
 
 
Figure 1.3  Survival of FL which transforms and does not transform 
Illustrated is the OS for patients diagnosed with FL and seen at St Bartholomew's Hospital between 
1981 and 2001 (reflecting the period from which FL / t-FL samples are investigated in this thesis 
project). The survival of those patients who never developed transformation (black line) is 
significantly better than those whose disease transformed at any period (red line). The data represent 
an update of a report from this institution (Montoto et al. 2007b). 
P = 0.0013 
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1.2 Transformation  
A particularly significant adverse disease event that can present as clinical relapse or 
progression at any stage of FL is its transformation to aggressive lymphoma (t-FL). 
The morphological appearances of such tumour samples resemble de novo DLBCL 
in the vast majority of cases although transformation to Burkitt lymphoma and acute 
lymphoblastic lymphoma or even Hodgkin lymphoma can occur, albeit rarely 
(LeBrun et al. 1994; Kroft et al. 2000). Two recent large studies with prolonged 
follow-up indicate transformation develops at a median of 3 to 4 years following FL 
diagnosis (Montoto et al. 2007b; Al-Tourah et al. 2008). Both reports indicate that 
around one third of FL will develop t-FL at some point in the course of their disease, 
with one suggesting a persistent risk of around 3% per year (Al-Tourah et al. 2008). 
Importantly, FL cases that develop t-FL have worse survival compared to those cases 
that do not Figure 1.3 and the outcome following transformation is particularly poor, 
with a median survival from this event of around 1.5 years. 
Clinical indicators of t-FL include an isolated enlarging lymph node, the onset of B 
symptoms (night sweats, fevers, unexplained loss of weight), unusual sites of new 
disease or organ involvement as well as biochemical abnormalities including 
hypercalcaemia and rising serum lactate dehydrogenase (LDH) level which should 
prompt further evaluation of the patient. Although the presence of at least one of 
these features distinguishes a group of FL patients who have similar outcome to 
those with biopsy proven transformation (Al-Tourah et al. 2008), until this approach 
is prospectively validated, obtaining histological confirmation of transformation will 
remain an important aspect of patient management.  
Treatment of t-FL is a clinical challenge and it remains to be seen whether the advent 
of rituximab immunotherapy will reduce the incidence of this event or improve its 
outcome. As it is usually histologically and clinically similar to de novo DLBCL, 
therapies developed for DLBCL are frequently applied to t-FL. However, treatment 
is often complicated by prior therapies and patients’ older age with attendant co-
morbidities. When prolonged remission is an appropriate goal then combination 
immuno-chemotherapy, which is consolidated by HDT and auto-HSCT or even RIC-
allo-HSCT in some centres, is appropriate (Montoto et al. 2007a; Thomson et al. 
2009). If symptom control is the primary objective then local radiotherapy alone or 
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attenuated immuno-chemotherapeutic regimes may be appropriate. However, few 
reports deal exclusively with the management of t-FL and there is a pressing need for 
co-operative studies addressing this issue. In this regard, current survival data for FL 
cases on the clinical database at St Bartholomew’s Hospital suggests there has been 
no improvement in survival of FL that transforms when cases from each of the last 
four decades are compared, log rank P = 0.44 (unpublished). Indeed, t-FL is a 
significant contributor to death in patients with FL as a previous study identified that 
42 / 95 (44%) deaths in FL over a period of 9 years from diagnosis were attributable 
to t-FL (Bastion et al. 1997) and, in an earlier study, 68% of cases who died after 
disease progression had evidence of histological transformation on post-mortem 
examination (Garvin et al. 1983).  
Prediction of transformation might facilitate better disease management and clinical 
parameters from FL diagnosis that are routinely available have been examined for 
their prognostic potential. Indeed, higher FLIPI scores associate with increased risk 
of subsequent t-FL (Gine et al. 2006; Montoto et al. 2007b) as does advanced stage 
(Montoto et al. 2007b; Al-Tourah et al. 2008) and, as previously reviewed (Muller-
Hermelink and Marx 2000), other studies suggest that grade 3b FL or FL with diffuse 
areas (before its re-classification (Swerdlow 2008)), may associate with 
transformation. However, in an earlier study, histological sub-types of FL determined 
according to the previously used Working Formulation ("The Non-Hodgkin's 
Lymphoma Pathologic Classification Project"  1982) did not associate with t-FL, and 
serum β2M was the only diagnostic FL parameter to correlate with risk of this event 
(Bastion et al. 1997). 
The same study also revealed that a high serum LDH level at transformation, as well 
as the type of and response to therapy administered as treatment of t-FL, correlate 
with outcome after transformation. A more recent study also suggests response to 
salvage therapy at t-FL is predictive of outcome (Montoto et al. 2007b) while 
another demonstrates that limited disease stage at t-FL associates with better survival 
(Al-Tourah et al. 2008).  Nevertheless, despite these prognostic factors, it is not yet 
possible to reliably predict t-FL occurrence or outcome for individual patients and 
this suggests these surrogate markers of disease have limited utility in its 
management.  
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Some recent reports provide insights in to the biological mechanisms underlying t-
FL, as reviewed by Bernstein and Burack (Bernstein and Burack 2009), but a 
definitive picture of the critical molecular aspects of transformation remains elusive. 
Nonetheless, these studies perhaps represent the first steps towards molecular 
profiling, an approach already used in other haematological malignancies to guide 
patient treatment. In FL, such a tool could be particularly relevant in developing risk 
adapted management through identifying, firstly, those FL cases destined to 
transform or not and, secondly, the most appropriate management options in those 
cases that develop t-FL. These are important goals as transformation remains a 
significant cause of morbidity and mortality in FL.   
1.3 Normal B cell development 
Before addressing the molecular aspects of FL / t-FL, it is important to consider the 
normal B lymphocyte as FL arises as a malignant clone of these cells and the genetic 
aspects of normal B cell ontogeny have a role in the development and progression of 
FL.  
The fundamental role of B cells is to produce immunoglobulin molecules as antigen-
specific antibodies that contribute to the immune response. B cells initially develop 
in the bone marrow from haematopoietic stem cells and undergo two distinct phases 
of development as have been extensively reported (Tonegawa 1983; Rajewsky 1996; 
van Zelm et al. 2007) and which are summarised here.  
Within the bone marrow an antigen independent differentiation phase includes 
rearrangement of the immunoglobulin (Ig) gene loci. There are three Ig gene loci 
IGH@ (on chromosome 14q32.3), IGK@ (chromosome 2p) and IGL@ (chromosome 
22q) the protein products of which form Ig molecules initially expressed on the cell 
surface as functional Ig receptors. An antigen dependent phase of differentiation then 
follows after passage of immature B cells from the bone marrow, via the blood, to 
secondary lymphoid organs. When these B cells bind compatible antigen in the 
peripheral compartment they undergo clonal proliferation and further differentiation 
in the germinal centre (GC) region of the lymph node (MacLennan 1994). It is in the 
GC that naive B cells develop in to centroblasts and subsequently centrocytes which 
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then form either plasma cells or long-lived memory B cells that each produce and 
secrete the antigen-specific Ig molecules as antibodies (Allen et al. 2007). 
The process of immunoglobulin formation is critical to B cell maturation and 
function and involves a complex series of steps involving both genetic events and 
post-translational glycosylation. The mature Ig molecule includes two heavy chains 
(IgH) and two light (either Igκ or Igλ) chains which are held together by disulphide 
bonds between cysteine residues in a “Y” shape. Indeed, the incorporation of only 
one or other light chain in to the Ig molecule is used routinely as an adjunct to 
histological diagnosis as, in B cell tumours, clonal expansion of the malignant 
population restricts them to surface expression of either Igκ or Igλ. By using probes 
against the κ and λ segments of the Ig molecule, clonality can then be inferred by 
detection of only one or other in the (presumed) malignant cells, helping to 
distinguish them from polyclonal B cell expansions (van Dongen et al. 2003). There 
is also diversity within the IgH molecules which creates five antibody subtypes (IgA, 
IgD, IgE, IgG, IgM), two of which require further structural modification to form 
dimers (IgA) or pentamers (IgM). These subtypes impart additional specifications on 
the anatomical locations of action and downstream functional consequences of 
antigen binding for the respective mature Ig molecules. 
The base of each Ig molecule is termed the FC region and is a conserved structure 
formed by the two heavy chains. The FC region interacts with immune effector 
mechanisms via FC-receptors on other cells including macrophages or interacting 
with proteins of the complement system to effect a range of physiological immune 
processes, including lysis of cells, recognition of opsonised particles and activation 
of other immune mediators (eosinophils, basophils, mast cells). The two arms of the 
Ig molecule are termed the FAB regions and each is each formed by heavy and light 
chains. They contain conserved (constant) domains but the heavy and light chain 
variable domains (VH and VL respectively) are the determinants of antigen 
specificity. Within these VH and VL regions, three areas bind antigen and are termed 
the complementarity determining regions (CDRs) and these are flanked by conserved 
sequences termed framework regions (FRs). 
There is a huge diversity in the antigen specificity of Ig molecules. This reflects the 
almost limitless number of antigens that might be encountered by a B cell and it is 
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physiological genetic changes that drive this variability. There are three stages in this 
process: 
a) The variable region of the Ig heavy chain includes three segments termed variable 
(V), diversity (D) and joining (J) while the light chains consist of only V and J 
segments. The first stage in selecting for antigen specificity in Ig molecules involves 
rearrangements of variable regions of the respective gene loci, first identified over 
thirty years ago (Hozumi and Tonegawa 1976; Brack et al. 1978). There are multiple 
V, D and J segments with, for example, a minimum of 66, 27 and 6 respective 
segments for IGH. Each developing B cell selects only one of the V / D / J or V / J 
gene segments for IGH and IGK/IGL, respectively. This is a random process termed 
V(D)J recombination Figure 1.4, which occurs within the developing B cells in the 
bone marrow, and the many different potential VDJ rearrangements translates in to a 
“combinatorial repertoire” reflecting around 2  106 Ig molecules (van Dongen et al. 
2003). The V(D)J recombination process is mediated by the protein products of the 
recombination activating genes, RAG1 and RAG2, which cause transient breaks in 
DNA to enable the selection of the different segments.  Further diversity is conferred 
on the variable region by the occurrence of small deletions and nucleotide insertions 
at the junction regions of V / D / J segments during the recombination process (van 
Dongen et al. 2003). VDJ recombination occurs first in IGH and then, after 
production of a functional IgH protein, VJ recombination occurs in IGK. At this 
stage IGK deletion may occur and, if so, VJ recombination occurs in IGL. Following 
V(D)J recombination, the complementary allele (which has not undergone 
rearrangement) is effectively silenced so the B cell can only produce one form of 
variable heavy and light chains (Bergman and Cedar 2004). This immature B cell 
containing the rearranged IGH and either IGK or IGL loci then passes from the bone 
marrow.  
The V(D)J process is relevant in B cell malignancy as clonal expansion means the 
tumour cells have a common IGH rearrangement with its detection already used as a 
management tool to monitor levels of minimal residual disease (MRD) in acute 
lymphoblastic leukaemia (Patel et al. 2010). Furthermore, the multiple IGH-VH 
segments can be grouped in to sub-family groups (1 to 7) based on the sequence 
similarity of three FRs in the VH segments. Consequently, the FR sites have been 
used for design of primers that are complementary to all VH segments within the   
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Figure 1.4  B cell development and B-NHL 
Top, schematic representation of the processes underlying B cell antibody affinity maturation. For 
illustrative purposes limited V (n = 3), D (n = 2) and J (n = 1) segments (highlighted by different 
colours) are shown to illustrate V(D)J  recombination, here for the IGH variable region and vertical 
black lines represent the sites of SHMs created by AID. Similarly, limited constant segments 
representing IgM (Cμ), IgG (C) and IgA (Cα) are used to illustrate the process of CSR, here selecting 
for an IgA heavy chain molecule. Bottom, B cell ontogeny in the bone marrow and periphery is 
indicated with circles representing the various cell stages. The sites and stages of the three aspects of 
V(D)J recombination (for IGH, IGK and IGL), SHM and CSR are indicated. The germinal centre is 
highlighted in grey and examples of different B-NHL corresponding to their cell of origin are given at 
the foot of the figure. The figure is an amalgam adapted from figures by Kuppers and colleagues, 
Kuppers and Dalla-Favera and van Zelm and colleagues (Kuppers et al. 1999; Kuppers and Dalla-
Favera 2001; van Zelm et al. 2007). ALL indicates acute lymphoblastic leukemia; CLL / SLL, chronic 
lymphocytic leukemia / small lymphocytic lymphoma; MCL, mantle cell lymphoma; MZL, marginal 
zone lymphoma; BL, Burkitt lymphoma; DLBCL, diffuse large B cell lymphoma; FL, follicular 
lymphoma; and MM, multiple myeloma. 
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respective IGH-VH subgroup (van Dongen et al. 2003). Application of these primers 
can then distinguish clonal from polyclonal B-cell proliferations as clonal expansions 
will reveal distinct, single PCR products that represent only one VH sub-family 
compared to heterogeneous PCR products obtained from polyclonal proliferations.  
b) The second phase of antigen diversity is mediated by the process of somatic 
hypermutation (SHM). This occurs in the GC of lymph nodes, requires T cell help 
through CD40-CD40L mediated interactions with B cells and involves the 
introduction of single nucleotide mutations in the variable regions of the Ig genes 
(Berek et al. 1991; Jacob et al. 1991; Kuppers et al. 1993), preferentially in the 
CDRs, by the activation-induced cytidine deaminase (AID) enzyme (Muramatsu et 
al. 1999; Muramatsu et al. 2000; Arakawa et al. 2002; Nagaoka et al. 2002) as 
illustrated in Figure 1.4. This can lead to changes in the amino-acid sequence of the 
antigen binding sites in the surface Ig receptor molecule and attendant changes in its 
antigen binding affinity. If the affinity is reduced then the B cell is selected for 
destruction by apoptosis. However, B cells with increased antigen affinity of the Ig 
molecule undergo preferential selection (Liu et al. 1989) and clonal expansion then 
subsequently secrete antibody (Kuppers and Dalla-Favera 2001). 
c) A final phase contributing to antibody diversity is termed class switch 
recombination (CSR). This also occurs in the GC and involves selection of single 
constant regions (Figure 1.4). The antigen affinity is not changed but the Ig molecule 
subtype can change from the IgM or IgD expressed on the surface of naive mature B 
cells to one of IgA, IgE and IgG. CSR involves deletion of sections of the IGH 
constant domain by the creation of DNA breaks and their subsequent repair thought 
to be mediated by AID and uracil DNA glycosylase (Casali and Zan 2004). This 
creates B cell progeny which have the same antigen affinity but differing Ig subtypes 
(termed isotypes). The differing immune effector mechanisms conferred by the 
respective isotypes provide alternative means by which the same antigen may be 
cleared, giving an additional degree of diversity in the antibody response to antigen. 
The antibody isotype has clinical utility, particularly in the most mature B cell 
malignancy, multiple myeloma (which is a clonal proliferation of plasma cells). The 
presence of excessive amounts of one antibody isotype in serum, or as secreted light 
chain fragments in the urine, suggests clonality and is used to monitor disease and its 
response to therapy.  
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As both V(D)J recombination and SHM also occur in malignant B cells arising from 
the GC, these features are used later in this thesis to establish the clonal relationship 
of FL and t-FL samples obtained from patients and to model the evolution of 
transformation. 
1.4 Genetic changes in FL   
The evidence that these physiological processes occur in various forms of B-NHL 
has contributed to the determination of normal B cell counterparts for a number of 
these tumours, as reviewed by Kuppers and colleagues (Kuppers et al. 1999) and 
illustrated in Figure 1.4. In FL, a report from 1986 was the first to demonstrate the 
presence of SHM sites in tumour cells by sequencing the IGH variable regions 
(Cleary et al. 1986b). Subsequently, malignant clonal expansion was shown to occur 
after the initiation of SHM (Zelenetz et al. 1992) a process which is ongoing in FL 
cells (Kon et al. 1987; Cleary et al. 1988; Zelenetz et al. 1992; Ottensmeier et al. 
1998). This indicates that FL has a GC B cell origin and that intra-clonal genetic 
diversity occurs within the tumour and can be detected by sequencing SHM sites in 
the variable region. Moreover, a recent report demonstrates that AID activity is 
required for the development of GC derived lymphoma in mouse models, providing 
experimental evidence that AID induced events (namely CSR and SHM) are required 
to generate the secondary genetic lesions (such as translocations and the ongoing 
SHM) occurring in the malignant transformation of B cells at the GC stage of 
differentiation (Pasqualucci et al. 2008). 
1.4.1 Translocation (14;18) 
Translocations of chromosomal material occur frequently in cancer ("Mitelman 
Database"  2011) and may drive the disease through disruption of normal gene 
function particularly through creation of fusion genes or dysregulation of gene 
expression (often the up-regulation of oncogenes). Many examples have followed the 
first description of a cancer associated translocation, the Philadelphia chromosome in 
chronic myeloid leukaemia (Tough et al. 1961) which juxtaposes the BCR and ABL 
genes leading to a fusion protein product that has a critical role in driving this 
malignancy. In B-NHL translocations involving IGH (and less commonly IGK / IGL) 
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are frequent events (Willis and Dyer 2000) reflecting the disruption and strand 
breaks caused to DNA during V(D)J recombination, SHM and CSR (Kuppers and 
Dalla-Favera 2001).  
In FL, around 85% of cases (Weiss et al. 1987; Yunis et al. 1987) harbour the 
translocation (14;18)(q32;q21), referred to herein as t(14;18), which occurs as a 
result of mistakes in VDJ recombination (Tsujimoto et al. 1985b) and juxtaposes the 
BCL2 gene to the IGH locus (Tsujimoto et al. 1984) as illustrated in Figure 1.5. This 
typically creates two derivative chromosomes, with the IGH breakpoints on 
chromosome 14 occurring in the JH region. The BCL2 breakpoints on chromosome 
18 cluster together principally in the 3’ UTR region of the gene (Tsujimoto et al. 
1985a; Cleary et al. 1986c), within a 150 bp site termed the major breakpoint region 
(MBR), although a second cluster occurs around 20 kb downstream of BCL2 (Cleary 
et al. 1986a; Buchonnet et al. 2000), termed the minor breakpoint region (mbr) and, 
more rarely still, breakpoints may be “atypical” (such as those within the gene’s 
large 3
rd
 exon). Significantly, a report has now demonstrated that the BCL2 MBR site 
can acquire altered DNA structure that can then be cut by RAG nucleases and so 
provides a potential mechanism underlying the consistent involvement of this site in 
translocations (Raghavan et al. 2004). Furthermore, t(14;18) can be detected in the 
blood of patients with FL and so has been used as a molecular marker of disease 
response, particularly following attempts to achieve long-term remission through 
HDT with Auto-SCT (Gribben et al. 1993; Mahe et al. 2003).  
The translocation leads to the over-expression of the anti-apoptotic BCL2 protein 
conferring a survival advantage on affected cells. The significance of BCL2 was 
illustrated in a series of publications through the 1980s and early 1990s (Tsujimoto 
and Croce 1986; Alnemri et al. 1992) with evidence that it was growth promoting in 
lymphoid cells (Nunez et al. 1989) and tumorigenic in mouse models (Reed et al. 
1988). However, despite its frequency in FL, an important study demonstrated that 
although t(14;18) promoted polyclonal lymphoid hyperplasia in mice, progression to 
lymphoma was associated with secondary changes. This suggests that t(14;18) in 
isolation is insufficient to cause lymphoma (McDonnell and Korsmeyer 1991). 
Support for this model in humans is provided by the lack of t(14;18), or sub-
karyotypic BCL2-IGH rearrangements, in around 10 to 15% of FL cases and a recent 
report proposing that a specific t(14;18) negative disease subtype exists that is  
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Figure 1.5  t(14;18) 
Illustrated is the process of translocation between the IGH and BCL2 loci. Left, a DNA double strand 
break in IGH occurs as part of V(D)J recombination. Right, the MBR situated in the 3' region of BCL2 
is prone to similar breaks (Raghavan et al. 2004). Bottom, aberrant repair of the breaks leads to the 
translocation, possibly facilitated by the spatial proximity of the IGH and BCL2 loci in B cells (Roix 
et al. 2003), and formation of derivative (der) chromosomes 14 and 18. For illustrative purposes both 
IGH and BCL2 are orientated 5' to 3' but they each occur on reverse DNA strands hence der 14 
contains IGH-BCL2. The figure is adapted from Lieber and colleagues (Lieber et al. 2006).  
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characterised by inguinal lymphadenopathy, diffuse histological features and 
presence of chromosome 1p deletion (Katzenberger et al. 2009). Furthermore, 
t(14;18) can be detected at low levels in the peripheral blood mononuclear cells of 
normal, healthy individuals (Limpens et al. 1995) at a prevalence of 23 to 50% 
(Dolken et al. 1996; Summers et al. 2001) as compared to the much lower rate of FL 
in the population (Morton et al. 2006; Friedberg et al. 2009), indicating other factors 
are important in disease development. Nonetheless, an age associated increase in the 
prevalence of t(14;18) in healthy individuals (Schuler et al. 2009), which parallels 
the distribution of FL cases across the population, provides epidemiological support 
for this translocation as a predisposing factor for this lymphoma. This is further 
supported by the demonstration that t(14;18) occurs in an atypical expanding 
population of B cells with FL-like characteristics in healthy individuals (Roulland et 
al. 2006) suggesting these constitute a pre-malignant cell pool from which FL can 
develop. 
1.4.2 Other genetic aspects of FL 
Additional cytogenetic events are common in FL. Instead of being translocated to the 
IGH region, BCL2 may occasionally be juxtaposed to IGK or IGL by 
t(2;18)(p11;q21) and t(18;22)(q21;q11), respectively (Hillion et al. 1991; Knutsen 
1997; Lin et al. 2008). Other translocations include those between 3q27 and the 
immunoglobulin gene loci (Otsuki et al. 1995), disrupting the BCL6 oncogene, and 
rare events such as t(16;18)(p13;q21) (Mahmoodi et al. 2004). Rearrangement of the 
MYC oncogene is observed in aggressive B-NHL (Burkitt lymphoma and 
intermediate BL/DLBCL) and is associated with a poor prognosis in DLBCL 
(Savage et al. 2009; Barrans et al. 2010). So called “double-hit” lymphomas 
containing both MYC and BCL2 rearrangements have a particularly poor outcome 
(Johnson et al. 2009b). Consistent with this, studies in FL suggest that MYC 
rearrangements might confer a more aggressive clinical course if present at diagnosis 
(Christie et al. 2008), the rearrangements can occur at disease progression (De Jong 
et al. 1988; Yano et al. 1992) and high level amplification of the MYC locus has been 
reported in FL (Bentz et al. 1996).  
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However, the most common events are chromosomal gains or losses with an early 
study suggesting that loss 6q and gains 7, 12q and 2p often accompanied a more 
clinically aggressive disease course (Yunis et al. 1987). A report then addressed the 
prognostic value of karyotypic changes, revealing that loss or disruption of 6q23-26 
or 17p associated with worse survival and predicted shorter time to transformation 
(Tilly et al. 1994) and around the same period a study of multiple NHL subtypes 
showed that loss 6q, gain 7 and gain 12 were enriched in FL (Johansson et al. 1995). 
In a large subsequent study (n = 165) assessing only t(14;18) containing FL 
diagnostic samples, almost all cases (97%) had additional cytogenetic changes 
(Horsman et al. 2001) at a median of 8 per case. A follow-up investigation (n = 336) 
revealed that secondary cytogenetic events delineate differing initial routes of disease 
development. In this study, loss 1p (20%) and loss 6q (30%) were the most common 
additional changes but only loss 17p or gain 12 associated with inferior survival 
(Hoglund et al. 2004). However, this study included a cohort of non-diagnostic cases 
who had received treatment prior to the included biopsy sample and prior treatment 
itself associates with an increase in karyotypic changes (Offit et al. 1991).  
These cytogenetic studies identified a large number of heterogeneous gains and 
losses. However, only a subset are recurrent and even less have prognostic relevance. 
Other studies have employed newer, higher resolution techniques in attempts to 
better distinguish regions of genetic change which may be important in FL. Using 
CGH (Kallioniemi et al. 1992), Viardot and colleagues identified 7p / 7q or 6q as 
most frequently affected by gain or loss, respectively. Furthermore, they could 
determine minimum common regions affected within these areas with loss 6q25 the 
single cytogenetic event to independently associate with worse survival (Viardot et 
al. 2002).  
During the course of this thesis, micro-array-CGH (array-CGH) (Pinkel et al. 1998) 
has been used to investigate diagnostic FL samples in a study recently reported by 
the British Columbia Cancer Agency (BCCA). This identified a number of regions of 
recurrent genomic copy number change (some as small as 184 kb) with two, loss 
1p36.22-p36.33 and loss 6q21-q24.3, predicting both overall survival and risk of 
future disease transformation independently of the IPI (Cheung et al. 2009b). The 
prognostic significance of these two regions builds on the previous reports 
identifying loss affecting 6q as a recurrent event with another recent array-CGH 
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study identifying that loss of 6q25 and 6q26 (as well as 9p21) associate with worse 
survival (Schwaenen et al. 2009). Furthermore, another micro-array study has 
identified that in 50% of FL loss of heterozygosity (LOH), as either copy number 
loss or copy neutral LOH, affects chromosome 1p36 (Ross et al. 2007) and therefore 
represents the second most common chromosomal change described in FL. Copy 
neutral LOH (termed acquired uniparental disomy; aUPD) affecting 1p36 has since 
been shown by our group to associate with worse survival in FL and aUPD 16p 
predicts shorter time to progression and increased risk of transformation (O'Shea et 
al. 2009). 
The frequency and prognostic value of the various cytogenetic associations is an 
important aspect of FL, however, a recent large study (n = 210) demonstrates that the 
complexity of cytogenetic aberrations does not associate with outcome (Johnson et 
al. 2008b). This emphasises that unravelling the underlying genetic events is a key 
aspect towards understanding the mechanisms that drive this disease. In this regard, 
although disruption of gene function is important in cancer, until recently little has 
been known as to its relevance in FL. However, mutations of the important tumour 
suppressor gene TP53, although only occurring in 6% of FL at diagnosis, are now 
known to associate with worse outcome (O'Shea et al. 2008) which is in keeping 
with the prognostic significance attributed to loss of chromosome 17p (Tilly et al. 
1994) which contains the TP53 locus.  
Other mechanisms may be important in FL but, although changes in RNA expression 
may reflect underlying gene disruption, a recent profiling study reveals a highly 
uniform pattern of gene expression at FL diagnosis (Glas et al. 2007) suggesting this 
approach may not be able to discriminate the critical events driving the malignant 
cells in this disease. Moreover, although DNA methylation appears important 
(Killian et al. 2009; O'Riain et al. 2009), the precise role of this phenomenon in FL 
remains unclear. Consequently, the genetic aspects of FL remain a fundamental area 
for exploration. Indeed, since commencement of this thesis project, other groups 
have identified mutations in two genes, FAS (Johnson et al. 2009a) and TNFRSF14 
(Cheung et al. 2010b), that predict FL outcome. Even more recently, genome-wide 
sequencing has revealed novel mutations in EZH2 (Morin et al. 2010a), CREBBP 
(Pasqualucci et al. 2011), MLL2 and MEF2B (Mendez-Lago et al. 2010; Morin et al. 
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2010b) at varying frequencies but all with potential functional significance giving 
intriguing new insights into FL which are discussed later in this thesis.  
1.5 Genetics of transformation 
The demonstration that loss 1p36 or 6q21-24 (Cheung et al. 2009b) as well as aUPD 
16p (O'Shea et al. 2009), when present at FL diagnosis, are independently predictive 
of future t-FL strongly suggests these regions contain factors that predispose to 
transformation. Sometime ago, loss 6q23-26 or 17p in FL were also associated with 
risk of transformation although insufficient events occurred to enable multivariate 
analysis (Tilly et al. 1994) and somatic mutations occurring in the first intron of 
BCL6 have since been shown to independently predict risk of t-FL (Jardin et al. 
2005). These molecular prognosticators may, in future, help guide a pre-emptive 
strategy aimed at preventing transformation. However, at present these genetic 
predictors have not been validated in prospective studies and do not form part of the 
standard diagnostic process, so they have yet to influence routine patient 
management. 
Other studies have attempted to determine transformation specific events which 
might therefore identify targets for therapy in the event that t-FL occurs. These have 
compared paired FL and subsequent t-FL biopsy samples from cases whose disease 
transformed.   
CGH studies have identified copy number changes detectable only at transformation. 
Gain 12q13-14 (including CDK4 and MDM2) occurred at transformation in half of 
the cases from a set (n = 24) with paired FL / t-FL samples (Hough et al. 2001). A 
small study (n = 6) then used micro-dissected FL tumour cells for comparison 
against paired t-FL samples and CGH analysis identified heterogeneous copy number 
changes acquired at transformation, including gain 7 in five cases (all initially grade 
1 or 2) (Boonstra et al. 2003). Another CGH study (n = 30) detected loss 6q16-21 
and gain 7pter-q22 only in t-FL (Berglund et al. 2007). Following the association of 
gain 7 with FL (Johansson et al. 1995), this was assessed further in FL and t-FL 
using a FISH probe which detected gain 7 occurring at FL progression and 
transformation (Bernell et al. 1998). As previously, new techniques have improved 
resolution for the detection of copy number changes affecting chromosomes and an 
Chapter 1 
45 
array-CGH study (n = 12) identified a range of copy number changes in both FL and 
t-FL (Martinez-Climent et al. 2003). In particular, 14 gains or losses that were not 
found in the diagnostic FL samples (or FL relapse) were present in t-FL samples with 
gains 12pter-12q12 and Xq25-q26 each detected in 2/10 t-FL but not in FL samples.  
Losses of 1p36 and 6q22-24 were present in 5/12 and 4/12 FL cases respectively 
suggesting enrichment in cases destined to transform. In a more recent study, LOH 
was detected more often at t-FL than FL and renders mutations of CDKN2A (9p) and 
TP53 (17p) homozygous in a subset of cases (Fitzgibbon et al. 2007). 
Mutations affecting TP53 were the first to be associated with transformation as 
reported by Lo Coco and colleagues. They detected TP53 mutation only at 
transformation in 3/5 t-FL cases and in both FL / t-FL samples from one of the two 
remaining cases whereas no mutations were detected in paired samples from a cohort 
of FL (n = 18) that had progressed but not transformed (Lo Coco et al. 1993).  Other 
reports indicate that TP53 mutations occur only rarely at FL diagnosis or 
progression, being more common at transformation (Sander et al. 1993; Davies et al. 
2005). Similarly, mutations and deletions of CDKN2A have been associated with t-
FL (Elenitoba-Johnson et al. 1998; Pinyol et al. 1998) and, indeed, loss of CDKN2A 
expression occurs with disease progression (Villuendas et al. 1998). Other 
mutational targets at transformation include BCL6 (Lossos and Levy 2000), BCL2 
(Matolcsy et al. 1996) and MYC (Lossos et al. 2002; Rossi et al. 2006) which is also 
frequently rearranged at FL progression (Lee et al. 1989; Yano et al. 1992). 
1.6 Evolution of t-FL  
The acquisition of additional genetic events at t-FL represents the culmination of the 
conventional model of FL progression by direct clonal evolution. Other studies have 
attempted to define functional models of transformation through expression 
profiling. These suggest roles for dysregulation of genes important in cell-cycle 
control including MYC and its target genes (Lossos et al. 2002; Davies et al. 2007) as 
well as MAPK (Elenitoba-Johnson et al. 2003) but the overall importance of these 
pathways in t-FL remains unclear. Moreover, the less common cases of composite, 
discordant and down-grade lymphoma (defined with regard to FL as: FL and 
DLBCL in same biopsy specimen; FL and DLBCL present simultaneously at 
different anatomical sites; and de novo DLBCL presenting subsequently with FL, 
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respectively) hint at complex evolutionary behaviour, while certain studies indicate 
genetic changes in FL / t-FL may occur non-sequentially. 
This was first suggested just over a decade ago by Matolcsy and colleagues who 
compared the SHM patterns from the IGH variable region in FL and DLBCL clones 
from a case of FL that transformed. This revealed certain SHMs were common to FL 
and DLBCL, some occurred exclusively in DLBCL but, importantly, others detected 
in FL were absent from DLBCL and a “common malignant ancestor” was proposed, 
in which divergent evolution of an FL subclone gave rise to DLBCL (Matolcsy et al. 
1999). Support for this model comes from the observation that a large proportion of 
t-FL samples lack cytogenetic or molecular alterations found in the preceding FL 
samples (Martinez-Climent et al. 2003; Fitzgibbon et al. 2007). Genetic changes in 
FL / t-FL can therefore be acquired in a pattern that does not mirror the clinical 
course of disease. Furthermore, a long-lived FL initiating cell can give rise to 
clonally divergent disease in separate patients, following transmission from donor to 
recipient of a haematopoietic stem cell transplant (Hart et al. 2007). Consequently, 
divergent (indirect) evolution from a common origin represents an alternative 
mechanism underlying transformation, a concept that is addressed further in Chapter 
5. 
1.7 Microenvironment 
In addition to the specific attributes of malignant cells, the cells which constitute the 
surrounding tumour microenvironment also have a significant role in FL. 
Significantly, Levy and colleagues demonstrated almost two decades ago that an 
immune response could be induced against autologous tumoral antigens in patients 
who had been treated for FL and this could lead to tumour regression in certain cases 
(Kwak et al. 1992). Subsequently, a large study by Dave and colleagues identified 
that RNA expression profiles derived from tumour infiltrating (non-malignant) 
immune cells independently associate with survival in FL (Dave et al. 2004) with 
favourable outcome for a profile enriched with T cell markers compared to a worse 
outcome with a profile containing predominantly macrophage derived markers. A 
more recent study that provides confirmation as to the importance of this association 
also addressed expression at the protein level, demonstrating that infiltrating 
macrophages associate with worse outcome (Byers et al. 2008). Several other studies 
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using immuno-histochemical staining have identified associations between tumour 
infiltrating immune cells and FL survival (Farinha et al. 2005; Alvaro et al. 2006; 
Lee et al. 2006a; Carreras et al. 2009). Although their results at times appear 
contradictory, a potential explanation is offered by one recent study which suggests 
the impact of tumour microenvironment on prognosis in FL depends on specific 
treatment protocols (de Jong et al. 2009). Furthermore, two relatively large studies 
have shown patterns of infiltrating T cells in FL correlate specifically with risk of 
future t-FL (Glas et al. 2007; Farinha et al. 2010) indicating it is not only tumour cell 
specific events that influence the process of transformation.  
Although the precise role of the cells that constitute the surrounding 
microenvironment in FL is not clear, an elegant review by Burger and colleagues 
(Burger et al. 2009) proposes three differing patterns of relationship between 
haematological cancers and the microenvironment. Two scenarios involve either 
tumour proliferation independent of stromal signalling, as in the case of Burkitt 
Lymphoma, or a dysfunctional environment in which tumour cells retain a 
dependence on stromal signalling for growth but “parasitize” in the 
microenvironment through altered stromal signalling, as in the case of the acute 
leukaemias. The third scenario (attributable to FL) involves a regulated co-existence 
of tumour cells with the microenvironment in which tumour proliferation is critically 
dependent on signals from the surrounding stroma. Furthermore, the association of a 
stromal cell ligand (APRIL) and FL cell receptor (TACI), causing proliferation of FL 
cells and cyclin D1 upregulation within them (Gupta et al. 2009), demonstrates one 
mechanism by which this might occur.  
Given the importance of the immune cell repertoire in normal B cell development, 
determining whether the acquired genetic changes that occur in FL modulate the 
interactions of these malignant B cells with the microenvironment may provide 
valuable insights into the progression of this disease. Alternatively, the associations 
between immune response and disease outcome might (at least to a degree) reflect 
innate differences in host ability to clear the malignant cells, suggesting an intrinsic 
immune predisposition to FL development.  However there remains much to learn 
about the microenvironment and its role in FL, and the sometimes contradictory 
findings require clarification so that their clinical relevance can be optimally 
established. 
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1.8 Predisposition to FL 
The potential relevance of immune predisposition to FL reflects a wider spectrum of 
both external (environmental) and internal (inherited) predisposing factors that 
contribute to cancer and which, in addition to the acquired genetic events already 
described, are relevant in FL. 
1.8.1 Environmental factors 
Significantly, the incidence of FL shows geographical variation, being higher in 
Western countries (Anderson et al. 1998), and studies hinting at an increased risk of 
NHL in spouses of cases have included occasional husband / wife FL pairs 
(Friedman and Quesenberry 1999; Villeneuve et al. 2009). Consequently, 
environmental factors may be important in FL and these have been examined in two 
recent comprehensive reviews of NHL epidemiology (Fisher and Fisher 2004; 
Alexander et al. 2007).  
Smoking is a major environmental carcinogenic determinant, as identified in a 
seminal report on lung cancer almost half a century ago (Doll and Hill 1964) and an 
association with FL risk is demonstrated in a recent meta-analysis (Morton et al. 
2005). Dietary factors may be also be relevant (Chang et al. 2005) as may use of 
hormone replacement therapy (Cerhan et al. 2002). In particular, the potential 
immune-modulatory properties of (allogeneic) blood transfusion have led to several 
studies investigating risk of FL following this procedure but a recent meta-analysis 
shows no association (Castillo et al. 2010). Furthermore, the increased use of 
pesticides over recent decades, their potential toxic effects and their early use in the 
Western world have, in combination with the concurrent increase in NHL incidence, 
prompted several association studies. Although pesticide exposure has been 
inconsistently associated with overall NHL risk, reports suggest a higher prevalence 
of t(14;18) containing cells in farmers exposed to pesticides (Roulland et al. 2004) 
and that development of t(14;18)-positive NHL is specifically associated with 
pesticide exposure (Schroeder et al. 2001; Chiu et al. 2006). Importantly, Agopian 
and colleagues have since demonstrated that pesticide exposure leads to clonal 
expansion of t(14;18)-containing cells and that these show similar properties to 
malignant FL cells (Agopian et al. 2009) providing a direct link between 
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environmental carcinogen exposure, t(14;18) frequency in peripheral blood and 
malignant progression which has significant public health implications. 
1.8.2 Familial predisposition 
Inherited predisposition may contribute to cancer and it is now four decades since 
Knudson first showed this for familial genetic determinants in retinoblastoma 
(Knudson 1971). Although it has been recognised for some time that germline factors 
contribute to risk of NHL (Linet and Pottern 1992), until recently less was known 
regarding the different subtypes.  
A report from the Surveillance, Epidemiology, and End Results (SEER) Program of 
the National Cancer Institute suggested that relatives of cases with FL had higher 
incidence of NHL (Chatterjee et al. 2004), and the multi-centre EpiLymph study 
showed an association between family history of haematological malignancy and risk 
of all lymphoid malignancies (although not specifically with FL) (Casey et al. 2006).   
However, an important report from the Swedish Cancer Registry (SCR) demonstrates 
that parental history of FL is associated with an increased risk of FL in offspring 
(Altieri et al. 2005). This was a cohort study surveying NHL cases diagnosed 
between 1993 and 2002 according to uniform histopathological criteria (Jaffe et al. 
2001) from a pool of almost 7 million offspring and over 6 million parents included 
in the registry.  Moreover, a subsequent study examining a larger cohort of FL cases 
(n = 2668) diagnosed between 1958 and 2004, and included in the (SCR), has 
demonstrated a fourfold increase of FL in parents and offspring (although not 
siblings) of FL cases as compared to control populations (Goldin et al. 2009). 
Consequently, these data suggest that a familial component does indeed contribute to 
risk of developing FL. 
1.9 Single nucleotide polymorphisms (SNPs)  
Studies have attempted to establish what heritable genetic determinants might confer 
the familial risk seen in FL. Two previous case reports of familial FL, one in a set of 
male monozygotic twins (Marco et al. 1999) and the other in a mother and daughter 
pair (Last et al. 2000), could not reveal any common genetic events. However, the 
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completion of the human genome project (Lander et al. 2001; Venter et al. 2001) has 
subsequently enabled germline genetic polymorphic variation between individuals to 
be examined in detail, particularly through the study of single nucleotide 
polymorphisms (SNPs).  
SNPs are termed “single-base differences in the DNA sequence that can be observed 
between individuals in the population” (Roses 2000) and represent heritable variation 
in the human genome. Within SNPs, the base with the higher frequency across a 
population can be termed the “A” (major) allele and that with the lower frequency 
the “a” (minor) allele giving the three possible genotypes of AA, Aa and aa (Figure 
1.6). Although SNPs may rarely involve more than two bases (by having alternative 
variant alleles) the vast majority involve only one major and one minor base, with 
this variation indicated as "A>a". SNPs therefore represent bi-allelic genomic 
markers and blocks of several SNPs that are consistently transmitted together can 
identify regions of the genome in high linkage disequilibrium (LD) termed 
haplotypes.  
Over 3 million SNPs have so far been described (Frazer et al. 2007) by the 
international haplotype mapping project ("The International HapMap Project" 2003), 
a consortium dedicated to determining human genomic variation with a view to 
identifying genetic determinants associated with human disease. At least 10 million 
SNPs are predicted to actually occur, with an estimated frequency of around one 
SNP every 100 to 300 bp.  
There is an increasing recognition that SNPs contribute to phenotypic differences in 
individuals. An example of this is the demonstration that the alleles of a single SNP 
(termed rs12913832) can differentiate blue and brown eye colour in a Northern 
European derived population (Sturm et al. 2008). This phenomenon appears to be 
mediated by the SNP minor allele (C) modulating DNA binding of a transcription 
factor at an intronic site 21 kb upstream of OCA2 that contributes to the expression 
of this gene (which is known to be important in human pigmentation).  
Moreover, a large study has examined the contribution of genome-wide germline 
genetic variation (using SNPs from the HapMap project) to variation in gene 
expression. It suggests that allele frequency differences may represent widespread 
functional variation in the human genome that can contribute to phenotypic  
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Figure 1.6  Single nucleotide polymorphism 
Illustration of a DNA sequence including one SNP with base C forming the major allele (in blue) and 
base T the minor, or variant, allele (in red) as indicated. Examples of surrounding DNA base 
sequences are given for each allele with the dashed lines representing the continuing dsDNA 
sequence. The SNP is termed with reference to the sense (+) strands. The three possible genotypes 
arising from the SNP (equivalent to AA, Aa, aa as detailed in the text) are illustrated. 
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differences both within and between populations (Stranger et al. 2007b). Notably 
population dependent variation in SNPs (as observed across the four different 
populations that were included in the HapMap project) is an important factor to 
consider in their investigation, giving a requirement for appropriately matched 
control populations in association studies. 
1.9.1 SNPs in FL 
The functional associations of SNPs may also be relevant in disease by influencing 
predisposition or clinical outcome.  Indeed, the observed familial associations with 
risk of FL may, at least in part, be determined by germline SNP variation. To date at 
least thirty studies have reported risk associations with SNPs in FL (Lossos et al. 
2001; Moller et al. 2002; Lincz et al. 2003; Matsuo et al. 2004; Skibola et al. 2005a; 
Skibola et al. 2005b; Willett et al. 2005; Nieters et al. 2006; Rollinson et al. 2006; 
Shen et al. 2006; Spink et al. 2006; Wang et al. 2006a; Wang et al. 2006b; Cerhan et 
al. 2007a; Lan et al. 2007; Lee et al. 2007; Novik et al. 2007; Purdue et al. 2007; 
Cerhan et al. 2008; Skibola et al. 2008a; Skibola et al. 2008b; Hoffman et al. 2009; 
Ismail et al. 2009; Morton et al. 2009; Novak et al. 2009; Skibola et al. 2009; Bracci 
et al. 2010; Conde et al. 2010; Kane et al. 2010; Nieters et al. ; Wang et al. 2010) 
and many of these have targeted SNPs in immune related genes, reflecting the 
relevance of the immune response in FL. However, considerably less is known 
regarding the impact of SNPs on clinical outcome in FL with few associations 
reported so far (Weng and Levy 2003; Jardin et al. 2005; Cerhan et al. 2007b; 
Hohaus et al. 2007; Racila et al. 2008; Han et al. 2010) and these, together with the 
risk associations, require independent validation. 
These studies have investigated small numbers of specific SNPs based on their 
association with genes which were either known or hypothesised to be relevant in 
FL. However, establishing the relevance of SNPs on a global genomic scale has 
benefited from a more systematic approach. This has been developed through the 
application of SNPs as genomic markers which, with the incorporation of specific 
probes for multiple different SNPs in micro-arrays, has led to the development of 
genome-wide association studies (GWAS). These studies have compared the allelic 
frequencies of hundreds of thousands of SNPs in case and control populations to 
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identify haplotypes and specific SNPs which associate with disease. Haplotypes can 
then be examined for specific genetic determinants of disease risk.  
GWAS have identified associations in both non-malignant conditions (for example 
bipolar disorder, coronary artery disease, Crohn's disease, rheumatoid arthritis, type 1 
and type 2 diabetes ("Wellcome Trust Case Control Consortium"  2007)) and various 
cancers, as recently reviewed by Stadler and colleagues (Stadler et al. 2010). Indeed, 
the first GWAS in FL has recently been reported and identifies polymorphic 
variation within the immune gene rich human leucocyte antigen (HLA) region on 
chromosome 6p21 as particularly important in FL (Skibola et al. 2009). 
1.10 Human Leucocyte Antigen (HLA) System 
The HLA region in humans, also termed the major histocompatibility complex 
(MHC) region, is associated with human disease. This region has been mapped ("The 
MHC sequencing consortium"  1999) and contains > 200 loci including the human 
leucocyte antigen (HLA) genes. These encode antigen presenting molecules which 
play a significant role in immune responses.  Similar functional properties of these 
proteins enable their grouping as Class 1 (HLA-A, B and C) which present non-self 
antigen to CD8+ T lymphocytes (cytotoxic T lymphocytes; CTLs) and Class 2 (HLA-
DR, DQ and DP) which present short antigen fragments to CD4+ T lymphocytes 
(helper T cells; TH) (Klein and Sato 2000a). The HLA loci show a high degree of 
polymorphic variability with multiple allelic variants described for each locus and 
this led to the introduction of standardised nomenclature which utilises a four digit 
code to distinguish HLA alleles that differ in the proteins they encode 
("Nomenclature for factors of the HLA system"  1988; Marsh et al. 2010). This 
diversity may affect antigen presentation and appears to be an important evolutionary 
phenomenon with differing alleles under selective pressure in different geographic 
regions (Parham and Ohta 1996) suggesting individuals possessing specific allele 
combinations gain a beneficial effect against deleterious events (such as infection).   
1.10.1 HLA and disease 
Specific HLA alleles predispose to a number of human diseases, particularly those 
with an autoimmune component or an infective basis.  The former involve an 
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aberrant response to self antigens whereas clearance of infection typically requires a 
targeted response to non-self antigens.  Differing HLA alleles may influence the 
presentation of both antigen groups and attendant modulations in immune responses 
may contribute to their association with disease risk. Therefore, perhaps not 
surprisingly, HLA associations with susceptibility to a wide range of auto-immune 
conditions as well as infections have been reported (Klein and Sato 2000b; Shiina et 
al. 2004; de Bakker et al. 2006). In certain instances an association with the clinical 
course of disease has also been attributed to HLA subtypes, such as progression of 
primary biliary cirrhosis (Nakamura et al. 2010). Furthermore, associations are also 
described with various tumours, indeed, a specific role for the HLA system in cancer 
predisposition has been recognised for some time with early reports indicating HLA 
antigen subsets associated with increased risk of nasopharyngeal carcinoma (NPC) in 
specific patient populations (Henderson et al. 1976) and over-representation of HLA-
DR5 in renal cell carcinoma (RCC) (DeWolf et al. 1981). Since these reports, the 
advent of PCR based DNA typing in the 1990s has greatly facilitated the high 
resolution discrimination of HLA alleles, precipitating the demonstration of both 
Class 1 and Class 2 associations with several other cancers (Shiina et al. 2004; de 
Bakker et al. 2006).  
1.10.2 HLA associations with lymphoma 
Within lymphoid malignancies, HLA antigen subtypes were recognised as important 
in the risk of endemic Burkitt Lymphoma three decades ago (Jones et al. 1980; Jones 
et al. 1985) with a link to childhood ALL also proposed at that time (Von Fliedner et 
al. 1983). More recently, specific HLA allele associations have been demonstrated 
for risk of Hodgkin Lymphoma (HLA-A*02) (Niens et al. 2007) and DLBCL (HLA-
DRB1) (Riemersma et al. 2006). Further study of MHC loci in NHL indicates both 
HLA and non-HLA loci are important in NHL. The TNF gene is a Class 3 MHC locus 
located on chromosome 6p21.3 between HLA-B and HLA-DR.  The role of TNF in 
lymphoid development, inflammation and cancer led to a study demonstrating 
polymorphic variation (TNF G-308A) predicts disease outcome in NHL and DLBCL 
(but not FL) (Warzocha et al. 1998). The variant allele (A) confers an increased risk 
of all NHL as well as DLBCL (Rothman et al. 2006; Skibola et al. 2010) and 
marginal zone lymphoma (Skibola et al. 2010) subtypes. In addition to the relevance 
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of the HLA loci on NHL risk, their influence on disease outcome has been assessed 
with HLA-DRB1*02 (Juszczynski et al. 2002) and a component of the AH 8.1 
ancestral haplotype (which includes HLA-A*01 and HLA-B*08) (Nowak et al. 2007) 
predicting both worse PFS and OS in NHL / DLBCL and NHL respectively (an 
effect independent of the IPI in a multivariate analyses). However, the role of the 
HLA loci in the risk and outcome of FL (including its transformation to DLBCL) has 
not been fully established. 
1.10.3 rs6457327 and rs10484561 
The GWAS performed by Skibola and colleagues (Skibola et al. 2009) identified a 
novel FL susceptibility locus within the MHC region on chromosome 6p21.33 
confined to a 26kb region of high linkage disequilibrium containing a single coding 
region, chromosome 6 open reading frame 15 (C6orf15). The validation of findings 
in three additional, independent cohorts conferred robust statistical significance, with 
a combined allelic P-value of 4.7  10-11 across the entire study of 645 cases and 
3377 controls for the association of this region with risk of FL. Two SNPs 
(rs6457327 and rs2517448) which are in complete linkage disequilibrium (LD) 
showed significant association with FL in the first phase of the study and subsequent 
genotyping of additional SNPs in their proximity delineated the 26kb risk locus. The 
sole gene within this locus, C6orf15, has also been termed STG following the initial 
identification of a homologue (rmSTG) expressed in simian taste buds (Neira et al. 
2001). It is located just telomeric to the psoriasis susceptibility region 1 (PSORS1) 
but does not itself associate with this disease (Sanchez et al. 2004).  
A further study has since expanded the initial GWAS through incorporation of a 
larger number of cases and performing analysis on non-pooled DNA in the first stage 
of the investigation (Conde et al. 2010). This confirmed the associations with FL 
from the initial study and identified that two further SNPs (rs10484561 and 
rs7755224) associate with risk of this disease. These are in complete LD and locate 
to chromosome 6p21.32, again in the MHC region, upstream and within 30kb of the 
HLA-DQB1 locus. Higher resolution SNP typing of this region identified additional 
SNPs in complete LD with rs10484561 and rs7755224 within a 100kb region of high 
LD containing HLA-DQB1 as well as HLA-DQA1 just downstream of HLA-DRB1. 
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One of these SNPs (rs6457614) is a tag SNP for HLA-DQB1*0501. Typing of this 
and two additional tag SNPs (markers for the haplotype most frequently containing 
HLA-DQB1*0501) revealed that the HLA-DRB1*0101 / HLA-DQB1*0501 / HLA-
DQA1*0101 / rs104845561 haplotype associates with risk of FL (P = 2.3  10-4).   
These two studies provide robust data as to the relevance of two segments within the 
HLA region that include rs6457327 or rs10484561, respectively, on chromosome 6p 
to risk of FL but the relevance of these loci to clinical outcome remains unknown. 
1.11 The MDM2-p53 axis 
Although SNPs rs6457327 and rs10484561 are strongly associated with FL risk, 
their functional relevance has not been determined. Conversely, SNPs influencing 
the MDM2-p53 axis, a critical component of cell-cycle control, have a role in several 
cancers but their contribution to FL is unknown. 
The p53 protein is the product of the TP53 gene and it maintains genomic integrity 
through initiation of DNA repair and acts as an inhibitory check-point to control cell-
cycle progression and appropriately select cells for apoptosis (Levine et al. 1991; Ko 
and Prives 1996; Vogelstein et al. 2000; Vousden 2000; Ryan et al. 2001). It acts as 
a transcription factor, the functional unit being a tetramer (Farmer et al. 1992), and 
induces the expression of several genes which mediate these processes (Jin and 
Levine 2001). In recognition of its central role in preventing cell-cycle disruption, a 
hallmark of cancer (Elledge 1996), p53 has been described as the “guardian of the 
genome” (Lane 1992). Indeed, loss of its tumour suppressor activity has long been 
recognised in malignant cells (Hollstein et al. 1991). 
Various cellular stresses (including, with particular relevance to cancer, DNA 
damage) activate p53 through at least three intra-cellular pathways (Vogelstein et al. 
2000) which lead to stabilisation and activation of the protein (Giaccia and Kastan 
1998). It then induces DNA repair mechanisms whilst the cell is held in growth arrest 
(Tanaka et al. 2000) or can induce apoptosis if the DNA damage is severe (Oda et al. 
2000a; Oda et al. 2000b). Both processes thereby prevent the replication of damaged 
DNA in daughter cells and are therefore pivotal in the early recognition and 
elimination of potential tumorigenic events. 
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Not surprisingly, this maintenance of genome integrity is tightly regulated and 
MDM2, the human homologue of the Murine Double Minute 2 protein (Mdm2), is a 
principle inhibitor of p53 function (Oliner et al. 1992). MDM2 binds p53 (Momand 
et al. 1992) inducing transit of this complex from the nucleus into the cytoplasm 
(Freedman and Levine 1998; Roth et al. 1998; Lain et al. 1999; Tao and Levine 
1999), so preventing the DNA binding necessary for its role as a transcription factor. 
Furthermore, MDM2 targets p53 for proteasomal degradation via its action as a 
protein ubiquitin ligase (Honda et al. 1997) and blocks p53 activation (Chen et al. 
1993; Oliner et al. 1993; Picksley et al. 1994). More recently, the critical need for 
Mdm2 to suppress p53 has been demonstrated in mouse models, where those lacking 
Mdm2 had spontaneous p53 activity and developed rapid and irreversible widespread 
apoptosis in bone marrow and intestine leading to loss of weight, diarrhoea, aplastic 
anaemia and death (Ringshausen et al. 2006). 
For optimal function p53 must escape the inhibitory action of MDM2, and this is 
possible through two processes. Firstly, phosphorylation of p53 by a series of protein 
kinases, including ATM (Banin et al. 1998; Canman et al. 1998), ATR (Canman et 
al. 1998), Chk1 (Shieh et al. 2000) and Chk2 (Hirao et al. 2000; Shieh et al. 2000) 
which form part of a molecular detection system for DNA damage, disrupts the 
binding site of MDM2. Secondly, other proteins (including Pim1) are recruited to 
form a p53 complex which induces a conformational change in p53 that further 
hinders MDM2 binding (Zacchi et al. 2002). However, p53 itself has a positive 
influence on MDM2 expression (Barak et al. 1993; Wu et al. 1993) providing an 
auto-regulatory negative feedback loop to prevent its uncontrolled activation.  
This intricate homeostatic control of p53 function mediated through MDM2 yields 
low levels of p53 in the normal intra-cellular environment that can rise rapidly 
following cell stresses, which include genotoxic insults causing DNA damage. This 
has led to this role of MDM2 being succinctly summarised as, “keeping p53 
checkpoint function in check” (Momand et al. 2000). 
1.11.1 MDM2 in cancer 
The importance of MDM2 homologues in tumour suppression has been 
demonstrated in animal models. Over-expression of Mdm2 in a mouse cell line 
Chapter 1 
58 
correlated with increased tumour formation (Fakharzadeh et al. 1991). Furthermore, 
a reduction of Mdm2 level by only a fifth in mice leads to a reduction in adenoma 
formation (Mendrysa et al. 2006) whereas increased expression leads to increased 
tumour formation (Jones et al. 1998). Human cancer cell lines may over-express 
MDM2 (Oliner et al. 1992) and one such cell line modulated to express a two fold 
increase in MDM2 shows reduced p53 function as compared to the unadulterated 
line (Ohkubo et al. 2006). Importantly, in primary human tumours MDM2 can be 
over-expressed and this may be associated with disease progression, resistance to 
therapy and survival (Cordon-Cardo et al. 1994; Freedman et al. 1999; Onel and 
Cordon-Cardo 2004). 
The alterations in MDM2 levels (and their impact in cancer) may arise as a 
consequence of disruption of its genetic locus. In mice, Mdm2 haplo-insufficiency 
leads to enhanced p53 function with increased sensitivity to DNA damage, lower 
transformation potential (Terzian et al. 2007) and delayed onset of lymphoma (Alt et 
al. 2003). In humans the MDM2 gene is located on chromosome region 12q12-14 
and amplification of this locus occurs in a range of tumours (Momand et al. 1998) 
and may be associated with increased expression of the MDM2 protein (Oliner et al. 
1992; Leach et al. 1993; Reifenberger et al. 1993; Florenes et al. 1994) notably in 
cases without TP53 mutations (Florenes et al. 1994). This is important in 
demonstrating the relevance of MDM2; as such mutations can prevent p53 feedback 
induction of MDM2 expression.  
However, in one form of haematological malignancy at least (acute myeloid 
leukaemia), increased expression of MDM2 can occur without gene amplification 
suggesting alternative contributory mechanisms (Bueso-Ramos et al. 1993). It seems 
unlikely that mutation of the MDM2 locus is such a mechanism as it is a rare event in 
cancer with only 3 single base pair substitutions identified in a series of 792 tumours 
in the Catalogue of Somatic Mutations in Cancer (COSMIC) database maintained by 
the Wellcome Trust Sanger Institute, Cambridge (Forbes et al. 2008), contrasting 
with the frequency of TP53 mutations in cancer. As regards MDM2 in FL, its locus is 
amplified in 52% of t-FL cases but not in the preceding FL counterparts (Hough et 
al. 2001) and MDM2 mRNA is increased between 10 and 45% in cases of t-FL 
compared to pre-transformation FL samples (Davies et al. 2005) suggesting that 
MDM2 and its expression may be relevant in the transformation of FL. 
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1.11.2 MDM2 SNP 309 
These acquired genetic changes demonstrate a role for the MDM2 protein in cancer 
including, notably, FL. However, germline genomic attributes including polymorphic 
variation may influence gene expression (Stranger et al. 2007a; Stranger et al. 
2007b; Shastry 2009) and a particularly important study by Bond and colleagues 
(Bond et al. 2004) identified that a SNP (T>G) located at nucleotide 309 in the first 
intron of MDM2 occurs in a region utilised by p53 to activate MDM2 transcription 
(Zauberman et al. 1995; Ries et al. 2000). The minor (G) allele was predicted to 
increase the length of a binding site for the transcription factor Sp1 and the study 
went on to demonstrate that Sp1 binding was enhanced by the presence of this 
variant. Furthermore, MDM2 levels correlated with the G allele and Sp1 binding at 
this site and a reduction in the stability of p53 was demonstrated in the presence of 
this allele (Bond et al. 2004). 
This SNP, rs2279744, is termed MDM2 SNP 309 and subsequent investigation 
revealed that the presence of the G allele associates with higher MDM2 protein 
levels and a lower apoptotic response than homozygosity for the T allele in surveys 
of cell lines (Bond et al. 2005) with homozygosity for the G allele associated with 
elevated MDM2 expression as compared to TT genotype (Hong et al. 2005). In the 
same year, the G allele was found to associate with inhibition of the transactivation 
of p53 dependent genes, as cell lines homozygous for this allele showed p53 binding 
to promoters of target genes but not transactivating them and this was due to MDM2 
being co-associated with p53 (Arva et al. 2005). In human subjects MDM2 SNP 309,  
is associated with worse prognosis in a variety of solid cancers including gastric 
carcinoma (Ohmiya, Taguchi et al. 2006) and oesophageal squamous cell carcinoma 
(Hong et al. 2005) where it is associated with increased risk of developing poorly 
differentiated carcinoma and advanced disease. Furthermore, a recent report has 
shown that homozygosity for the G allele predicts increased risk of death and earlier 
disease progression in the squamous cell carcinoma subgroup of oesophageal cancer 
(Cescon et al. 2009) and, significantly, the GG genotype correlates with earlier onset 
of de novo diffuse large B-cell lymphoma (DLBCL) in adult females (Bond et al. 
2006). The MDM2 SNP 309 G allele may also exert a dominant effect in tumour 
development as demonstrated in cases from families with the Li-Fraumeni syndrome 
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(who have heterozygous germline TP53 mutations) in which presence of the G allele 
(as either TG or GG genotypes) predicted earlier age at first tumour development 
(Bond et al. 2004). 
1.11.3 TP53 in cancer 
TP53 is the most common mutational target in cancer (Vogelstein et al. 2000) with 
over 26000 mutations described so far in the International Agency for Research on 
Cancer (IARC) TP53 database (version R15, November 2010), available at website 
http://www-p53.iarc.fr (Petitjean et al. 2007). The TP53 mutations typically translate 
in to deleterious amino acid changes and are often accompanied by loss of the second 
allele (Soussi et al. 2000). The multitude of acquired mutations described at the TP53 
locus (which also affect p53 function) can associate with poor outcome in a variety 
of solid tumours (Pricolo et al. 1996; Hardingham et al. 1998; Kandioler et al. 2002; 
Stander et al. 2004) and haematological cancers (Stirewalt et al. 2001) including 
DLBCL (Young et al. 2007). This reflects the importance of p53 disruption in cancer 
which is evident in FL where (as detailed earlier) TP53 mutations confer a poor 
prognosis (O'Shea et al. 2008) and are more common at disease progression or 
transformation (Lo Coco et al. 1993; Sander et al. 1993; Davies et al. 2005).  
1.11.4 TP53 Arg72Pro 
The frequency of TP53 mutations in cancer and the importance of p53 in cell cycle 
control suggest that germline variation might influence p53 function and the 
development or progression of tumours. Indeed, one well characterised SNP, 
rs1042522 also termed TP53 Arg72Pro, involves a non-synonymous substitution 
(G>C) at transcript nucleotide 466 of exon 4 in TP53 (Matlashewski et al. 1987). 
This effects an amino acid change (arginine to proline) at residue 72, which modifies 
the functional properties of the p53 protein by conferring reduced potential to induce 
apoptosis or suppress cell transformation (Thomas et al. 1999; Marin et al. 2000; 
Dumont et al. 2003), and has been associated with increased risk of solid tumours 
including lung cancer (Zhang et al. 2006) in which a multiplicative effect with 
MDM2 SNP 309 is observed. Another report identifies that an earlier onset of 
tumours in patients who carry a Li-Fraumeni germline TP53 mutation occurs in cases 
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with the MDM2 SNP 309 minor allele (G) and this effect may actually be amplified 
by presence of the TP53 Arg72Pro major allele (G) (Bougeard et al. 2006). Reports 
also suggest the SNP may be important in the clinical course of cancer including 
cases of squamous cell lung carcinoma in which homozygosity for the minor allele 
(C) is associated with worse outcome (Wang et al. 1999). 
However, despite the correlation of MDM2 expression and TP53 mutation with FL 
outcome and the association of both MDM2 SNP 309 and TP53 Arg72Pro in risk and 
outcome of other cancers, the role of these SNPs in FL remains unknown. 
1.12 Aims and objectives 
In light of the familial influence and diverse cytogenetic events, this project 
addressed the contribution of inherited and acquired genetic factors to FL and its 
transformation. 
The first phase of study aimed to assess the contribution of germline polymorphic 
variation influencing the MDM2-p53 axis (through MDM2 SNP 309 and TP53 
Arg72Pro) and occurring in the HLA region (at rs6457327 and rs10484561), to FL 
and its transformation. The second phase set out to identify important acquired 
genetic factors influencing transformation and the third phase sought to model the 
evolutionary basis of transformation. Specific objectives were the clinical correlation 
of the SNP genotypes in germline DNA from a large series of FL cases, the high 
resolution genetic profiling of a series of sequential FL and t-FL samples and the 
subsequent molecular mapping of FL / t-FL evolution. 
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Chapter 2    Materials and Methods 
Current regulations concerning health and safety at work were adhered to throughout 
the course of this study. 
2.1 Ethical Considerations 
Ethical approval was gained from East London and the City Health Authority (HA) 
Local Research Ethics Committee (LREC) with the following approval numbers: 
05/Q0605/140 “The impact of the tissue microenvironment and immune 
system on haematological malignancies” (with a substantial amendment in 
2007 to include: t(14;18) monitoring and genetic analysis of haematological 
malignancies); and 
06/Q0605/69 “Clonal evolution of indolent and aggressive lymphoma arises 
from a common B-cell ancestor”.  
The clinical information used during the course of the study was available from the 
clinical database maintained within the Department of Medical-Oncology at Barts 
and the London NHS Trust. To preserve patient confidentiality, each patient was 
assigned a unique identifier code under which relevant clinical information was 
supplied by the Data Manager. Only the database management team could access 
information that might identify patients.  
2.2 Patient Samples 
Relevant patient identifier codes were then used by the Tissue Storage Manager to 
identify appropriate and available patient samples for the study. These included those 
involved by lymphoma and were typically obtained from lymph node biopsies but 
occasionally from biopsies of skin, spleen or breast. Further patient samples not 
involved by lymphoma represented patient germline samples and were obtained from 
biopsies of bone marrow, peripheral blood, saliva, tonsil and (reactive) lymph nodes 
not involved by lymphoma. All study patients were required to have a diagnosis of 
FL and a cohort who all subsequently developed transformation to DLBCL and had 
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sequential samples available were also included. These diagnoses were confirmed 
prior to entry on the clinical database by expert histopathologists (Dr A Norton, Dr 
M Calaminici and Dr H Rizvi) through a weekly multi-disciplinary team meeting 
(MDM) held at Barts and the London NHS Trust. 
2.3 Cell lines  
Cell lines analysed included B-NHL, EBV transformed B-cell lymphoblastoid and 
myeloid cell lines which were obtained from Cell Services, Cancer Research UK 
(CRUK), Clare Hall Laboratories, South Mimms, Herts, UK. They were maintained 
as suspensions in RPMI-1640
®
 (Gibco) nutrient medium plus 10% foetal calf serum 
and 1% penicillin / streptomycin at 37C in sterile culture flasks in a humidified 
incubator with 5% CO2 (CB150; Binder, D-78532, Tuttingen, Germany). Cell 
concentration and percentage viability was determined using Trypan Blue 0.4% 
(Sigma) staining and manual cell counting on a haemocytometer under phase 
microscopy (Wilovert
®
, Helmut-Hund GmBH, D-6630 Wetzlar 21, Germany) prior 
to passage every 48 to 72 hours. 
2.4 DNA  
2.4.1 Genomic DNA extraction 
Patient DNA was obtained from tissue biopsy samples, cell suspensions, peripheral 
blood, bone marrow aspirates or saliva. Whole tissue from biopsy samples was used 
to make the cell suspensions prior to being snap frozen on day of biopsy procedure 
and stored in liquid nitrogen. Subsequently, the frozen tissue was removed and 
powdered using a pestle and mortar or frozen cell suspensions thawed at 37°C and 
centrifuged to obtain a white cell pellet. For peripheral blood and bone marrow 
samples, red cell lysis was initially performed through the addition of 10 volume of 
ddH2O prior to pelleting by centrifugation. The powdered sample or pellets were 
then incubated overnight at 55°C in digestion buffer (1mL per ~1  108 cells) with 
0.1mg/mL proteinase K. DNA was then extracted using the phenol / chloroform 
method (Gross-Bellard et al. 1973; Albarino and Romanowski 1994). Briefly, an 
equal volume of phenol was added to the digestion mix, spun at 14000rpm for 10 
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minutes at 4°C and the top (aqueous) layer removed. This was added to an equal 
volume of 50:50 phenol / chloroform mix, spun again, the aqueous layer removed 
and added to an equal volume of chloroform and spun once more. The aqueous layer 
was the removed and DNA precipitated by adding 1/10 volume 3M sodium acetate 
(pH 5.2) and 2 volume 100% ethanol. The DNA was pelleted by centrifugation 
before being washed in 70% ethanol and air dried prior to re-suspension in TE buffer 
and storage at 4°C. In certain cases, saliva was collected as a source of germline 
(non-tumour) DNA using the Oragene DNA collection kit (DNA Genotek Inc., 
Ottawa, ON, Canada) according to the manufacturer’s instructions.  
2.4.2 DNA quantity and quality determination 
These stock solutions of DNA were used to prepare working concentrations of DNA. 
To determine adequate quantity and quality of DNA, the light absorbance of stock 
solutions relative to the suspension medium (TE or tris) was determined using a 
NanoDrop
®
 ND-1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, 
USA).  The sample absorbance of light at a wavelength of 260nm generates an 
optical density (OD) value (OD260) which was multiplied by a factor of 50 to 
establish DNA quantity (ng/μl). OD at 280nm (OD280) was used to generate the 
OD260/OD280 ratio with values 1.80 - 2.00 indicating high purity (low protein 
contamination) of the DNA sample. A further measure of OD at 230nm (OD230) 
enabled the OD260/OD230 ratio to be established as a secondary measure of DNA 
quality (with high purity values > 2.0). 
2.4.3 Conventional (qualitative) polymerase chain reaction 
Conventional polymerase chain reaction (PCR) was performed in a volume of 20 to 
50μl in thin walled MicroAmp 0.2ml PCR tubes (Applied Biosystems, Foster City, 
CA, USA) or Thermo-Start 24 and 96 0.2ml well PCR plates (Thermo Scientific) 
on a PTC-225 Peltier Thermal Cycler (MJ Research, San Francisco, CA, USA) over 
30 to 40 cycles (with more amplification cycles performed particularly if DNA 
template levels were low). Reaction mixes were assembled on ice using dedicated 
work spaces, pipettes and filter tips. Each mix typically contained 1 PCR buffer 
with 1.5mM MgCl2, 1 unit of DNA Taq polymerase (Promega), deoxyribonucleotide 
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triphosphates (dNTPs) at 500μM, forward and reverse primers at 400 - 800nM 
(concentration determined after primer optimisation) and 10 to 50ng DNA. Cycling 
conditions consisted of an initial denaturation step at 94°C for 3 minutes followed by 
cycles of 94°C (denaturation), 54-66°C (primer annealing) and 72°C (extension) 
each for 30 - 60 seconds and a final step of at 72°C for 10 minutes to ensure full 
extension and deoxynucleotide addition at the 3’-terminal A overhang.  
Prior to each aspect of the study, specific reaction concentrations and annealing 
temperatures were optimised for respective primer combinations and the predicted 
amplicon length for each PCR reaction determined the extension time (based on a 
Taq polymerase rate of approximately 1000 bp per minute). Primers used are detailed 
in Appendix 2 Table 1. 
In the latter stages of the study, the HotStarTaq Plus DNA polymerase kit (Qiagen, 
Valencia, CA, USA) was used. This is a master-mix (consisting of buffer, hot start 
DNA polymerase, dNTPs) to which are added the respective primers and DNA 
template as well as a gel loading dye. This facilitated PCR on lower DNA 
concentrations, which helped to maximise use of samples with limited DNA stock.  
Success of the PCR reactions was assessed through agarose gel electrophoresis of the 
PCR products followed by inspection of photographs of the gels (as described in 
section 2.4.8 below). 
2.4.4 Allele specific oligonucleotide primers and probes 
The study required allele specific oligonucleotide (ASO) primers and probes for PCR 
mediated detection of acquired somatic hypermutation (SHM) sites in the 
immunoglobulin heavy chain variable (IGH-V) region, or DNA mutations, in certain 
FL and t-FL samples. Detailed inspection of IGH-V sequences was performed in 
order to identify combinations of SHM sites which were best suited as templates for 
primer design. Several ASOs were designed manually (using the general principles 
detailed by Lowe and colleagues (Lowe et al. 1990)) for each target and, after 
optimisation, the most specific (lack of non-specific amplification) and sensitive 
(most easily visualised PCR product) combinations were preferentially used in the 
study. 
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Fluorescently labelled ssDNA oligonucleotide probes (which bind the DNA segment 
between primers) facilitated SNP genotyping (section 2.4.5) or DNA quantitation 
(section 2.4.7) and were designed using Primer Express
®
 software v3.0 (Applied 
Biosystems). 
2.4.5 Allelic discrimination (AD) PCR 
A real-time PCR allelic discrimination multiplexed endpoint assay (AD-PCR) with 
the ABI PRISM
TM
 7700 or 7900HT Real-Time PCR Sequence Detection Systems 
(Applied Biosystems) was used to determine germline SNP genotypes. Reactions 
were performed at least in duplicate on a MicroAmp
®
 Optical 96 well (0.1ml) 
reaction plate with three positive controls (one for each possible SNP genotype) and 
a no DNA template control included in each AD-PCR run.  Each reaction included 
either: 
1 TaqMan® Universal PCR Master Mix (Applied Biosystems) [which 
incorporates the hot-start AmpliTaq Gold
®
 DNA polymerase to limit non-
specific DNA amplification, optimized buffer, dNTPs and a passive internal 
fluorescence reference (ROX™ dye)], 10ng DNA and the respective 
oligonucleotide primers (at 300 to 900 nM) and fluorogenic probes (at 150 to 
200 nM) in a final volume of 25l; or 
custom made Taqman
®
 Genotyping Assays (incorporating primers and 
probes) and 1 Taqman® Genotyping Master Mix (Applied Biosystems) 
[which is a more recent and further optimized master mix specific for SNP 
genotyping], with 2 to 10 ng of genomic DNA in a final volume of 10l. 
Probes specific to each SNP allele were labeled at the 5’ end with either 6-
carboxyfluorescein (FAM™) or proprietary VIC® fluorescent reporter dyes and at 
the 3’ end with tetramethyl-6-carboxyrhodamine (TAMRA™), a non-fluorescent 
quencher. The 5’ nuclease activity of the DNA polymerase resulted in cleavage of 
the probe during PCR elongation causing separation of the 5’ reporter dye from the 
3’ quencher. This generated an increase in fluorescence from the reporter dye 
specific to its respective SNP allele. Cycling conditions consisted of an initial 
AmpliTaq Gold
®
 activation step of 95°C for 10 minutes then 40 cycles of 95°C 
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(denaturation) for 15 seconds followed by 60°C (primer annealing and extension) for 
60 seconds. 
Interpretation of reaction end-point AD-PCR results was performed using the 
Sequence Detection Systems (SDS) software version 2.3 (Applied Biosystems) with 
real-time PCR curves generated during the AD-PCR runs used to determine 
genotypes in the cases deemed undetermined by end-point analysis. 
2.4.6 Control samples for establishing SNP risk associations 
To examine risk associations between SNPs and FL in the United Kingdom (UK) 
population, a case-control analysis was performed. Individuals with available 
genotype data from the Wellcome Trust Case Control Consortium 2 (WTCCC2) 
1958 birth cohort (BC58) formed control populations for the respective SNPs. 
Further details regarding the WTCCC are available on the website 
http://www.wtccc.org.uk.  
The BC58 cohort includes blood samples obtained from 3000 individual volunteers. 
The (germline) DNA from these samples had been applied to two genome-wide SNP 
micro-array chips, the Affymetrix SNP 6.0 (Affymetrix, Santa Clara, CA) and 
Illumina 1.2M (Illumina, San Diego, CA) platforms, enabling the genotypes of over 
one million SNPs to be determined for each case. These individuals were originally 
included in the second of four Perinatal Mortality Surveys (the others occurring in 
1946, 1970 and 2000/01) which enrolled all the people born in the week 3 - 9 March 
1958 in England, Scotland and Wales and was designed initially to examine social 
and obstetric factors associated with still birth and neonatal death, with its first 
results reported five decades ago (Butler 1961). They remain in long-term follow-up 
as part of the larger longitudinal National Child Development Study (NCDS) 
initiative and were approached between 2002 and 2004 in a collaboration funded by 
the Medical Research Council (MRC), involving the second project of the WTCCC 
(WTCCC2), for blood sampling and storage of their DNA for analysis. The 
individuals who provided these samples form the WTCCC2 BC58 cohort.  
For the current study, filtering was applied to the WTCCC2 BC58 results to enable 
control populations to be constructed for each target SNP. Cases in which the 
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respective SNP genotypes were not determined were excluded, furthermore 
individuals who were population outliers or showed significant relatedness were also 
excluded. These groups are only truly representative of the UK population born in 
1958 who stayed alive until 2002 - 2004, but they do represent a valid and close 
approximation to the current UK population. Importantly, the NCDS cohorts were 
augmented during the course of the longitudinal studies with immigrants who were 
born in the same time periods and so at least in part reflect the differing ethnic / 
racial distributions present in the UK. (This is significant as differing SNPs can have 
marked differences in allele frequencies within different human populations, as 
described in Chapter 1.)  
2.4.7 Quantitative PCR 
Real-time quantitative PCR (qPCR) was employed for the determination of t-FL 
DNA levels in preceding FL tumour samples. Reactions were performed in triplicate 
on a MicroAmp
®
 plate in a final volume of 25l including TaqMan® Universal PCR 
Master Mix (Applied Biosystems), IGH-VH region primers (400nM) and 5’ FAM™ 
labelled probe (200nM) with 500ng DNA. A control gene (β2M) was used to 
normalise the level of amplification and was assayed in parallel but using 240nM of 
primers and 80nM of probe. Reaction conditions were as indicated in Table 2.1. 
Working FL and t-FL DNA sample concentrations were 100ng/l with ten-fold 
dilutions (10
-1
 to 10
-5
) of the t-FL samples prepared in pooled peripheral blood 
mononuclear cell (MNC) DNA derived from eight healthy individuals to enable 
estimation of the level of any t-FL detected in the FL sample. Reactions were 
performed on the same 7700 / 7900HT systems as used for AD-PCR with results 
interpreted using SDS v.2.3 software.  
ASOs (section 2.4.4) were designed on SHM sites that were unique to the respective 
FL and t-FL major clones identified by homo-duplex band analysis (as described in 
section 2.4.9 below). A median of 5 different primers was designed for each t-FL 
major IGH-VH clone sequence. Sensitivity of different primer / probe combinations 
was determined by analysis of serial ten-fold dilutions (from 10
-2
 to 10
-5
) of t-FL 
DNA diluted in MNC DNA. Only primer / probe combinations optimised to a 
detection sensitivity of 10
-4
 were used, with two different combinations applied in 
Chapter 2 
69 
   
Table 2.1  qPCR conditions  
 
#To increase the resolution for detection of low level targets, amplification was performed 
over 50 cycles (as compared to 40 cycles which are typically used in qPCR). 
 
 
 
 
 
Table 2.2  12% polyacrylamide gel 
 
Constituent 
30% Acrylamide (29:1 acrylamide:bisacrylamide) 
H2O 
5 TBE 
10% ammonium persulphate  
TEMED* 
Volume (ml) 
40 
38.33 
20 
1.67 
0.083 
 
Total 100  
 
*TEMED added just prior to pouring of the gel to facilitate acrylamide polymerisation. 
Temperature* (°C) Time Cycles# 
50  
95  
95  
58  
2 min  
10 min 
15 s 
1 min  
 
 
50 
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separate reactions for each FL / t-FL pair analysed. Assays were performed in 
triplicate and specificity of reactions was indicated by no amplification in normal 
MNC derived DNA.  
2.4.8 Agarose gel electrophoresis  
DNA fragments were separated by agarose gel electrophoresis. Gels were made 
using agarose (Life Technologies, Paisley) dissolved in 1 TBE buffer to 2% by 
microwave melting with the volume made determined by the number of wells 
needed. After partial cooling either ethidium bromide (final concentration 0.5 μg/ml) 
or 1 GelRed (Biotium, Hayward, CA) solutions were added to the gel. The gel mix 
was poured into appropriately sized gel cast trays with combs applied to create 
sample wells. Samples mixed with 1 gel loading buffer were added to individual 
wells with either 1 kb (Gibco, Paisley, UK) or 100 bp (Promega, Madison, WI, USA) 
DNA ladders in a separate well as a size reference. Electrophoresis was performed 
with 2 to 10 Volts per cm applied across the gel in 1 TBE running buffer within an 
electrophoresis tank (Jencons Scientific Limited, Leighton Buzzard, UK). DNA was 
visualised by transillumination under ultraviolet (UV) light and photographed. 
2.4.9 Homo-duplex analysis 
For DNA homo- and hetero-duplex formation (to determine the major clones by 
IGH-V SHM pattern within FL and t-FL samples), PCR products were incubated at 
94°C for 5 minutes (denaturation) then 50°C for 1 hour (prolonged re-annealing). 
Following this, samples were promptly placed on ice, mixed with 1 gel loading 
buffer and applied to individual wells of a non-denaturing 12% polyacrylamide gel 
(made as indicated in Table 2.2 on the preceding page) with the 1 kb DNA ladder 
included as a size reference. 
Electrophoresis was then performed with 20mA applied to the gel in TBE running 
buffer for 14 hours at 4°C in a DV-2020 vertical electrophoresis tank (Scotlab Ltd., 
Luton, UK). The gel was then immersed for 30 minutes in TBE buffer containing 
ethidium bromide (2.5μg/ml) so that homo- and hetero-duplex bands could be 
viewed under UV transillumination. Small fragments (approximately 2  4 mm in 
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surface dimensions) containing the homo-duplex bands (representing the major 
tumour clones) were then excised from the gel and placed in separate 1.5ml micro-
centrifuge tubes prior to extraction of DNA. 
2.4.10 Gel Extraction 
DNA was extracted from gel fragments using the QIAquick
®
 Gel Extraction Kit 
(Qiagen, Düsseldorf, Germany) followed according to the manufacturer’s 
instructions. This system was used as it recovers purified DNA ≥70 bp and none of 
the predicted homo-duplex DNA complexes were smaller than this in size. The DNA 
products were then re-amplified by PCR, visualised through agarose gel 
electrophoresis and directly sequenced (following the method described below in 
section 2.4.12). 
2.4.11 Cloning 
For characterisation of differing IGH-V SHM patterns in tumour sub-clones, PCR 
products were cloned. The TOPO TA Cloning
®
 system (Invitrogen, Paisley, UK) 
was applied according to the manufacturer’s protocol. The technology utilises a non-
template-dependent terminal transferase activity of Taq polymerase that adds a single 
deoxyadenosine (A) to the 3’ ends of PCR products. Topoisomerase I generates 
specific breaks in the dsDNA of the plasmid vector creating single overhanging 3’ 
deoxythymidine (T) residues which then allows PCR products to ligate with the 
vector. Consequently, single PCR amplicons can be incorporated in to different 
plasmid vectors which are then transformed into E. coli. Following bacterial 
colonisation, individual colonies contain multiple copies of the DNA sequence 
(established from a single PCR amplicon). These can be amplified by PCR and their 
sequences compared to investigate any heterogeneity within the initial PCR product. 
A 4μl aliquot of fresh PCR product was incubated with 1μl salt solution (200 mM 
NaCl and 10mM MgCl2) and 1μl pCR
®
2.1-TOPO
®
 vector at room temperature for 5 
minutes. A 2μl aliquot of this reaction was then added to a vial of One Shot® 
chemically competent E. coli cells and incubated on ice for 30 minutes. The cells 
were then “heat-shocked” for 30 seconds at 42°C, placed on ice and 250μl of S.O.C. 
medium added before shaking the tube at 37°C for one hour. Either 50μl or 100μl 
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from each transformation was spread on pre-warmed agar plates containing 
ampicillin (50mg/mL) and X-gal (20mg/mL) with colonisation then performed by 
incubation at 37°C overnight. The pCR
®
2.1-TOPO
®
 vector contains an ampicillin 
resistance motif facilitating ampicillin mediated selection of only E. coli successfully 
transformed with the vector; it also contains a LacZα motif coding for β-
galactosidase (which cleaves X-gal creating a blue product) and M13 forward and 
reverse primer sites. The vector’s cloning site lies within the LacZα motif so 
successful incorporation of a DNA product disrupts transcription of this locus 
leading to white colonies. Individual white colonies were then directly used as DNA 
templates for PCR amplification using M13 forward (CATTTTGCTGCCGGTC) and 
M13 reverse (GTCCTTTGTCGATACTG) primers. 
2.4.12 Direct sequencing  
PCR products were directly sequenced using the dideoxy chain termination method 
(Sanger et al. 1977). Oligonucleotide primers and unincorporated deoxynucleotides 
were firstly removed by clean-up using the Montage
®
 spin filter column protocol 
(Millipore, Billerica, MA, USA) according to the manufacturer’s instructions or 
through an exonuclease I and shrimp alkaline phosphatase (SAP) protocol (ExoSap), 
as detailed in Table 2.3.   
Sequencing was then performed in a reaction volume of 10 or 20μl including BigDye 
Terminator
®
 Master Mix version 3.1 (Applied Biosystems) [which incorporates 
buffer, fluorescently labelled DNA chain terminators, deoxynucleotides and 
AmpliTaq DNA polymerase], the forward or reverse primer from the preceding PCR 
at a final concentration of 160nM and 1 to 2μl of cleaned PCR product. Reaction 
conditions included an initial enzyme activation step at 96°C for 1 minute, then 26 
cycles of 96°C for 30 seconds (denaturation), 50°C for 15 seconds (annealing) and 
60°C for 4 minutes (extension). 
Unincorporated dye terminators were removed using the DyeEx™ 2.0 Spin column 
kit (Qiagen), as per the manufacturer’s instructions, and each reaction then vacuum 
dried in a DNA 120 SpeedVac
®
 Concentrator (Savant Instruments Inc, Farmingdale, 
NY, USA). The dried DNA products were stored at -20°C and protected from light 
until their transfer for sequence reading by capillary electrophoresis on a 3730xl 
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Table 2.3  ExoSap protocol 
 
 
  
Reagents for  ExoSap master-mix 
ddH2O  
Exonuclease (20U/μl) 
SAP (1U/μl) 
Volume (μL) 
179 
1 
20 
 
Total 200  
Reaction mix Volume (μL)  
ExoSap master-mix   
PCR product  
Total 
2 
2.5 
4.5 
 
Conditions Temperature Time 
Reaction      
Enzyme inactivation 
37°C 
80°C 
4°C 
15 minutes 
15 minutes 
hold 
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DNA Analyser (Applied Biosystems) in a service provided by Dr Graham Clark, 
Equipment Park, Cancer Research UK (CRUK), 44 Lincoln’s Inn Fields, London. 
When high volume sequencing was performed, sequence reaction products were left 
in solution on 96 well plates and magnetic bead capture of DNA was performed by 
the Equipment Park using the Biomek
®
 FX liquid handling robot (Beckman Coulter, 
Brea, CA, USA) immediately prior to sequence reading. 
Sequence results were analysed and interpreted using the Lasergene
®
 Editseq and 
SeqMan
®
 software packages (DNAStar Inc., Madison, WI, USA) in combination 
with 4Peaks software (available at http://mekentosj.com/science/4peaks/). Visual 
comparison of sequences was performed against reference sequences obtained from 
the human genome release 18 on the Ensembl genome browser (available at 
http://www.ensembl.org). For analysis of IGH-V region sequences, comparisons 
were made to reference sequences obtained from the ImMunoGeneTics IMGT/V-
QUEST system (http://imgt.cines.fr).  
2.5 Genome-wide DNA copy number assay  
A detailed protocol for the assay was downloaded from www.affymetrix.com. Two 
protocols are available for the assay (Genome-Wide SNP 6.0 Assay for 48 or 96 
Samples and Affymetrix® Cytogenetics Copy Number Assay) the difference 
between the two being the number of samples processed in parallel and the method 
used to pool and purify PCR products. The Cytogenetics Copy Number Assay was 
followed in this study as it is tailored to lower volume sample throughput and 
determination of copy number changes (as opposed to the former protocol which is 
preferably used in high-throughput genome-wide association studies [GWAS]).    
2.5.1 Genomic DNA preparation 
To ensure success of the assay, high quality genomic DNA free from potential 
inhibitors of enzymatic processes and of sufficient quantity (500ng) to ensure an 
adequate level of PCR amplification was required.  
All DNA samples were subject to electrophoresis on 2% agarose gels. Samples that 
failed to reveal a band of approximately 10 to 20 kb in size (representing intact, high 
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quality genomic DNA) or those that showed smearing (indicating DNA degradation) 
were excluded at this stage as indicted in Figure 2.1. 
Concentrations of stock DNA samples were determined by the Nanodrop
®
 system 
and working dilutions of each were prepared by addition of the appropriate volume 
of ddH2O to achieve DNA concentrations of 50ng/μL in a volume of at least 10μL. 
High DNA quality in working dilutions was ensured by OD260/OD280 ratios of ~1.80.  
The DNA preparation, reagent storage and reaction mix preparation for the 
restriction enzyme digest, adaptor ligation and PCR steps of the assay occurred in a 
pre-PCR room to minimise risk of cross-contamination of genomic DNA by PCR 
products. The digest and ligation reactions were performed on a dedicated pre-PCR 
PTC-220 (DYAD™) Peltier Thermal Cycler (MJ Research). All reagents used in 
enzymatic stages were thawed on ice and the respective master-mixes prepared on 
ice. Although the protocol could be interrupted with storage of samples at -20°C after 
the digestion, ligation, PCR, pooling / purification and labelling steps this was 
avoided wherever possible, as is recommended by the manufacturer. 
2.5.2 Restriction enzyme digestion 
Master-mixes for two restriction enzymes, NspI and StyI (Table 2.4), were prepared 
on ice. For each sample, two separate DNA aliquots of 250ng in 5μL were prepared 
in parallel by addition of 14.75μL of one or other master-mix and mixed gently. The 
preparations were incubated at 37°C for 2 hours then 65°C for 20 minutes.  
2.5.3 Adaptor Ligation 
Ligation master-mixes were prepared on ice for NspI and StyI (Table 2.5) and 
5.25μL of the respective mix was added to the digested samples and mixed by 
pipetting. The 25μL reaction volume was incubated at 16°C for 3 hours then 70°C 
for 20 minutes. 
Immediately following this step, each DNA ligation sample was diluted by addition 
of 75μL ddH2O giving a sample volume of 100μL.  
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Figure 2.1  Genomic DNA quality assessment by agarose gel electrophoresis  
Patient DNA samples (n = 19) are indicated by the black bar. The majority (n = 16) show a band 
equivalent to molecular size >12 kb. Three samples show suboptimal DNA quality. One sample (*) 
had no detectable intact DNA and two other samples (#) showed smears indicating DNA degradation. 
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Table 2.4  Digestion master-mix for NspI or StyI 
Reagents 
NEbuffer 2 or NEbuffer 3 (10) 
BSA (100, 10mg/ml) 
NspI or StyI (10U/μl) 
H2O 
Volume (μl) 
2 
0.2 
1 
11.55 
 
Total 14.75  
 
 
 
Table 2.5  Ligation master-mix for NspI or StyI 
Reagents 
NspI adaptor or StyI adaptor (50μM) 
T4 DNA ligase buffer 
T4 DNA ligase (400U/μl) 
Volume (μl) 
0.75 
2.5 
2 
 
Total 5.25  
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2.5.4 PCR  
PCR reactions were performed in quadruplicate for the NspI and in triplicate for the 
StyI diluted ligated samples. PCR master-mix was prepared on ice as described in 
Table 2.6. A 10μl aliquot of the diluted ligated DNA sample from either the NspI or 
StyI processes was added to a fresh tube and mixed with 90μl of the appropriate PCR 
master-mix. The seven reaction mixes gave a combined PCR reaction volume of 
700μl for each DNA sample which was designed to ensure sufficient PCR product 
was generated to enable adequate DNA hybridisation to each array. Reactions were 
performed on a PTC-225 (Tetrad™) Peltier Thermal Cycler (MJ Research) under the 
conditions given in Table 2.7.  
To ensure consistent PCR results, a 3μl aliquot from each PCR reaction was run on a 
2% agarose gel at 120V for 30 minutes. Verification that the average product 
distribution was between 250 to 1100 bp was then performed by comparison with 
DNA ladder size markers on inspection of a gel photograph (as illustrated in Figure 
2.2).  
2.5.5 PCR product pooling and purification 
The PCR products from the seven reactions performed for each DNA sample were 
pooled together in one capped 2.0mL micro-centrifuge tube. A 100μl aliquot of 
AMPure® magnetic beads (Agencourt Bioscience, Beverly, MA, USA) was added to 
each pooled 700μl sample and mixed by gentle inversion 10 times. Following 
incubation at room temperature for 10 minutes, the samples were centrifuged at 
16100rcf for 3 minutes and then each tube was placed in a DynaMag™-2 magnetic 
stand (Invitrogen). The supernatant was carefully removed without disturbing the 
bead pellet which formed.  
Pellets were washed by the addition of 1.5ml 70% EtOH to each tube which was then 
shaken at 2000rpm for 2 minutes in a MixMate desktop shaker (Eppendorf, 
Hamburg, Germany). The sample tubes were then re-applied to the magnetic stand 
and the supernatant removed without disturbing the bead pellet. Each tube was 
centrifuged at 16100rcf for 30 seconds, placed back in the magnetic stand and the 
remaining small volume of liquid removed from the base of the tube without  
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Table 2.6  PCR master-mix 
 
Reagents 
Water 
Titanium Taq PCR buffer (10) (Clontech) 
dNTP (10mM) 
Betaine (5M) 
Primer 002 (100μM) 
Titanium  Taq (50) (Clontech) 
Volume (μl) 
39.5 
10 
14 
20 
4.5 
2 
 
Total 90  
 
 
 
Table 2.7  PCR conditions 
 
 
 
Temperature (°C) Time Cycles 
94  
94  
60  
68   
68   
4    
3 min  
30 s 
30 s 
15 s  
7 min  
hold overnight 
  
 
30 
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Figure 2.2  PCR product visualization 
An example demonstrating that PCR product distribution was between 250 to 1100 bp. The black bar 
indicates test sample PCR products.  
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disturbing the pellet. The tubes were then left uncapped at room temperature for 15 
minutes to enable evaporation of any residual EtOH. 
DNA was eluted from the magnetic bead by addition of 55μL Tris-buffer to each 
tube which were then vortexed for 1 minute and shaken for 10 minutes at 2000rpm 
on the MixMate to re-suspend the beads. Following this, the tubes were centrifuged 
at 16100rcf for 30 minutes and then placed in the magnetic stand for 5 minutes. 
Taking care not to disturb the bead pellet, 47μL of the eluted sample was removed. 
2.5.6 Quantitation 
A 2μL aliquot of each purified sample was added to 18μL of ddH2O in separate wells 
of a 96 0.2mL well plate and mixed by pipetting, giving a 1/10 dilution. Sample 
quality and quantity were determined using the Nanodrop
®
 system. An OD260/OD280 
value between 1.8 and 2.0 was acceptable and a DNA yield of 450 to 700 ng/μL was 
required (representing a concentration in the purified sample of 4.5 to 7 μg/μL).  
2.5.7 Fragmentation 
A 5μl aliquot of 10 fragmentation buffer was added to each purified sample. Care 
was taken to minimise handling of the fragmentation enzyme (DNase I) tube in view 
of its extreme temperature sensitivity during preparation of the fragmentation master-
mix. Enzyme concentration could vary by batch so the volumes of DNase I and H2O 
in the master-mix were adjusted to give a final DNase I concentration of 0.1 U/μL as 
indicated in Table 2.8. The water and fragmentation buffer were mixed and allowed 
to cool on ice for 5 minutes prior to addition of the enzyme. After briefly vortexing 
(3  1 second) followed by spin down for 30 seconds, 5μL of the master-mix was 
added to the sample with fragmentation buffer giving a reaction volume of 55μL. 
These samples were incubated at 37°C for 35 minutes then 95°C for 15 minutes to 
terminate the enzyme activity. The labelling step was immediately commenced and, 
while the labelling reaction was underway, 2μl of each fragmentation reaction were 
run on 2% agarose gel by electrophoresis at 120V for 20 minutes to confirm 
fragment sizes were < 180 bp (Figure 2.3). 
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Table 2.8  Fragmentation master-mix 
Reagents 
Water 
10 Fragmentation buffer 
Fragmentation  reagent (DNase I) 
Volume (μL) 
4.5 - x 
0.5 
x 
 
Total 5  
N.B. x = [0.1/y]*5 (where y = fragmentation reagent concentration; range 2 to 3 U/μL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3  Visualisation of fragmentation products 
Pooled and fragmented PCR products from 6 samples run on agarose gel demonstrating fragment 
sizes <180 bp. 
 
 
Ladder Samples 
134 bp 
220 bp 
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2.5.8 Labeling 
The labeling master-mix was prepared as indicated in Table 2.9, with 19.5μL added 
to the remaining fragmented sample which was then incubated at 37°C for 4 hours 
then 95°C for 15 minutes.  
2.5.9 Hybridisation mix 
A hybridisation master-mix was prepared as detailed in Table 2.10 and 190μL added 
to each labelled sample (72.5μL) in a fresh 1.5mL micro-centrifuge tube. These 
samples were then passed to the designated Affymetrix micro-array operator in our 
institution (Mrs T Chaplin) who performed hybridisation, washing, staining and 
scanning of the array chips. 
2.5.10 Hybridisation, washing, staining and scanning 
Each sample of hybridisation mix and labelled DNA was incubated at 95°C for 10 
minutes and then 49°C, at this stage 200μl of the sample mix was removed and 
loaded into individual arrays pre-warmed to room temperature. After sealing the 
loading ports on the chips, they were placed in a GeneChip
®
 Hybridisation Oven 640 
(Affymetrix) and rotated at 50°C, 60rpm for 16 to 18 hours to enable DNA 
hybridisation onto the array. After extraction of the hybridisation mix, each array 
was washed and stained in the GeneChip
®
 Fluidics Station 450 (Affymetrix). An 
initial wash performed with 6 SSPE, 0.01% Tween 20 buffer at 25°C was followed 
by a stringent wash with 0.6 SSPE, 0.01% Tween 20 buffer at 45°C. A three step 
staining process was then performed with, firstly, 10μg/mL streptavidin R-
phycoerythrin (SAPE) (Molecular Probes, Paisley, UK) applied to the chip to bind 
the biotin labelled DNA fragments that had been hybridised to the probes on the 
array. Following a further wash with 6 SSPE, 0.01% Tween 20 buffer at 25°C, 
signal amplification was enabled by addition of 5μg/mL biotinylated goat anti-
streptavidin antibody (Vector Laboratories, Burlingame, CA, USA) and further 
10μg/mL SAPE to each array. The three staining steps were performed in a 6 SSPE, 
0.01% Tween 20, 1 Denhardt’s solution buffer at 25°C and were followed by a final 
wash with 6 SSPE, 0.01% Tween 20 buffer at 30°C. The arrays were scanned in a  
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Table 2.9  Labelling master-mix 
Reagents 
Terminal deoxynucleotidyl transferase (TdT) buffer (5) 
DNA labeling reagent (30mM) 
TdT (30U/μL) 
Volume (μL) 
2 
14 
3.5 
 
Total 19.5  
 
 
 
 
Table 2.10  Hybridisation master-mix 
Reagents 
MES (12; 1.25M) 
Denhardt’s solution (50) 
EDTA (0.5M) 
HS-DNA (10mg/mL) 
OCR, 0100 
Human Cot-1 DNA
®
 (1mg/mL) 
Tween-20 (3%) 
DMSO (100%) 
TMACL (5M) 
Volume (μL) 
12 
13 
3 
3 
2 
3 
1 
13 
140 
 
Total 190  
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GeneChip
®
 Scanner 3000 7G (Affymetrix) and signal intensity values for each 
hybridised probe were obtained using Affymetrix GeneChip
®
 Command Console 
(AGCC) software. 
2.5.11 Data Preparation for Analysis 
Using AGCC, the signal intensities from each probe were adjusted for background 
signal intensities on the array to create normalised image files (.cel files). Three 
quality control (QC) steps were performed with Genotyping Console™ on the .cel 
file data:  
i. An estimate of the efficiency of signal generation from all probes on the 
array was provided by measuring the Call Rate on a sub-set of 3022 
SNPs. A level >97% indicated a satisfactory performance of the assay 
from the initial DNA digestion step through to the array scanning; 
ii. The accuracy of discrimination of the three allele combinations for each 
SNP was estimated by the Contrast QC algorithm (CQC) which is a better 
indicator of genotyping performance for samples than the Call Rate alone. 
Values >0.4 were satisfactory provided no more than 10% of sample 
values <1.0 and mean value across the sample set >1.7 (Affymetrix White 
Paper: Quality Control Assessment in Genotyping Console™; September 
30, 2008 Revision 1); and 
iii. The log2ratio of target sample to reference sample normalised probe 
signal provided the relative copy number, for the target sample, at the 
DNA location complementary to the probe. The Median Absolute 
Pairwise Difference (MAPD) was calculated as the median of all values 
produced from determining the differences between log2ratios for each 
adjacent pair of probes (in terms of genomic distance) on the array. 
MAPD therefore estimated variability in the log2ratio and reflected 
accuracy of copy number estimation with values <0.4 considered 
satisfactory (Affymetrix White Paper: Median of the Absolute Values of 
all Pairwise Differences and Quality Control on the Affymetrix Genome-
Wide Human SNP Array 6.0; February 11, 2008 Revision 1).   
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Samples with QC values outside these limits were likely to provide less reliable 
results and factors contributing to poorer performance of the assay include 
suboptimal quality of initial DNA sample, non-adherence to protocol and variation in 
reagents including the hybridisation cocktail. A further limitation was presence of 
germline DNA in tumour samples as this would also generate signals by 
hybridisation to probes. As genotyping calls are determined from ratios of one allele 
signal to the other, the presence of germline signals in combination with target 
(tumour) signals can generate a combined signal that is outside the limits utilised by 
the software algorithms for genotype allocation. Genotype is then not assigned and 
the probe signal is classed as a “no call” (as are any failed probe hybridisations). 
Similarly, as copy number loss or gain is a ratio of target to reference, the degree of 
these changes in a tumour target can be underestimated by the effect of co-occurring 
normal copy number signal from germline tissue within the sample that effectively 
dilutes the signal of tumour DNA. Two study aspects help to limit these issues: 
i. samples with at least 70% tumour content (<30% germline tissue) are 
preferably used as the software algorithms can most robustly determine 
genotyping and copy number changes above this level; and  
ii. where possible, target samples are compared to paired separate germline 
samples from the same case thereby maximising detection of features 
specific to the target DNA 
The .cel file data was exported in to the PARTEK
®
 Genomics Suite (Partek 
Incorporated, St Louis, MI, USA), a software package in which genotype and DNA 
copy number could be determined. A second platform, the Genome Orientated 
Laboratory File (GOLF) software, developed and maintained by Professor Bryan 
Young within this institution (and available at 
https://bioinformatics.cancerresearchuk.org/~cazier01/Golf.html), was also used in 
data analysis. Datasets compatible with GOLF were established by applying the 
Affymetrix Genotyping Console™ Software Birdseed algorithm to the .cel file data. 
This assigned genotype calls (.chp file) and signal intensities for copy number state 
determination (.cn.chp file). Data was extracted from these files as tab delimited text 
(in .txt and .si files respectively) and exported into GOLF. 
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2.5.12 Analysis workflow 
DNA copy number changes were determined as a relative change of the target 
sample (tumour DNA) signal intensity compared to the corresponding signal 
intensity of a paired baseline reference (germline DNA) using log2 ratios (as 
indicated in section 2.5.11). The germline baseline consisted of DNA extracted from 
bone marrow / peripheral blood / saliva samples that were uninvolved by lymphoma. 
For cases with no germline DNA available, a pooled reference, constructed by taking 
the median values of each probe signal across unpaired germline samples (n = 17), 
served as a baseline. Direct comparison of t-FL to FL was not performed as this 
could create misleading CN estimates as these are established relative to baseline so, 
for example, a loss in FL could be interpreted as gain in t-FL (as illustrated in 
Appendix 1 Figure 1). Consequently, FL and t-FL were each assessed relative to the 
germline baseline. This established separate FL and t-FL CN estimates that could 
then be compared so establishing the actual (rather than relative) differences between 
samples. 
2.5.13 Segmentation 
The Partek Genomics Suite includes two algorithms to determine copy number. The 
first is based on the statistical hidden Markov model (HMM) and is best used on a 
homogenous cell population with anticipated integer value copy numbers. However, 
by the nature of FL / t-FL there are both normal and tumour cells within samples 
which can provide heterogeneity to copy number values. As it can account (at least in 
part) for this variation a second algorithm (termed segmentation), which compares 
adjacent regions using differences in the log2 values to determine aberrations in copy 
number, has been developed and was applied here. Segmentation has the additional 
benefit that it uses a two sample t-test to determine whether there is a difference 
between the mean log2 ratio for adjacent regions allowing identification of adjacent 
segments with similar copy number. 
Varying parameters contribute to determining each segment. Firstly, as the number 
of consecutive genomic markers determines the size of a segment, resolution was 
maximised by defining the smallest segments as those with the minimum number of 
genomic markers (n = 10) as recommended by the segmentation algorithm. The 
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median spacing of markers on the array is 700bp giving a resolution of around 
7000bp with this approach (although this varies throughout the genome due to 
differing probe densities and spacings on the array). A range of spread above or 
below the baseline of the log2 ratios (typically 0.3) was set as the threshold for 
allocation of “gain” or “loss” to a possible copy number change in the sample under 
investigation. As the samples included a degree of germline tissue, the relative copy 
number (section 2.5.12) could be underestimated and in order to minimise this, the 
range was varied on a case-by-case basis. For 30 / 31 cases, the values were 0.2 to 
0.3 with a single case requiring a range of 0.13 due to a higher proportion of normal 
tissue. A one-sided one sample t-test was performed by the Partek genomics suite to 
establish if segments were significantly above or below the range and a stringent P 
value (<1  10-4) was used to minimise the inclusion of false positives. 
However, each sample contains within in it signal intensities attributable to 
background “noise” (non-specific signal) which may cause false positives to be 
included in copy number estimates. Consequently, reducing the range to increase 
detection of copy number changes can reduce specificity of the analysis by 
increasing the number of false positives. The “signal to noise” coefficient (the ratio 
of mean difference of the signals of two neighbouring segments to the standard 
deviation of the signals from the whole chromosome) can limit this effect and so a 
stringent cut-off level (0.8) was applied to the data set to limit the number of these 
false positives. A guide to this level is provided by the segmentation copy number 
results; if on inspection of the traces clear false positives are being included the 
signal to noise coefficient can be raised until these are (largely) eliminated. 
2.5.14 Exclusions 
As a subset of cases did not have paired germline DNA available, the copy number 
estimates for the respective tumours could include artefact changes at the sites of 
known polymorphic copy number variations (CNVs) (Iafrate et al. 2004; Redon et 
al. 2006; McCarroll et al. 2008) present in samples within the DNA germline pool 
(but not necessarily the investigated sample). Consequently, known CNVs (as 
previously determined on the SNP 6.0 array (McCarroll et al. 2008) were excluded 
from the copy number estimates of these samples as it was not possible to determine 
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if apparent gains or losses at these sites were real or were false positives due to 
CNVs in the baseline pool (analogous to the erroneous CN estimates that could occur 
by comparing t-FL directly to FL).  
FL is a germinal centre derived B-cell malignancy and the tumour cells have 
undergone the normal B-cell process of V(D)J recombination at IGH, IGK +/- IGL 
(as described in Chapter 1) which can be used to indicate clonality of the B cell 
population (as shown for all 109 FL cases examined in a recent report (Evans et al. 
2007)). As a consequence, these loci were also excluded from the copy number 
determination as CNA losses here might represent this normal B-cell process (which 
excludes segments of the respective genes). The T cell receptor loci, TCRA / TCRB / 
TCRG / TCRD, were also excluded for two reasons: firstly, in polyclonal T cells of 
healthy individuals a large proportion of those with TCR show restriction to V9–
J1.2 and V2–J1 (Triebel et al. 1988; Breit et al. 1994) so any infiltrating T-cells 
within biopsies might create a loss at  (chromosome 7p14.1) or  (chromosome 
14q11.2) loci and, secondly, TCR re-arrangements may be detected in 10 - 13% of 
FL (Szczepanski et al. 1998; Evans et al. 2007). 
2.6 RNA 
Total RNA was extracted for gene expression analysis. The extraction method 
preferentially collected RNA >70bp, enriching for mRNA. Random hexamers were 
used in reverse-transcription to give maximal conversion of RNA to cDNA as both 
spliced and unspliced variants were assessed. 
2.6.1 RNA extraction 
The RNeasy
®
 plus Mini kit (Qiagen, Hilden, Germany), which involves a series of 
steps performed in spin columns by centrifugation, was used for extraction of RNA 
from primary sample cell suspensions and cell line cultures according to the 
manufacturer’s instructions. Briefly, around 3  106 cells were lysed in buffer 
containing guanidine-isothiocyanate to inactivate RNases then homogenized through 
a QIAshredder (Qiagen) spin column. After centrifugation in a genomic DNA 
eliminator column, RNA was captured in a silica-membrane then purified through 
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spin column washes and finally eluted in 30μl RNase-free H2O. RNA was then used 
immediately or stored at -80°C. 
Quality and quantity of the sample was determined using the NanoDrop
®
 system (as 
described in section 2.4.2), but using an RNA mode with the absorbance at 260nm 
multiplied by a factor of 40 to give RNA quantity and satisfactory sample quality 
indicated by OD260/280 ratio ~2.0 and OD260/230 ratio1.8 - 2.2. 
2.6.2 RT-PCR: two step process 
Two-step RT-PCR assessment of RNA expression involved first-strand cDNA 
generation with the M-MLV Reverse Transcriptase RNase H Minus, Point Mutant 
kit (Promega, Madison, WI, USA) according to the manufacturers protocol. This 
involved incubation of the total RNA preparation in the RNA random hexamer 
annealing mix (as detailed in Table 2.11) at 70°C for 5 minutes followed 
immediately by cooling on ice for 5 minutes. The reverse-transcription (RT) mix 
(Table 2.12) was then added to the RNA preparation with incubation performed for 
one hour at 42°C followed by a final step at 95°C for 5 minutes to inactivate the RT 
reaction. Second strand cDNA synthesis and PCR amplification were then performed 
in combination by using the HotStarTaq Plus DNA polymerase kit (as described in 
section 2.4.3). 
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Table 2.11  First Strand cDNA synthesis: RNA random hexamer annealing mix 
 
Reagents 
Total RNA* sample 
RNase free H2O 
Random hexamers (50μM) 
Volume (μL) 
x 
10.5 - x 
1.5 
 
Total 12  
*1μg of RNA was used (but differing sample concentrations meant volume [x] could vary) 
 
 
 
 
 
Table 2.12  First strand cDNA synthesis: reverse-transcription mix 
 
Reagents 
5 M-MLV RT reaction buffer  
dNTPs (10mM) 
M-MLV RT (H-) 
Volume (μL) 
6 
10 
2 
 
Total 18  
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Chapter 3    Germline factors  
3.1 Introduction 
The increasing appreciation that germline genetic factors contribute to cancer both 
through conferring predisposition to its development and by impacting on the clinical 
outcome of established malignancy led to the first phase of this project.  
The advent of GWAS that can identify germline polymorphic variation, in the form 
of SNPs, with clinical associations has been a significant advance in the study of 
inherited determinants of disease. As SNPs can influence genetic regulation through 
various mechanisms including the modulation of transcription factor binding sites 
and generation of amino acid substitutions, they might influence cancer development 
and progression. A growing body of evidence suggests that this indeed the case and, 
in FL, several studies have investigated risk of developing disease particularly with 
regard to immune-gene related SNPs as detailed in Chapter 1. However, far less is 
known as to the effect of such polymorphic variation on the outcome of FL.  
To address this further, four SNPs which might be relevant to the clinical course of 
FL, as indicated by their potential biological effects and known clinical associations, 
were included in the study. Two of the SNPs, rs2279744 (known as MDM2 SNP 
309) (Bond et al. 2004) and rs1042522 (known as TP53 Arg72Pro) (Matlashewski et 
al. 1987), are well characterised functional SNPs that can modulate the MDM2-p53 
axis, a critical tumour suppressor pathway. TP53 is one of the most important tumour 
suppressor genes and its protein product (tumour protein 53; p53) has a critical role 
in cell-cycle progression, initiation of DNA repair and the appropriate selection of 
apoptosis (Levine et al. 1991; Ko and Prives 1996; Vogelstein et al. 2000; Vousden 
2000; Ryan et al. 2001). As maintenance of genome integrity is highly regulated, p53 
activity is tightly controlled and is suppressed by MDM2, its principal inhibitor 
(Oliner et al. 1992), until various cellular stresses, including DNA damage, lead to 
upregulation of its activated form (Giaccia and Kastan 1998; Vogelstein et al. 2000). 
However, although acquired defects in the MDM2-TP53 axis are important in FL 
(Davies et al. 2005; O'Shea et al. 2008) and both MDM2 SNP 309 and TP53 
Arg72Pro are known to impact on risk and outcome of other cancers, the role of 
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these SNPs in FL remains unclear.  
Two further SNPs, rs6457327 and rs10484561, were recently identified as robust risk 
predictors in the first genome-wide association studies (GWAS) of FL. Both are 
within the immune gene rich human leukocyte antigen (HLA) region on chromosome 
6p21 with rs6457327 in a 26 kb region of high linkage disequilibrium (LD) that 
contains only one coding region C6orf15 (Skibola et al. 2009) and rs10484561, 
upstream of HLA-DQB1, located in an independent 100 kb region of high LD (Conde 
et al. 2010). The GWAS used a three stage process to provide robust validation of 
the risk associations of both SNPs with FL but the relationship of rs6457327 and 
rs10484561 to FL outcome has not yet been examined. 
3.2 Aims and objectives 
The role of disruption to the MDM2-p53 axis in FL and the known contribution of 
MDM2 SNP 309 and TP53 Arg72Pro to the outcome of other cancers, together with 
the risk associations of rs6457327 and rs10484561 with FL and the importance of the 
immune response to the clinical outcome of this disease, led to this study to 
determine the relevance of these four SNPs to the clinical course of FL and its 
transformation.  
Study objectives included examination of the respective SNPs’ genotypes in a large 
series of DNA samples from patients diagnosed with FL and comparison of genotype 
frequencies to non-FL cases so that associations with disease risk could be examined.  
The associations of genotypes with both patient presentation characteristics and 
clinical outcome variables were established; and significant clinical outcome 
associations were addressed in a subset of cases that had originally presented to this 
institution and so had extensive, comprehensive follow-up data. Finally, the potential 
molecular basis of positive associations was explored through assessment of a linked 
genetic locus.  
Data generated from the two phases of this chapter have subsequently been published 
over the course of this thesis (Wrench et al. 2009; Wrench et al. 2011). 
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3.3 Materials and Methods 
3.3.1 Case selection 
Study cases (n = 231) were selected retrospectively from the haemato-oncology 
database maintained at St. Bartholomew’s Hospital. Cases were included in this 
study if the following criteria were met: 
1. Prior histological diagnosis of FL 
2. One tissue sample not involved by tumour taken at some point over the 
disease course 
3. Sufficient amount of previously extracted DNA available in the tissue archive 
at St Bartholomew’s Hospital from the uninvolved sample OR sufficient 
quantity of uninvolved tissue available for DNA extraction  
4. Satisfactory DNA quality (Section 2.4.2) 
3.3.2 Samples  
The uninvolved DNA samples represented germline and were used to determine the 
constitutional SNP genotypes of each case. The sample tissue sources included bone 
marrow or peripheral blood samples (n = 226) and rare reactive lymph node samples 
(n = 5), which were uninvolved by lymphoma and obtained throughout the course of 
disease from patients diagnosed with FL between 1977 and 2005 and managed at 
Bart’s and the London NHS Trust.  
In addition, DNA from diagnostic FL samples obtained at this institution (n = 50) 
and from FL samples (n = 12) examined in a previous investigation conducted by 
this institution in collaboration with the LLMPP (O'Shea et al. 2009) were included 
in the study. 
3.3.3 Controls 
For determination of risk, SNP genotype frequencies were compared to published 
control populations including those derived from previous reports and the HapMap 
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project ("The International HapMap Project" 2003). Potential risk associations were 
confirmed and validated by comparison of SNP genotype frequencies for the FL 
study population against genotype frequencies of controls derived from the 
WTCCC2 BC58 cohort which is described in detail in section 2.4.6.  
3.3.4 SNP Genotyping  
A real-time polymerase chain reaction allelic discrimination multiplexed endpoint 
assay protocol (AD-PCR) determined the genotypes of MDM2 SNP 309, TP53 
Arg72Pro, rs6457327 and rs10484561 for the study samples. For MDM2 SNP 309 
and TP53 Arg72Pro, oligonucleotide primers were designed to amplify 109 bp and 
74 bp amplicons incorporating MDM2 SNP 309 and TP53 Arg72Pro, respectively. 
Oligonucleotide probes labeled with either FAM or VIC fluorescent reporter dyes 
were designed for each allele of the respective SNPs. Details of the respective 
primers and probes used for the two SNPs are shown in Appendix 2 Table 1. For 
rs6457327 and rs10484561, Taqman® SNP Genotyping custom assays 
C__11197333_10 and AHHR6XS (Applied Biosystems) were employed, 
respectively. These assays had been custom made and optimized to give maximal 
discrimination of genotypes and represent an important advance in this technique. 
Full details of reaction mixes and conditions as well as interpretation of results are 
provided in Section 2.4.5.  
3.3.5 Direct sequencing 
Confirmation of SNP genotypes on a 10% subset of the AD-PCR study cohort and 
gene mutation screening were performed using direct sequencing as described in 
Section 2.4.12. The oligonucleotide primers employed are shown in Appendix 2 
Table 1. 
3.3.6 FL characteristics for correlation with SNP genotypes 
To examine the relationships between SNPs and disease presentation characteristics, 
parameters including age, gender, stage, haemoglobin (Hb), lactate dehydrogenase 
(LDH), hydroxybutyrate dehydrogenase (HBD), number of nodal sites involved by 
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disease, follicular lymphoma international prognostic index (FLIPI) risk groups, 
tumour grade (1, 2 or 3a), B symptoms, performance status and number of extra-
nodal disease sites were included in the study.  
For correlation of SNP genotypes with the course of disease both management and 
outcome parameters were assessed and included: initial management, date of and 
response to first therapy, dates of first relapse and transformation and date of death or 
last follow-up. Associations were validated through multivariate analysis performed 
on a subset of cases (n = 130) which had been diagnosed at St Bartholomew’s 
Hospital and so had prolonged follow-up data available. 
3.3.7 Statistical validation of FL risk associations 
Single marker association tests were conducted using the one degree of freedom (df) 
allelic chi-squared test, 2df genotypic test and 1df association test under an additive 
model (Cochran-Armitage trend test) implemented in the PLINK 1.07 software 
(http://pngu.mgh.harvard.edu/~purcell/plink/). PLINK v1.07 was also used to test 
deviations from Hardy-Weinberg equilibrium in controls. Odds ratios (OR) and 95% 
confidence intervals (95% CI) were calculated for the minor allele and for the variant 
allele carriers (homozygous or heterozygous versus homozygous common allele 
carriers) by median-unbiased estimation using the mid-p method from the epitools R 
package (http://cran.r-project.org/web/packages/epitools/index.html). 
3.3.8 Statistical validation of clinical outcome associations 
Associations with diagnostic parameters were determined using the Wilcoxon-Mann-
Whitney test or analysis of variance (ANOVA) for continuous variables and either 
Chi-squared or Fisher’s exact tests for categorical data. Initial response to therapy 
was examined by the Kruskal-Wallis test which allowed the ordering in the response 
to treatment categories to be considered when assessing the importance of the SNP 
genotypes. Survival analysis was performed using the Kaplan-Meier survival 
function with log rank test for equality of survival (censoring at death or last follow-
up).   
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Univariate associations were examined by multivariable analyses. For association 
with categorical data, potential confounders were investigated by Mantel-Haenszel 
analysis and those which caused a ≥10% change in the crude odds ratio (OR) were 
then assessed by logistic regression. Any confirmed confounders (those causing a 
≥10% change to the estimated effect as indicated by crude odds ratios in the logistic 
regression analysis) were included in a final model incorporating both crude and 
adjusted ORs. For association with survival data, potential confounders which gave a 
≥10% change to the estimate of effect indicated by altering the crude hazard ratio 
(HR) were included in a Cox regression analysis. Potential confounders identified by 
clinical hypotheses were also included in the regression analyses. 
Analyses were performed using the STATA 11.1 (Stata Corporation, College Station, 
TX, USA) and GraphPad Prism version 5.03 (GraphPad Software Inc., La Jolla, CA) 
computer software packages. Results were considered statistically significant when P 
< 0.05. 
3.3.9 RNA 
RNA expression was determined for an additional series of available samples 
including 16 FL and 2 t-FL tumour samples (lymph nodes), 1 benign lymph node and 
4 tonsils. Six B-cell NHL cell lines (Su-DHL4, RL, Su-DHL6, K422, SC1 and 
DoHH2) and 2 lymphoblastoid cell lines (HRC57 and NC-NC) were also examined 
as well as two myeloid cell lines (K562 and U937) which were included as non-
lymphoid haematological tissue. The extraction of RNA and its subsequent 
amplification by RT-PCR were performed as described in section 2.6. The primers 
used for PCR of cDNA are indicated in Appendix 2 Table 1. 
3.4 Results 
This study was performed in two stages. Firstly, MDM2 SNP 309 and TP53 
Arg72Pro were genotyped to determine the relevance in FL of these SNPs which 
may have functional influence on a major tumour suppressor axis. During the course 
of the study, the first GWAS in FL were reported and these identified rs6457327 and 
rs1048456 as risk determinants which were then examined here for their influence on 
the clinical characteristics of FL. 
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3.5 MDM2 SNP 309 and TP53 Arg72Pro 
3.5.1 Patient and sample characteristics 
A total of 226 cases were included with a median age at diagnosis of 46 years (range 
21 – 85). The source of DNA was bone marrow (n = 207), peripheral blood (n = 14) 
or lymph node (n = 5). Median follow-up of the patients remaining alive was 9.5 
years (range 1.4 to 30.6) and other presentation clinical characteristics are 
summarised in Table 3.1. 
3.5.2 MDM2 SNP 309 and TP53 Arg72Pro do not predict FL risk 
An example of the AD-PCR genotyping results is illustrated in Appendix 3 Figure 1. 
Direct sequencing of the validation set (n = 24) revealed genotypes that were in full 
concordance with those determined by AD-PCR. The distributions and relative 
frequencies of the 226 genotypes for both MDM2 SNP 309 and TP53 Arg72Pro 
across the study population are indicated in Table 3.2. These were not significantly 
different when compared to genotypes in previously reported control groups (taken 
from populations with similar demographics to the study cohort) or to data available 
from the HapMap project. This suggests that MDM2 SNP 309 and TP53 Arg72Pro 
do not predict risk of FL. 
3.5.3 SNP genotype groups for correlation with clinical outcome 
Both MDM2 SNP 309 and TP53 Arg72Pro can negatively impact on p53 function 
and so have potential for biological synergy through disruption of the MDM2-p53 
axis. In view of this and their reported multiplicative relevance in cancer 
development (Hong et al. 2005; Zhang et al. 2006), the combined influence of 
MDM2 SNP 309 and TP53 Arg72Pro on FL outcome was determined in addition to 
the individual effects of each SNP.  
Cross-tabulation of the respective SNP genotypes was performed which indicated 
there were no cases homozygous for both minor (MDM2 SNP 309 G or TP53 
Arg72Pro C) alleles (Appendix 3 Table 1) and less than ten cases in each group with  
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Table 3.1  MDM2 / TP53 SNP genotypes & FL presenting features 
 
 
*number (percentage) unless indicated as median and range 
#LDH performed from the year 1989 onwards and HBD performed up to 1989 
PS indicates performance status as per the ECOG criteria (Oken et al. 1982); LDH, lactate 
dehydrogenase; HBD, hydroxybutyrate dehydrogenase; iu, international units; Hb, haemoglobin; 
g/dL, grams per decilitre; ULN, upper limit of normal; IQR: inter-quartile range. 
Characteristic Subtype n (%)
*
 
MDM2 SNP 309 
P 
TP53 Arg 72 Pro 
P 
 
TT TG+GG GG GC+CC  
Age (years)  Median (range) 46 (21 - 85)   0.80   0.77  
 <60 years 181 (80) 73 108  83 98   
 ≥60 years 45 (20) 26 19  22 23   
Sex Male 124 (55) 55 69 0.89 57 67 0.89  
 Female 102 (45) 44 58  48 54   
Stage 1 / 2 48 (25) 17 31 0.18 22 26 1.00  
 3 / 4 146 (75) 69 77  67 79   
 missing 32        
B symptoms Absent 89 (77) 44 44 0.66 40 48 0.51  
 Present 27 (23) 12 15  10 17   
 missing 111        
PS 0 - 1 74 (93) 39 35 1.00 30 44 1.00  
 2 - 4 6 (7) 3 3  2 4   
 missing 146        
Extranodal  0 - 1 65 (80) 33 32 0.78 24 41 0.40  
 2 - 4 16 (20) 7 9  8 8   
 missing 145        
Nodal sites 0-4 45 (59) 23 22 0.82 19 26 0.64  
 5-8 31 (41) 17 14  11 20   
 missing 150        
LDH/HBD
#
 
(iu) 
≤ULN 74 (77) 35 41 1.00 37 39 0.08 
 
 >ULN 22 (23) 9 11  5 15   
 missing 130        
Hb (g/dL) Median (IQR) 13.6 (12.6 - 14.7)   0.18   0.92  
 ≥12g/l 91 (84) 42 49  40 51   
 <12g/l 17 (16) 7 10  6 11   
 missing 118        
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Table 3.2  MDM2 SNP 309 and TP53 Arg72Pro case control study 
 
SNP Genotype 
FL Cases  Published controls* 
MAF  
cases/controls 
P 
Number Frequency (%)  Number Frequency (%) 
 TT 99 44  26 48   
MDM2 SNP 309 TG 98 43  22 40 0.34  / 0.32 0.82 
 GG 29 13  7 12   
         
 GG 105 46  87 50   
TP53 Arg72Pro GC 105 46  76 44 0.30 / 0.28 0.43 
 CC 16 7  10 6   
 
 
*As per previous reports for MDM2 SNP 309 (Bond et al. 2005) and TP53 Arg72Pro (Pierce et al. 2000). 
MAF, minor allele frequency. 
MAF calculated using numbers from genotypes = [(2*homozygous minor genotype) + heterozygous genotype] / [total cases*2]. 
Both SNPs were in Hardy-Weinberg equilibrium in this cohort of FL cases (P > 0.1 for each SNP), which suggests they are not under selective pressure supporting the lack of 
differences in genotype frequencies when compared to controls. 
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homozygosity for one minor allele. However, there were satisfactory numbers in the 
four groups generated by cross-tabulation of cases who were minor allele carriers 
(either heterozygous cases or those homozygous for the minor allele) and cases who 
were homozygous for major alleles (as, respectively, TG+GG and TT for MDM2 
SNP 309; GC+CC and GG for TP53 Arg72Pro), as summarised in Appendix 3 Table 
2. Consequently, these genotypes were assessed for the respective SNPs and the four 
genotype combinations from this cross-tabulation (MDM2 SNP 309 TT with TP53 
Arg72Pro GG; MDM2 SNP 309 TT with TP53 Arg72Pro GC+CC; MDM2 SNP 309 
TG+GG with TP53 Arg72Pro GG; and MDM2 SNP 309 TG+GG with TP53 
Arg72Pro GC+CC) were examined regarding the combined effect of MDM2 SNP 
309 and TP53 Arg72Pro in FL. Such groupings also enable the relevance of minor 
(variant) alleles (MDM2 SNP 309 G or TP53 Arg72Pro C) to be determined.  
3.5.4 MDM2 and TP53 SNPs do not predict FL presentation features 
There were no significant associations with age, gender, presentation stage, presence 
of B symptoms, performance status, extra-nodal disease, number of nodal sites 
involved, LDH or HBD, and haemoglobin at FL diagnosis for MDM2 SNP 309 
genotypes and TP53 Arg72Pro genotypes (Table 3.1) or the four combinations of 
MDM2 SNP 309 and TP53 Arg72Pro genotypes (Table 3.3), P ≥ 0.18. 
3.5.5 MDM2 and TP53 SNPs do not predict clinical outcome of FL 
Similarly, examination of the relationships between these SNP genotypes and clinical 
outcome revealed there was no association with response to first therapy for these 
genotypes (also P ≥ 0.18) and, in particular, there was no association with risk of 
transformation (illustrated in Table 3.4), P ≥ 0.62. Furthermore, there was no 
evidence for association of these genotype combinations with the survival outcomes 
of time to disease transformation (TTT), time to first relapse and overall survival 
(OS), P ≥ 0.17. Examples for TTT and OS are illustrated in Figure 3.1 and Figure 
3.2, respectively. 
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Table 3.3  MDM2 / TP53 SNP combinations & FL presentation characteristics  
 
 
†Too few values were present in the subsets for PS to satisfy Chi square criteria. On a restricted 
analysis of homozygosity for both major alleles (Neither rare) versus any minor allele present (Rare 
TP53 + Rare MDM2 + Both rare) by Fisher’s exact test, there was no significant association. 
Neither rare indicates MDM2 SNP 309 TT with TP53 Arg72Pro GG; Rare MDM2, MDM2 SNP 309 
TG or GG with TP53 Arg72Pro GG; Rare TP53, MDM2 SNP 309 TT and TP53 Arg72Pro GC or CC; 
and Both rare, MDM2 SNP 309 GT or GG and TP53 Arg72Pro GC or CC genotypes.  
Abbreviations are as indicated for Table 3.1.  
  
Characteristic Subtype 
MDM2 SNP 309 & TP53 Arg72Pro genotypes 
P 
Neither 
rare 
Rare 
TP53 
Rare 
MDM2 
Both 
rare 
Age (years)  Median (range)      
 <60 years 35 38 48 60 0.79 
 ≥60 years 10 16 12 7  
Sex Male 27 28 30 39 0.67 
 Female 18 26 30 28  
Stage 1 – 2 11 6 11 20 0.13 
 3 – 4 30 39 37 40  
 missing = 32      
B symptoms Absent 21 23 19 25 0.65 
 Present 6 6 4 11  
 missing =111      
PS 0 – 1 18 21 12 23 - 
† 
 2 – 4 1 2 1 2  
 missing = 146      
Extranodal  0 – 1 13 20 11 21 0.49 
 ≥ 2 5 2 3 6  
 missing = 145      
Nodal sites ≤ 4 12 11 7 15 0.89 
 ≥ 5 7 10 4 10  
 missing = 150      
LDH/HBD (iu) ≤ULN 18 17 19 22 0.29 
 >ULN 2 7 3 8  
 missing = 130      
Hb (g/dL) Median (IQ range)     0.91  
 ≥12g/l 17 25 23 26  
 <12g/l 4 3 2 8  
 missing = 118      
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Table 3.4  MDM2 & TP53 SNP combinations and transformation risk 
 
 
 
 
Parentheses include percentages transformed or never transformed for each genotype. The total 
number of cases which transformed or never transformed in the cohort are indicted for comparison. 
#Genotypes are as detailed in Table 3.3. 
  
SNP Genotype Transformed 
Never 
transformed 
P 
MDM2 SNP 309 TT 33 (33) 66 (67) 0.89 
 GT or GG 44 (35) 83 (65)  
     
MDM2 SNP 309 / 
TP53 Arg72Pro# 
Neither rare 13 (29) 32 (71) 0.86 
Rare TP53 20 (37) 34 (63)  
Rare MDM2 21 (35) 39 (65)  
Both rare 23 (34) 44 (66)  
     
TP53 Arg72Pro GG 34 (32) 71 (68) 0.62 
 CC or CG 43 (36) 78 (64)  
     Total cases       77(34)      149(66)  
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Figure 3.1  MDM2 SNP309 / TP53Arg72Pro and time to transformation  
Example Kaplan-Meier plots and log rank test statistics for survival from diagnosis of FL to 
transformation (censored at last known follow-up +/- death). Top, MDM2 SNP 309 restricted 
genotype groups (as labelled). Bottom, combined MDM2 SNP 309 and TP53 Arg72Pro restricted 
genotype groups (as indicated to the right); these groups are as detailed in Table 3.3.  
 
P = 0.88 
 P = 0.68 
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Figure 3.2  OS for MDM2 SNP 309 or MDM2 / TP53 SNP combinations 
Kaplan-Meier plots and log rank test statistics for overall survival (OS) from diagnosis of FL. The top 
and bottom of the figure as well as the combination genotype groups are as indicated in Figure 3.1 
with the exception that censored subjects are those alive at last follow-up. 
 
P = 0.41 
P = 0.17 
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3.5.6 MDM2 SNP 309 does not predict t-FL in younger females 
There were no differences in the median age at diagnosis for the MDM2 SNP 309 
and TP53 Arg53Pro genotypes (Appendix 3 Table 3). Importantly, the MDM2 SNP 
309 minor (G) allele shows association with earlier onset of DLBCL in women under 
51 years of age (Bond et al. 2006) and this gender specific effect may be due to the 
SNP variant modulating the known influence of oestrogen receptor alpha on MDM2 
expression (Phelps et al. 2003). Consequently, the relationship of this SNP to age at 
FL diagnosis and its transformation (as DLBCL) was examined in females who were 
less than 51 years old at time of FL diagnosis (n = 66). When assessing either the 
cases homozygous for the major T allele versus the minor allele carriers or the three 
separate genotypes there were no associations with either age at FL diagnosis and 
age at transformation (Table 3.5) or risk of transformation (Table 3.6) in this 
subgroup and, furthermore, there were no associations observed for the group of 
females who developed transformation < 51-y-o (Table 3.5), P ≥ 0.11.
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Table 3.5  MDM2 SNP 309 and age at FL / t-FL diagnosis in females <51 years 
 
 
 
 
 
 
 
 
 
 
Also, there were no associations (P ≥ 0.15) between the two genotype groups TT v TG+GG and any of the three median ages at FL or t-FL. 
 
 
 
 
Table 3.6  MDM2 SNP 309 and t-FL risk for females <51 years at FL diagnosis 
 
 
 
 
 
In addition, there was no association (P = 1.0) between the two genotype groups TT v TG+GG and risk of t-FL in females < 51-y-o. 
MDM2 SNP 309 
Genotype 
Females < 51 years at FL diagnosis (n = 66) 
 
Females < 51 years at t-FL (n = 17) 
 
Median age at 
FL 
P 
Median age 
at t-FL 
P 
 Median age at 
t-FL 
P 
 
TT 41   45    43    
TG 44  0.11 49  0.14  45 0.29  
GG 44   45    42   
MDM2 SNP 309 
Genotype 
Transformed Never transformed P* 
TT 9 18  
TG 8 21 0.17 
GG 6 4  
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3.6 rs6457327 and rs10484561 
The rs6457327 and rs10484561 SNPs are located on chromosome 6p and although 
no functional consequences have been described, both are found in independent 
small sections of high linkage disequilibrium (as illustrated in Appendix 4 Figure 1 
and Appendix 4 Figure 2, respectively). These regions contain genes which might 
therefore be relevant and this, in combination with the risk associations of both SNPs 
(Skibola et al. 2009; Conde et al. 2010), led to further examination of these two loci 
in FL. 
3.6.1 Patient and sample characteristics 
This investigation was performed following the MDM2 SNP 309 / TP53 Arg72Pro 
study. Due to new sample availability and exhaustion of some previous samples, a 
slightly revised cohort (n = 218) of FL cases was examined. For this cohort, 
genotyping of rs6457327 and rs10484561 was performed on germline DNA samples 
obtained from either bone marrow (n = 203) or peripheral blood (n = 15) and 
examples of the results plots are illustrated in Appendix 4 Figure 3. 
3.6.2 rs6457327 and rs10484561 predict risk of FL in the UK population  
The genotype frequencies of rs6457327 and rs10484561 for the 218 FL cases were 
similar to those reported in the cases included in the GWAS studies (Skibola et al. 
2009; Conde et al. 2010). The rs6457327 minor allele (A) appeared less commonly 
in FL (with a frequency of 0.32) than in the control population of the initial report by 
Skibola and colleagues (Skibola et al. 2009); and the rs10484561 minor allele (G) 
was enriched in FL (with a frequency of 0.21) compared to the controls in the 
follow-up report by the same group (Conde et al. 2010).  
To further address the risk association of these SNPs in the UK population, the 
rs6457327 and rs10484561 genotypes of the study cohort were compared to those of 
the WTCCC BC58 derived control populations (Table 3.7). Importantly, no 
departures from Hardy-Weinberg equilibrium were detected among these controls, 
with P > 0.80 for each set used in the comparisons for rs6457327 (n = 2691) and  
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Table 3.7  SNPs rs10484561 and rs6457327 and risk of developing FL in the UK 
 
SNP Genotype 
Genotype count 
MAF 
cases/controls 
HWE 
controls 
Variant allele  
OR (95% CI)‡ 
Allelic  
OR (95% CI) ‡ 
Allelic P Trend P Genotypic P 
Cases* Controls† 
rs10484561 
GG 
 
GT 
 
TT 
5 
 
82 
 
131 
34 
 
548 
 
2102 
0.21/0.11 0.92 2.40 (1.80-3.19) 2.07 (1.61-2.63) 3.50  10-9 2.74  10-9 6.34  10-9 
rs6457327 
AA 
 
AC 
 
CC 
19 
 
103 
 
96 
408 
 
1272 
 
1011 
0.32/0.39 0.81 0.77 (0.58-1.01) 0.75 (0.61-0.93) 0.01 0.01 0.02 
 
 
MAF indicates minor allele frequency, HWE, Hardy-Weinberg equilibrium; OR, odds ratio; and CI, confidence interval. 
*FL cases from St Bartholomew’s Hospital (n = 218 for both SNPs).  
†Controls from WTCCC2 BC58 (as described in Chapter 2). Both control populations maintain Hardy-Weinberg equilibrium. 
‡ORs calculated for the variant allele carriers (homozygous or heterozygous) versus homozygous common allele carriers (Variant allele OR) and for minor versus major allele (Allelic OR). 
Furthermore, these risk associations do not appear restricted to younger onset of disease (Appendix 4 Table 1). 
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rs10484561 (n = 2684) genotypes, respectively. On examination of the three 
genotype combinations for each SNP in FL cases compared to BC58 controls, both 
rs6457327 (P = 0.02) and rs10484561 (P = 6.34  10-9) were associated with risk of 
FL in the UK population. Furthermore, a significant difference was observed 
between the minor allele frequency (MAF) for rs6457327 (A allele) of 0.32 and 0.39 
[P = 0.01, OR 0.75 (95% CI 0.61 - 0.93)] and for rs10484561 (G allele) of 0.21 and 
0.11 [P = 3.50  10-9, OR 2.07 (1.61 - 2.63)] in the FL cases and BC58 control sets 
respectively (Table 3.7). These findings confirm the GWAS results and indicate that 
both SNPs associate with risk of FL in the UK. 
3.6.3 Correlating rs6457327 and rs10484561 with clinical outcome of FL  
Following examination of the correlation between rs10484561 or rs6457327 and 
clinical outcome parameters in FL for the whole cohort of cases (n = 218), only 
associations between rs6457327 and risk of transformation (P = 0.01) or time to 
transformation (P = 0.01) were observed. To confirm these findings, clinical 
outcome associations were determined for the subset of cases (n = 130) initially 
diagnosed at Barts and the London NHS Trust which consequently had prolonged 
clinical follow-up data. 
It was important to confirm that there were no differences in genotype and allele 
frequencies for each SNP in the 130 cases evaluated for clinical outcome compared 
to the remaining 88 cases from the case-control study. This was indeed the case, as 
illustrated in (Appendix 4 Table 2), indicating the sub-population assessed for 
clinical associations is representative of the whole FL cohort as regards these SNPs. 
As there were limited numbers of cases homozygous for the variant (minor) alleles (3 
and 9 cases for genotypes GG and AA of rs10484561 and rs6457327 respectively) 
analysis of clinical associations was performed on restricted genotype groups similar 
to those described in the MDM2 / TP53 study. These were minor allele carriers and 
cases homozygous for the major allele which gave comparisons of rs10484561 
genotypes GG+GT versus TT and rs6457327 genotypes AA+AC versus CC.  
Presentation characteristics and subsequent management / events for the cohort of 
130 cases are summarised in Table 3.8. The median age at diagnosis of 52 years is as  
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Table 3.8  Correlating rs10484561 / rs6457327 with FL clinical features 
Characteristic Subgroup n* 
P†  
rs10484561 rs6457327  
Presentation      
Age at Dx, years  52 (26-87)¶    
 <60 95 (73) .59 .73  
 ≥60 35 (27)    
Sex Male 72 (55) .81 .29  
 Female 58 (45)    
Stage 1-2 33 (26) .77 .51  
 3-4 96 (74)    
  Missing 1    
LDH / HBD, iu‡ ≤ULN 94 (82) .74 .91  
 >ULN 21 (18)    
 missing  15    
Haemoglobin, g/L ≥120 105 (83) .80 .66  
 <120 22 (17)    
 Missing 3    
Nodal sites ≤4 61 (58) .13 .90  
 ≥5 45 (42)    
  Missing 24    
FLIPI group§ Low 39 (31) .53 .90  
 low / int 11 (9)    
 Int 37 (29)    
 int / high 11 (9)    
 High 28 (22)    
 Missing 4    
Histological grade 1 75 (64) .87 .82  
 2 31 (27)    
 3 11 (9)    
 Missing 13    
Management      
Initial management Observation 51 (39) .54 .24  
 RT alone 12 (9)    
 single chemo 51 (39)    
 comb chemo 15 (12)    
 Other 1 (1)    
Response to 1st Tx| | CR 30 (27) .25 .93  
 CR(u) 39 (35)    
 PR  26 (23)    
 Stable 4 (3)    
 Progression 14 (12)    
  Missing 17    
Events      
RFS, months Relapse 30 (7-180) # .40 .17  
TTT, months transformation 30 (2-242) # .38 .01  
Transformation Occurred 45 (35) .60 .006  
OS, years death  12 (8-20)** .19 .97  
 
The significant univariate associations are highlighted in bold.  
*
Number (percentage of non-missing) unless indicated. 
†
Associations for GG+GT v TT and AA+AC v CC genotypes of SNPs rs10484561 and rs6457327 respectively. 
‡
ULN range for LDH = 480 iu and ULN range for HBD = 140 iu. Cases had either LDH or HBD results.  
§
For FLIPI risk group determination, 11 cases had FLIPI scores of ≤2 and 11 had scores of ≥2 but none of these 22 cases could 
be further categorized in to one of the three FLIPI risk groups due to missing data so are indicated here as low / int (score ≤2) 
and int / high (score ≥2). 
| |As per the “Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphomas” (Cheson 
et al. 1999). 
¶
Median (range) for all cases (n = 130). 
#
Median (range) for those cases who relapsed (n = 91) or transformed (n = 45). 
**
Median (inter-quartile range) established from the reverse Kaplan-Meier test on the whole population (n = 130). 
Dx indicates diagnosis; LDH, lactate dehydrogenase; HBD, hydroxybutyrate dehydrogenase; iu, international units; g/L, grams 
per litre; FLIPI, follicular lymphoma international prognostic index; Tx, treatment; RFS, relapse free survival; TTT, time to 
transformation; OS, overall survival; ULN, upper limit of normal range; int, intermediate; RT, radiotherapy; comb, 
combination; chemo, chemotherapy; CR, complete response; CR(u), complete response unconfirmed; and PR, partial response. 
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expected in a tertiary referral cancer centre. Furthermore, the gender, grade, stage, 
remaining parameters contributing to the FLIPI scoring system (Hb, LDH/HBD, 
number of nodal sites involved by disease) and the proportion of cases in each FLIPI 
risk group are similar to those previously described in FL (Solal-Celigny et al. 2004). 
An initial “watch and wait” policy of observation (expectant management) was 
adopted in 51/130 (39%) of cases with 12 cases (9%) never receiving any treatment 
through the course of their disease. Complete or partial responses, determined 
according to the recommendations of the “Report of an International Workshop to 
Standardize Response Criteria for Non-Hodgkin’s Lymphomas” (Cheson et al. 
1999), were achieved in 95 of 113 assessable cases (84%) including 30 (27%) with 
complete response (CR). One third (45/130) of cases experienced disease 
transformation at a median time of 2.5 years (range 0.2 – 20.1) from diagnosis, 
similar to recent findings both from this institution and elsewhere (Montoto et al. 
2007b; Al-Tourah et al. 2008). In the 91 cases whose disease relapsed, median time 
to first relapse was 2.5 years. The estimated median overall survival for all 130 cases 
(censoring at last follow-up) was 12 years and the 67 surviving patients were 
followed up for a median of 9.3 years (range 1.6 – 30.5) with 94% seen for > 5 years. 
3.6.4 rs6457327 predicts risk of and time to transformation of FL  
Although SNP rs10484561 showed the strongest association with risk of FL, it 
showed no associations with any of the presentation characteristics (P ≥ 0.13) and 
clinical outcomes (P ≥ 0.19) tested (Table 3.8). 
In comparison, rs6457327 AA+AC genotype showed significant associations with 
both risk of disease transformation P = 0.006, OR 2.95 (95% CI = 1.35 - 6.48), as 
indicated in Table 3.8 and Table 3.9, and time to transformation P = 0.01, HR 2.25 
(95% CI 1.16 - 4.36) (Table 3.8 and Figure 3.3). Transformation occurrence was 
more than doubled in carriers of the minor allele (Table 3.9). These associations 
were maintained on comparison of the three separate rs6457327 genotypes (AA, AC 
and CC) for both risk of transformation, P = 0.02 and time to transformation, P = 
0.02. Furthermore, on comparison of individual alleles there was a significant 
association of allele A, as compared to C, with risk of transformation, P = 0.03; OR 
1.88 (1.10 - 3.23).   
Chapter 3 
113 
 
 
 
 
 
 
Table 3.9  SNP rs6457327 genotypes and risk of transformation 
 
 
 
 
 
 
 
 
Percentages for each genotype are included in parentheses. 
 
 
  
rs6457327 genotype 
Transformed 
P 
Yes No 
AA + AC 33 (45) 41 (55) .006 
CC 12 (21) 44 (79)  
Total 45 (35) 85 (65)  
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Figure 3.3  SNP rs6457327 genotypes and time to transformation  
Kaplan-Meier plots with log rank test statistic P value of time to transformation for the rs6457327 
AA+AC or CC genotype groups from the study cases diagnosed at Barts and the London NHS Trust 
(n = 130). 
 
 
P = 0.01 
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Although no other associations with rs6457327 were seen for any of the presentation 
or outcome parameters (Table 3.8), assessment of these against transformation 
yielded significant associations for FLIPI risk group and initial management with 
risk of transformation (P ≤ 0.02); and for response to first therapy, FLIPI risk group 
and age at diagnosis with time to transformation (P ≤ 0.03), indicating these might 
have confounding effects on the associations of rs6457327 with transformation. 
These associations concur with previous reports examining risk factors for 
transformation (Bastion et al. 1997; Gine et al. 2006; Montoto et al. 2007b) although 
the association with initial management reported in a previous study from this 
institution, which included 89/130 cases from the current study (Montoto et al. 
2007b), was not reproduced in a subsequent study from Vancouver (Al-Tourah et al. 
2008). 
Further potential confounders were identified as follows: 
i. rs10484561 genotype was included for both risk of and time to 
transformation despite lack of association with either outcome as this SNP 
(although not in linkage disequilibrium with rs6457327) is located within 1.6 
Mb on the same chromosome arm, 6p; 
ii. response to 1st treatment was included as a potential confounder for risk of 
transformation with P = 0.10 (Fisher’s exact test) in view of its previously 
reported association with transformation (Bastion et al. 1997) and its 
association here with time to transformation; and  
iii. initial management was included as a potential confounder for time to 
transformation [with crude HR = 3.89 (0.90 - 16.77), P = .07 for observation] 
in view of a previous report of initial observation associating with subsequent 
transformation (Montoto et al. 2007b) and its association here with risk of 
transformation. 
The potential confounders, as summarised in Table 3.10, were then taken into 
multivariate analyses assessing the associations of rs6457327 with risk of 
transformation and time to transformation.  
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Table 3.10 Potential confounders included in multivariate analyses 
  
 Risk of transformation Time to transformation 
Potential confounders 
FLIPI risk group  
P = 0.02 
 
Initial management  
P = 0.02 
 
rs10484561 genotype  
P = ns 
 
Response to 1st Treatment  
P = ns 
 
Response to 1st Treatment  
HR 4.44 (1.70 – 11.55) P < 0.01 for progressive disease 
  
FLIPI risk group  
HR 2.95 (1.16 – 7.50) P = 0.02 for intermediate / high 
 
Age at FL Diagnosis  
HR 2.07 (1.06 – 4.02) P = 0.03 for age ≥60 years 
 
rs10484561 genotype  
P = ns 
 
Initial management  
P = ns 
 
 
HR indicates hazard ratio; and ns, not significant. 
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The approach for the association between rs6457327 and risk of transformation 
utilized Mantel-Haenszel analysis and this revealed that FLIPI risk group, initial 
management and response to 1
st
 treatment caused ≥ 10% change in the crude odds 
ratio for this association. Consequently, these were considered probable strong 
confounders and were therefore incorporated in to logistic regression analysis. This 
identified FLIPI risk group and response to 1
st
 treatment as confounders and so these 
were included in the final adjusted model for the risk of transformation. 
For the association between rs6457327 and time to transformation, the five potential 
confounders detailed in Table 3.10 were incorporated in to multivariate analysis 
using Cox regression. None of the potential confounders altered the Cox regression 
hazard ratio by ≥ 10% so the final adjusted model includes only rs6457327 genotype. 
Importantly, the two final adjusted models (Table 3.11) revealed that for risk of 
transformation only rs6457327 AA+AC genotype [P < .01, adjusted OR 5.48 (1.94 - 
15.51)] and progression after first therapy [P = .01, adjusted OR 8.63 (1.56 - 47.74)] 
remained predictive and only rs6457327 genotype retained its predictive value for 
time to transformation [P = .02, HR 2.25 (1.16 - 4.36)]. 
3.6.5 C6orf15 near rs6457327 is not a promising candidate in FL 
The initial GWAS study by Skibola and colleagues (Skibola et al. 2009) revealed 
that the 26kb region of high linkage disequilibrium (LD) marked by rs6457327 
contained a single open reading frame (C6orf15). In view of the significant 
association between rs6457327 and FL outcome (transformation), analysis of 
C6orf15 was performed for acquired aberrations that might influence the clinical 
course of FL.  
Direct sequencing of C6orf15 in DNA extracted from a series of 50 diagnostic FL 
tumour samples revealed no mutational events. Subsequently, the expression of 
C6orf15 for both malignant and germline lymphoid tissue was determined using 
reverse transcriptase (RT)-PCR, as the single probe for this locus on current gene 
expression arrays (GeneChip® Human Genome U133 and U133 Plus 2 gene 
expression arrays; Affymetrix) has shown only limited efficacy in other FL series 
(Dave et al. 2004). However, expression of the spliced C6orf15 transcript was not  
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Table 3.11  Final adjusted models for rs6457327 associations with transformation 
 
Risk of transformation  Time to transformation  
Adjusted OR (95% CI) P  Adjusted HR (95% CI) P  
rs6457327 genotype       
AA + AC 5.48 (1.94 - 15.51) <0.01  2.25 (1.16 - 4.36) 0.02  
CC 1   1   
FLIPI score risk group       
High 0.86 (0.24 - 3.09) 0.81     
Int / High 4.88 (0.78 - 30.60) 0.09     
Int 0.30 (0.07 - 1.17) 0.08  n.a. n.a.  
Low / Int 3.87 (0.51 - 29.22) 0.19     
Low 1      
Response to first treatment       
Progression 8.63 (1.56 - 47.74) 0.01     
Stable - -     
PR 1.37 (0.33 - 5.73) 0.67  n.a. n.a.  
CR(u) 2.17 (0.61 - 7.71) 0.23     
CR 1      
 
The models were generated following multivariate analysis incorporating potential confounders using logistic regression for risk of transformation and Cox regression for 
time to transformation. There were no cases that had stable disease as response to 1st treatment which subsequently developed disease transformation so no odds ratio data is 
available. Significant associations are highlighted in bold. 
OR indicates odds ratio; CI, confidence interval; HR, hazard ratio; Int, intermediate; PR, partial response; CR(u), complete response unconfirmed; CR, complete response; 
and n.a., not applicable. 
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detected in malignant B-cell lines and primary tumour samples (n = 24) nor in a 
reactive lymph node, 2 lymphoblastoid B-cell lines (and 2 myeloid cell lines) 
whereas in 3 of 4 tonsil samples expression was observed (Figure 3.4). Neither was 
expression of the un-spliced transcript detected in any of the primary tumour, nor 
other, samples used in this study (illustrated for three FL samples in Figure 3.5). 
This absence of expression was confirmed by using three different primer 
combinations (Appendix 2 Table 1) on the samples (including a previously 
published primer pair used to demonstrate expression of the un-spliced transcript in a 
single lymphoblastoid cell line (Skibola et al. 2009)). Consequently, although 
C6orf15 is unlikely to have a role in FL, the correlation between rs6457327 and 
transformation suggests the HLA region does contain factors important in FL 
outcome. Furthermore, these might help explain the selective basis of chromosome 
6p gain or aUPD that are detected in more than a quarter of FL cases (Cheung et al. 
2009b; O'Shea et al. 2009).  
3.7 Discussion 
Germline factors are increasingly recognised as having relevance in FL. Several 
targeted studies have investigated the role of specific SNPs in disease development 
(Skibola et al. 2007) and suggest that major and minor alleles from several SNPs 
confer differing lifetime risks of FL. Importantly, in the first GWAS of FL, Skibola 
and colleagues demonstrated a risk locus on chromosome 6p (Skibola et al. 2009). 
However, less is known as to the role of germline determinants in established 
disease. 
The MDM2-p53 axis is critical to cell cycle control and, although SNPs may 
influence the function of this axis and are important in some malignancies, little is 
known as to their role in FL. To address this, the current study established the 
genotypes of MDM2 SNP 309 and TP53 Arg72Pro in a series of 226 FL cases. The 
tissue used had no evidence of significant involvement by lymphoma and so 
extracted DNA represented germline sequence. This is important as tumour DNA 
may acquire changes (such as loss of heterozygosity and mutation) which could lead 
to incorrect germline SNP genotype assignment. Of course, acquired changes may 
themselves have clinical relevance and are investigated in Chapters 4 and 5. 
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Figure 3.4  RT-PCR amplification of C6orf15 
Top, primary tumour samples and bottom, cell lines and non-malignant tissue. C6orf15 and GAPDH RT-PCR products are shown as indicated to the right. PCR reactions 
included oligonucleotide primers designed over splice sites in C6orf15 and GAPDH. A commercial size marker (Promega) is in the left most lanes with band sizes indicated.  
Top, lane 1: pooled MNC DNA (no amplification PCR negative control); lane 2: H2O (no template PCR negative control); lane 3: cDNA from commercially prepared tonsil 
RNA (positive control); lanes 4 – 18: FL sample cDNA; lanes 19 and 20: t-FL sample DNA. (The FL and t-FL samples in lanes 18 and 19 respectively are from the same 
patient.) Bottom, lanes 1-6: B-NHL cell line cDNA  [lane 1: Su-DHL4; lane 2: RL; lane3: Su-DHL6; lane 4: K422; lane 5: SC1; lane 6: DoHH2]; lanes 7 and 8: 
lymphoblastoid cell line cDNA [lane 7: HRC57; lane 8: Nc-Nc]; lane 9: reactive lymph node cDNA; lanes 10 to 13: non-malignant tonsil cDNA; lanes 14 and 15 myeloid 
cell line cDNA [lane 14: K562; lane 15: U937]; lane 16: pooled MNC DNA (no amplification PCR negative control); lane 17: H2O (no template PCR negative control); lane 
18: cDNA from commercially prepared tonsil RNA (positive control). 
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Figure 3.5  RT-PCR amplification of unspliced C6orf15 transcript 
Top, the two images include products obtained from PCR using one primer in exon1 and the other in exon 2 of C6orf15 so that unspliced cDNA could be detected. The 
MNC genomic DNA control (1) amplifies a product which includes the single 197 bp intron within C6orf15 and so represents the expected size of unspliced cDNA. Middle, 
for comparison the two images show PCR products from the same samples but amplified using one primer sited over the C6orf15 splice site and so products are specific to 
the spliced cDNA. Bottom, the two images show PCR products obtained using GAPDH cDNA specific primers.  
Lane 1: pooled MNC DNA (positive or no amplification PCR control for unspliced C6orf15 or spliced C6orf15/GAPDH, respectively); lane 2: cDNA from commercially 
prepared tonsil RNA; lane 3: H2O; lanes 4 – 6 cDNA from primary FL samples; lane 7: H2O (negative PCR control); lanes 8 – 12 are the PCR products obtained from the 
RT-negative controls for the cDNA samples used in lanes 2 to 6. RT indicates reverse transcriptase; pos, positive; and neg, negative. 
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A challenge in the genotyping process was the number of cases classified as 
undetermined by the SPS software programme (using an end-point result) and so 
required inspection of real-time PCR curves to enable genotype determination. This 
was required for fewer than 10% of the TP53 Arg72Pro results but just under 20% of 
the MDM2 SNP 309 results and reflects the less distinct clustering of genotypes 
observed in the latter AD-PCR plots. This did not invalidate the results as curves 
clearly distinguished genotypes in these cases but it did add an extra interpretation 
step for almost 50 cases. Use of independently optimised commercial genotyping 
assays may help with this issue, so these were applied to genotype rs6457327 and 
rs10484561 which limited the need to assess real-time curves to less than 6% of 
cases. 
With a median age younger than that typically seen in FL, the study population is 
likely to be affected by a degree of selection bias, reflecting this institute’s status as a 
tertiary referral centre. This might limit the study’s ability to determine the impact of 
SNP genotype on later age of FL onset. However, reports suggest that minor alleles 
can predispose to earlier onset of disease (Bond et al. 2004; Bond et al. 2006) a 
particularly important clinical facet which could be addressed in this cohort. 
3.7.1 MDM2 SNP 309 and TP53 Arg72Pro 
In this regard, there was no association with age at FL onset for MDM2 SNP 309 or 
TP53 Arg72Pro or the combined genotypes. Furthermore, for both MDM2 SNP 309 
and TP53 Arg72Pro the similarity of allele frequencies to published controls (Pierce 
et al. 2000; Bond et al. 2005) and their concordance with HWE (suggesting stability 
of the SNP alleles within the study population) indicate that neither SNP predicts FL 
risk.  
The rarity of the variant (minor) alleles (MDM2 SNP 309 G and TP53 Arg72Pro C) 
limited the significance which could be attributed to any impact of their 
homozygosity. Consequently, analysis was restricted to two groups: homozygosity 
for the major allele and presence of the minor allele. This enabled any dominant 
effect attributable to the minor allele, as in other malignancies (Bond et al. 2004), to 
be examined. However, MDM2 SNP 309 and TP53 Arg72Pro genotypes did not 
predict diagnostic features of FL and there were no associations with its clinical 
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course suggesting that the potential influence of different genotypes does not 
translate into poorer outcome. Importantly, although i) MDM2 expression may be 
modulated by MDM2 SNP 309, ii) MDM2 over-expression is associated with t-FL 
and iii) earlier age of DLBCL onset is associated with MDM2 SNP 309 (at least in 
younger females) no association between MDM2 SNP 309 and either risk of or time 
to FL transformation was observed. In view of the lack of outcome associations, 
multivariate analysis was not performed and the FLIPI prognostic risk groups were 
not determined. 
aUPD affecting chromosome 12q15 (the site of MDM2) occurs in 10% of all FL 
(O'Shea et al. 2009) and more frequently (19%) in FL that transforms (Fitzgibbon et 
al. 2007). As the minor allele (G) of MDM2 SNP 309 can influence MDM2 
expression (Bond et al. 2004), when rendered homozygous it might associate with 
increased tumour MDM2 protein and help explain the selective basis of 12q aUPD in 
FL. However, when examining a subset of study cases (n = 14) also included in a 
previous investigation (Davies et al. 2005), there was no difference in tumour 
MDM2 protein level across TT (n = 6) and GG (n = 3) genotypes. This is consistent 
with mantle cell lymphoma (MCL) where there is no association between tumour 
MDM2 SNP 309 genotype and MDM2 expression (Hartmann et al. 2007).  
The role of MDM2 SNP 309 in other cancers remains unclear, as reports of risk 
(Wilkening et al. 2007; Chua et al. 2010)) and outcome (Gryshchenko et al. 2008; 
Zenz et al. 2008) have been inconsistent. However, the varying significance in 
different cancers may in part be explained by a recent study that suggests MDM2 
SNP 309 genotype may have a tissue specific influence on MDM2 mRNA expression 
and tumour occurrence (Post et al. 2010). Nevertheless, although genomic lesions 
targeting the MDM2-p53 axis are an important feature of FL, this study has 
demonstrated that MDM2 SNP 309 and TP53 Arg72Pro do not appear to be 
significant in FL. 
3.7.2 rs10484561 and rs6457327 
The second section of this study (n = 218) establishes that SNPs rs10484561 and 
rs6457327 on chromosome 6p both predict risk of FL in the UK population. The data 
confirms the recent GWAS (Skibola et al. 2009), which demonstrated that the 
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rs6457327 minor allele confers a protective effect against FL, and supports a follow-
up study (Conde et al. 2010) that identified rs10484561 as a major susceptibility 
locus for this disease. Significantly, the current study adds to these observations by 
demonstrating for the first time that rs6457327 predicts clinical outcome of FL, as 
genotypes containing the minor (A) allele associate with a higher risk of 
transformation and shorter time to transformation, in an extensively followed-up 
population. The single other factor that could be confirmed as an independent 
predictor of t-FL in this study was progression (as response to initial therapy) and 
this correlation has been identified in other reports (Bastion et al. 1997; Al-Tourah et 
al. 2008).  
The correlation of rs6457327 with both risk of FL and its subsequent transformation, 
meant that the single open-reading frame C6orf15 (also termed STG) that is in high 
LD with this SNP (Skibola et al. 2009) was prioritised as a candidate gene for 
testing. Although limited data exists as to the role of this gene, it is expressed in skin, 
taste-buds and tonsils (Neira et al. 2001; Sanchez et al. 2004). More recently, its 
mouse homologue (emprin) has been shown to code for an extra-cellular matrix 
(ECM) protein (Manabe et al. 2008). This role may be relevant in cell-cell 
associations, which is of interest in FL due to the frequently advanced stage of 
disease at presentation (indicating a propensity to early metastatic processes) and 
importance of the surrounding immune micro-environment to outcome (Dave et al. 
2004; Byers et al. 2008).  
C6orf15 consists of two short exons so the entire gene could be sequenced directly. 
However, no mutations were identified from a cohort (n = 50) of diagnostic FL 
samples that included 15 cases which transformed and 12 cases with aUPD affecting 
the region of chromosome 6p containing rs6457327 (O'Shea et al. 2009). This is 
important as aUPD may preferentially select for mutations that confer a competitive 
advantage to the cell). Although its expression has been demonstrated in whole blood 
and a single lymphoid cell line (Skibola et al. 2009), transcripts were not detected in 
primary FL / t-FL samples, DNA from pooled peripheral blood mononuclear cells 
taken from healthy volunteers, a reactive lymph node sample and eight (consisting of 
six malignant and two virally transformed, non-malignant) lymphoid cell lines in the 
current study. Expression of the spliced transcript was observed in tonsillar tissue 
which is in keeping with previous reports (Neira et al. 2001; Sanchez et al. 2004). 
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Consequently, these data suggest it is unlikely that disruption of C6orf15 in FL cells 
underlies the correlation of rs6457327 with transformation and its role will not be 
examined further by our group. 
Other genetic loci linked to rs10484561 or rs6457327 might have a role in FL. In this 
regard, the location of rs10484561 near HLA-DRB1 and HLA-DQB1 in a region of 
high LD (Appendix 4 Figure 2) may help explain its significant risk association with 
FL. However, sufficient samples were not available for correlation of 4 digit HLA-
genotypes with risk of FL (as recently demonstrated by Wang and colleagues (Wang 
et al. 2010)) or its clinical outcome. Although tag SNPs have been used to 
demonstrate an association between HLA-DQB1 and FL risk (Conde et al. 2010), this 
locus was not included in the study by Wang so is incompletely characterised 
regarding FL risk, and its effect on clinical outcome is unknown. This should be 
addressed in future studies investigating germline determinants of FL, in particular 
whether differences between germline and tumour HLA haplotypes, for example 
through LOH, are relevant. Furthermore, although C6orf15 is the only gene in the 
risk locus of high linkage disequilibrium (LD) (indicated by R
2
 > 0.8) surrounding 
rs6457327 (Appendix 4 Figure 1), several candidate genes lie more distally in an 
area of moderate LD (R
2
 > 0.5). Two of these, POU5F1 and TCF19 are transcription 
factors which may influence embryonic stem cell pluripotency and cell cycle 
progression, respectively, and POU5F1 has been implicated in the clinical outcome 
of other cancers (Chang et al. 2008; Saigusa et al. 2009; Wang et al. 2009).  
Although rs6457327 is a germline factor, acquired changes affecting this locus might 
contribute to the association with clinical outcome. Indeed, LOH disrupting 
chromosome 6p, principally by aUPD as illustrated in Figure 3.6, is a recurrent 
finding in FL tumours (O'Shea et al. 2009) and so might show bias for one of the 
rs6457327 alleles. However, a preliminary investigation of tumour samples (n = 12) 
known to have aUPD of this locus revealed rs6457327 AA (33%) and GG (67%) 
genotypes occurred at similar frequencies to allele frequencies in germline controls 
(Table 3.7) suggesting there is no selection for either allele by aUPD.  
As described in Chapter 1, over thirty studies have reported SNPs associated with FL 
risk. However, only the recent GWAS were validated in multiple patient cohorts and 
the current study is the first to independently confirm the risk associations of SNPs  
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Figure 3.6  rs6457327 & rs10484561 in a region affected by aUPD or gain 
On the left is a vertical G-banding map of chromosome 6 with associated regions of aUPD and gain (and loss) affecting chromosome 6 illustrated in a figure adapted from 
the recent study by O’Shea and colleagues (O'Shea et al. 2009).  On the right is a schematic representation of the positions of rs6453727 and rs10484561 on chromosome 6p 
with the nearby genes illustrated.  
aUPD indicates acquired uniparental disomy; kb, kilo base pairs;  Mb, million base pairs. 
 
. 
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rs10484561 and rs6457327 identified in those investigations. Moreover, SNP effects on 
disease course have generally not been tested, so fewer associations with FL outcome have 
been reported (Weng and Levy 2003; Jardin et al. 2005; Cerhan et al. 2007b; Hohaus et al. 
2007; Racila et al. 2008; Han et al. 2010). Indeed, at the time of writing, there is only a single 
report of a SNP (within intron 1 of BCL6 on chromosome 3q27) that associates with 
transformation (Jardin et al. 2005) and this was in an FL cohort assessed prior to the FLIPI 
era. The majority of these studies have included fewer cases than this thesis project (Weng 
and Levy 2003; Jardin et al. 2005; Hohaus et al. 2007; Han et al. 2010), although one study 
assessed a similar number (n = 133) regarding the impact of C1q SNPs specifically in the 
outcome of rituximab treated FL (the majority at relapse) (Racila et al. 2008) and a larger 
study assessed SNPs in immune related genes for 278 FL cases and correlated these with 
clinical and demographic parameters (Cerhan et al. 2007b) but neither of these reports 
included FLIPI scoring. Importantly, the inclusion of this independently validated prognostic 
index (Solal-Celigny et al. 2004; van de Schans et al. 2009) in the current study provides an 
FL population assessed according to current clinical practice so gives particular credibility to 
the disease outcome correlations. 
As a robust clinical correlation between rs6457327 and t-FL was observed, this should help 
focus molecular study of transformation which remains a major cause of morbidity and 
mortality in FL. Moreover, the association provides further evidence as to the importance of 
the immune gene rich HLA region on chromosome 6p. This builds on previous reports in to 
the relevance of both acquired (Cheung et al. 2009b; O'Shea et al. 2009) and germline 
variation (Wang et al. 2010) at this locus in FL and the known importance of the immune 
response to FL outcome (Dave et al. 2004). Although the underlying mechanism of the 
rs6457327 association with t-FL remains to be determined, it represents a step forward in 
characterising inherited predictors of clinical outcome which, together with recently 
described acquired predictors (O'Shea et al. 2008; Cheung et al. 2009b; O'Shea et al. 2009; 
Cheung et al. 2010b), represent a growing pool of molecular markers in FL. Prospective 
validation is needed before their suitability can be established for incorporation into clinical-
molecular prognostic (and predictive) indices which could help optimise and tailor patient 
management. 
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Chapter 4    Acquired genetic events and t-FL 
4.1 Introduction 
The transformation of FL is an event marked by clinical and radiological indicators 
suggestive of disease progression that typically lead to sampling of suspicious 
lesions. Histological detection of aggressive lymphoma (usually DLBCL) then 
provides a formal diagnosis of t-FL. Transformation represents a significant event as 
it confers a worse prognosis on FL (Figure 1.3), survival from t-FL is particularly 
poor (Montoto et al. 2007b; Al-Tourah et al. 2008) and its management is often 
complicated by previous treatments. As t-FL is not reliably predicted by current 
profiling methods, a more comprehensive understanding of the underlying processes 
will be an important aspect of addressing the major clinical challenge posed by this 
event. 
As described in Chapter 1 and recently reviewed by Relander and colleagues 
(Relander et al. 2010), t-FL is accompanied by genomic changes that are not 
detectable in FL. However, the changes reported are diverse and mirror the marked 
clinical heterogeneity of transformation which may develop throughout the course of 
FL (Montoto et al. 2007b; Al-Tourah et al. 2008). Indeed, the risk of t-FL is 
maintained at around 3% per year (Al-Tourah et al. 2008) which, with the median 
age at FL diagnosis of around 60 years, hints that most FL have a propensity to 
transform. This observation is supported by the demonstration of transformation in 
most FL cases examined at autopsy (Garvin et al. 1983).  
So, if FL has an intrinsic potential for transformation then why do only certain cases 
manifest this clinically over the course of their disease? The identification in Chapter 
3 that germline polymorphic variation associates with transformation, together with 
reports that secondary genetic changes present at FL diagnosis can predict this event 
(Cheung et al. 2009b; O'Shea et al. 2009), supports a model in which the combined 
influence of inherited and acquired predisposing genetic variation contributes to 
subsequent t-FL development. However, as not all cases with these risk factors go on 
to present with transformation it is clear that additional changes are necessary.  
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Indeed, genetic studies comparing sequential FL / t-FL samples have identified that 
disruption of certain genes is more prevalent in t-FL (Lo Coco et al. 1993; Matolcsy 
et al. 1996; Pinyol et al. 1998; Lossos and Levy 2000; Lossos et al. 2002). However, 
as this occurs in only a subset of cases such events cannot drive the majority of 
disease transformation, and their specific role remains unclear. Other studies have 
determined higher level chromosomal changes in t-FL (Hough et al. 2001; Martinez-
Climent et al. 2003; Fitzgibbon et al. 2007) but, in part due to the limits of 
resolution, these remain a diverse group of aberrations that have only rarely 
identified potential key underlying events. Moreover, gene expression profiling 
indicates that transformation may develop through differing functional modes 
(Lossos et al. 2002; Elenitoba-Johnson et al. 2003; Davies et al. 2007), paralleling 
this genetic diversity.  
Recent advances in genetic profiling techniques include genome-wide interrogation 
by micro-arrays containing many thousands of DNA probes, which are included on 
current platforms at a median genomic spacing of 700 bp (as compared to the 300 kb 
spacing used in initial studies of FL (Fitzgibbon et al. 2007)). This now enables high 
resolution mapping of acquired DNA alterations in tumour genomes. By examining 
sequential FL / t-FL samples in combination with matched germline DNA, this 
approach could enable better characterisation of the genetic changes associated with 
t-FL and help focus on important disease mechanisms. Furthermore, it might reveal 
events in FL that are suitable for further examination in large homogenously 
managed case cohorts to determine their clinical relevance in the prediction and 
management of transformation. 
4.2 Aims and Objectives 
This study sought to determine DNA copy number aberrations in FL / t-FL as well as 
examine gene mutation status and further characterise the genetic evolution of 
transformation.  
To facilitate this, analysis was restricted to germline, FL and t-FL DNA samples 
obtained sequentially from a series of patients with prolonged clinical follow-up. 
Specific objectives included high resolution genome-wide DNA copy number 
determination for these samples using the Affymetrix
®
 genome-wide SNP 6.0 micro-
Chapter 4 
130 
array; establishing the clinical significance of copy number changes; characterising 
mutational events in FL / t-FL; and mapping the genetic evolution of transformation 
using copy number or mutation profiles. The data generated from this study has since 
been presented at the 52
nd
 annual meeting of the American Society of Hematology 
(Wrench et al. 2011). 
4.3 Materials and Methods 
4.3.1 Patients and samples  
Cases with sequential FL / t-FL samples were included for genome-wide array 
analysis based on the availability of tissue samples. Each had at least one (earliest 
available) FL and a subsequent t-FL sample with additional FL / t-FL and germline 
samples included where possible. In total 90 samples from 31 cases were examined 
along with the WSU-NHL cell line. In a further cohort of 56 presentation samples, 
mutation frequencies at FL diagnosis were assessed. An additional set of DNA 
samples (n = 31) was included from the study performed in our institution for the 
LLMPP (O'Shea et al. 2009). 
4.3.2 DNA 
DNA was extracted and stored as previously described (section 2.4.1). 
4.3.3 PCR 
Standard (qualitative) PCR was performed as detailed in section 2.4.3 using either 
Taq polymerase (Promega) with proprietary buffer (final concentration 1), dNTPs 
(500μM), MgCl2 (1.5mM), primers (400nM) with 10 ng DNA in reaction volume of 
20μl or (later in the project) HotStarTaq Plus Mastermix with 2.2 ng DNA in a final 
volume of 10μl. PCR products were then visualised following agarose gel 
electrophoresis as described in section 2.4.8.  
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4.3.4 Sequencing 
Following visualisation of distinct bands, the PCR products were purified using the 
ExoSap protocol (Table 2.3) then directly sequenced using BigDye
®
 Terminator 
chemistry (section 2.4.10). The primers used in PCR and sequencing are given in 
Appendix 2 Table 1. 
4.3.5 DNA micro-arrays 
High resolution DNA copy number assays were performed on the sequential FL / t-
FL samples using 0.5μg of high quality DNA (section 2.5.1). To enable successful 
generation of adequate hybridisation signals on the micro-arrays, PCR amplification 
was performed following DNA restriction enzyme digestion and PCR-adaptor 
ligation at the restriction sites (sections 2.5.2 to 2.5.4). PCR products were then 
pooled and purified (section 2.5.5) before being fragmented using DNase I, with the 
fragments then biotin-labelled ahead of hybridisation to the micro-array (sections 
2.5.7 to 2.5.9). After an overnight incubation, hybridisation signals were established 
by application of phycoerythrin labelled streptavidin (sections 2.5.10). Quality 
control steps were included at the DNA preparation (section 2.5.1), PCR / 
quantitation (2.5.5 and 2.5.6) and fragmentation stages (2.5.7). 
4.3.6 Interpretation of copy number aberrations 
Raw data files (.cel files) were established from the hybridisation signals generated 
from the micro-arrays using the methods and quality control (QC) steps detailed in 
section 2.5.11. Interpretation and analysis of the data was performed using the 
Partek
®
 Genomics Suite and an institutional software package: GOLF available at 
https://bioinformatics.cancerresearchuk.org/~cazier01/Golf.html (as described in 
sections 2.5.12 to 2.5.14). Genomic coordinates and gene annotations were applied 
according to human genome version 18 (hg18), which corresponds to the National 
Center for Biotechnology Information (NCBI) genome build 36 on which the 
Affymetrix micro-arrays used in this study had been designed. 
Summary plots of DNA copy number aberrations (CNAs) were generated using an 
on-line interface maintained by Dr J-B Cazier, The Wellcome Trust Centre for 
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Human Genetics, University of Oxford and accessible at 
http://www.well.ox.ac.uk/~jcazier/GWA_View.html. This platform was also used to 
determine the genomic coordinates of “minimum common regions” (MCRs) of CN 
gain or loss that were common to more than one sample and so might contain genes 
relevant in the progression of FL / t-FL.  
The number of CNAs in FL and t-FL was compared using two-way ANOVA and 
recurrent minimum common regions (MCRs) of copy number gain or loss were 
compared to disease outcome parameters using Kaplan-Meier plots and the log-rank 
test statistic. CNAs and MCRs were then examined for their frequency, gene 
associations (with reference to hg18 using the genome browser website 
www.ensembl.org), clinical outcome association and pattern of acquisition. 
The copy number estimates obtained through Partek
®
 analysis for each sample were 
directly viewed in GOLF which enabled selection of appropriate raw copy number 
dot-plots for use in illustrative figures of results.  
4.4 Results 
4.4.1 Patient samples for copy number profiling 
For genome-wide examination of DNA copy number aberrations in FL / t-FL, 90 
samples were available from 31 cases. Each case had FL and t-FL biopsies, 19 
having germline samples. Further samples included additional FL biopsies 
subsequent to FL but prior to transformation (n=6), relapse of t-FL (n=1) and FL 
recurrence after t-FL (n=2). The majority of samples (n = 66) where obtained from 
lymph nodes, with the remainder sourced from bone marrow (n = 15), peripheral 
blood (n = 2), skin (n = 2), buccal mucosa (n = 2), breast (n = 1), abdominal mass (n 
= 1) or spleen (n = 1) (Table 4.1). The time-points at which study samples were 
taken relative to the individual disease course for respective cases are indicated in 
Figure 4.1; the initial FL samples were the earliest available and occurred at 
diagnosis (n = 7) and pre-treatment (n = 8) with remainder from episodes of FL 
progression or relapse after treatment. 
For this cohort of FL patients, the median age at diagnosis was 46 years (range 22-
71) and, with median follow-up of patients who remained alive (n = 8) of 10 years                                                                                                                         
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Table 4.1  Study cases and samples
   
Study 
Number 
Sample 
source 
Sample 
type 
   
1 LN FL1 
   LN t-FL 
2 BM Germline 
  LN FL1 
  LN t-FL 
4 LN FL1 
  LN t-FL 
5 LN  FL1 
 
LN  t-FL 
6 BM Germline 
  LN FL1 
  LN t-FL 
7 Skin FL1 
  LN t-FL 
8 BM Germline 
  LN FL1 
  LN t-FL 
9 PB Germline 
  LN FL1 
  LN t-FL 
  LN t-FL2 
10 LN FL1 
  LN t-FL 
  LN FL post t-FL 
11 LN FL1 
  LN FL2 
  LN t-FL 
12 LN FL1 
  LN t-FL 
13 BM Germline 
  LN FL1 
  LN t-FL 
15 BM  Germline 
  LN FL1 
  LN t-FL 
16 BM Germline 
  LN FL1 
  LN t-FL 
17 BM Germline 
  LN FL1 
  LN t-FL 
18 LN FL1 
  LN t-FL 
19 BM Germline 
  LN FL1 
  LN t-FL 
   
 
 
 
 
 
 
   
Study 
Number 
Sample  
source 
Sample  
Type 
   
20 Buccal Germline 
  LN FL1 
  Abdo mass t-FL 
21 LN FL1 
  LN t-FL 
  Breast FL post t-FL 
22 LN FL1 
  LN t-FL 
23 BM Germline 
  LN FL1 
  LN FL2 
  Spleen t-FL 
24 BM Germline 
  Skin FL1 
  LN t-FL 
25 LN FL1 
  LN t-FL 
26 BM Germline 
  LN FL1 
  LN t-FL 
27 LN FL1 
  LN t-FL 
28 BM Germline 
  LN FL1 
  LN t-FL 
30 BM Germline 
  LN FL1 
  LN t-FL 
31 PB Germline 
  LN FL1 
  LN t-FL 
32 Buccal Germline 
  LN FL1 
  LN FL2 
  LN FL3 
  LN FL4 
  LN t-FL 
33 BM Germline 
  LN FL1 
  LN FL2 
  LN t-FL 
34 BM Germline 
  LN FL1 
  LN t-FL 
   
LN indicates lymph node; BM, remission bone marrow; PB, remission peripheral blood; Buccal, 
oral epithelium via saliva; Abdo, abdominal;, FL1, earliest available FL sample; FL2, 2nd available 
FL sample; FL3, 3rd available FL sample; FL4, 4th available FL sample; t-FL, earliest available t-FL 
sample; t-FL2, 2nd available t-FL sample (at relapse of transformation); FL post t-FL, earliest 
available relapse FL sample after t-FL. 
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Figure 4.1  Study sample time-lines 
Illustrated for each of the 31 study patients are the time points at which the sequential samples were 
obtained. Patient numbers are to the left of the figure. For each patient the time-line commences at FL 
diagnosis (left hand diamond). FL samples are illustrated by green diamonds and t-FL samples by red 
spots. If the diagnostic FL sample was not available for this study the left hand diamond is black. The 
left most spot represents t-FL diagnosis (also coloured black if the sample was not available for this 
study. 
Chapter 4 
135 
(2-19), the median time to transformation was 4 years (1-16) which is similar to 
recent large series (Montoto et al. 2007b; Al-Tourah et al. 2008)). Cause of death 
was available for 22 / 23 patients who died, with lymphoma (n = 17) and treatment (n 
= 4) constituting 95% of deaths and one case dying from a second malignancy. 
4.4.2 Micro-array quality control  
Quality control (QC) data were satisfactory and are presented in Appendix 5 Table 
1. The median call rate of 98.99% (range 96.59 to 99.61), with 85 / 90 (94%) 
samples having rates >97%, indicated good overall applicability of the assay from 
DNA preparation to micro-array probe hybridisation signal generation. Contrast QC 
was satisfactory at a median of 1.94 (range 0.58 to 3.18) with only 6 samples (7%) < 
1.0. The MAPD results had a median of 0.29 (range 0.23 to 0.40) with only one 
sample above 0.4. A final QC step was performed in GOLF by comparing the signals 
of 100 randomly selected SNPs in each of the 90 samples. This generated a 
dendrogram (hierarchical tree) of the relatedness of all samples and is illustrated in 
Figure 4.2. It reveals that, for each case, the respective samples cluster together 
indicating that the samples did indeed originate from the same patient.  
4.4.3 Copy number aberrations in FL / t-FL 
In total, 1114 of CNAs were identified across all 71 tumour samples including 511 
CN gains and 603 CN losses. The median number of CNAs per initial FL sample 
was 11 (range 1 - 43) and per t-FL sample was 16 (range 0 to 56); with gains at a 
median of 5 (0 to 13) and 8 (0 to 33) and losses at a median of 5 (0 to 39) and 7 (0 to 
30) in FL and t-FL respectively. All samples except one t-FL (Case 23) showed 
CNAs of at least one chromosome. CN losses occurred on every chromosome and 
only chromosome 4, in FL, was unaffected by CN gains. 
Four cases had additional FL samples available which showed heterogeneity in their 
CNA acquisition compared to the preceding FL: for case 11 the second FL had more 
(n = 14) CNAs compared to the initial FL (n = 6); for case 23 the second sample had 
fewer CNAs (n = 3) as compared to the initial sample (n = 41); in the four sequential  
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Figure 4.2  Confirmation of sample origin 
Dendrogram generated in the GOLF software package by comparing genotypes of 100 randomly selected SNPs across the 31 study cases. The respective samples 
from each case cluster together, illustrated by alternating blue / red, indicating they are highly related and do indeed arise from the same patient. Differences between 
germline and tumour samples for each case give the divergence seen to the left of the plot.  
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FL samples available for case 32 the CNAs numbered 5, 2, 2 and 5 respectively; and 
the second FL had slightly fewer CNAs (n = 2) than the preceding FL (n = 4) for 
case 33. 
The two FL samples (for cases 10 and 21) occurring post-t-FL showed more CNAs 
compared to the preceding FL (33 versus 24 and 23 versus 16 for cases 10 and 21, 
respectively) but not the t-FL (which had 32 and 56 CNAs respectively). The sole 
additional t-FL sample (in case 9) showed a marked increase in the number of CNAs 
(n = 39) compared to the preceding FL (n = 6) and t-FL (n = 5) samples. 
To compare FL and subsequent t-FL, the sets of 31 earliest FL and corresponding 
earliest t-FL samples were examined and no differences were observed in the overall 
frequencies of gains or losses or total CNAs between the FL and t-FL sets (Figure 
4.3). The complete set of CNAs for the earliest FL samples and earliest t-FL samples 
are illustrated Figure 4.4 and Figure 4.5, respectively. The minimum common 
regions (MCRs) of gain or loss (defined as the common areas affected by losses or 
gains that overlap in different samples) that were present in at least 20% cases (n ≥ 7) 
were used to identify the sites most frequently subject to CNAs. In FL, MCR gains (n 
= 15) and losses (n = 11) were identified across 9 chromosomes (Table 4.2) and in t-
FL MCR gains (n = 20) and losses (n = 7) were identified across 10 chromosomes 
(Table 4.3). The most frequent CNAs were loss 1p36 and gains 7p, 7q, 18p, 18q in 
FL samples (n ≥ 10); and loss 1p36 and gains 2p15, 18p, 18q, Xq in t-FL samples (n 
≥ 10). 
4.4.4 Clinical outcome associations 
To examine whether these recurrent CNAs might predict clinical outcome, their 
associations with overall survival (OS) and time to transformation (TTT) from FL 
diagnosis (FL CNAs) and survival from transformation (SFT) (t-FL CNAs) were 
determined. Of the 57 MCR gains and losses, gain 2p15-16 in FL samples (n = 7), 
predicted overall survival (Figure 4.6) with a median survival of 5.2 years compared 
to 12.9 years for those cases without this CNA. No cases with this gain remained 
alive beyond 10.9 years whereas over half of cases (13/24) without the gain survived 
for more than 11.1 years post FL diagnosis. The MCR of gain 2p15-16 is just over 2 
Mb in size and contains 13 genes, of these REL and BCL11A are established  
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Figure 4.3  Comparison of CNAs in FL and t-FL 
The mean per case (vertical bars) with 95% confidence intervals (vertical lines with caps) is illustrated 
for the number of CNAs (all gains and losses, gains only and losses only) across the 31 samples in the 
earliest FL and earliest t-FL sets. There were no significant differences between the groups.  
ns indicates P value is not significant. 
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Figure 4.4  Summary of all CN gains and losses in initial FL  
 
Gains and losses are illustrated as vertical bars positioned by their start and end co-ordinates with 
respect to the G-band representation of the chromosome to the left in each plot. All co-ordinates and 
mapping are done with respect to human genome mapping hg18 (NCBI build 36). 
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Figure 4.5  Summary of all CN gains and losses in t-FL 
The plot layout is as described for Figure 4.4.  
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Table 4.2 Minimum common regions of CN gain or loss in initial FL 
 
 
Shown are the genomic start / end chromosome coordinates, length and cyto-band location of the MCRs of copy number (CN) loss or gain in the set of 31 initial FL 
samples. The number of genes within each MCR and examples of possible candidates for involvement in FL / t-FL (identified by their known function + / - disruption 
in other malignancies) are indicated together with the amount and identity of the cases involved. Chr indicates chromosome. 
Chr Start End Length Type Cyto-band No. Genes  Candidate genes  Cases  Case numbers involved 
1 2430024 2617647 187623 Loss 1p36.32 4 PANK4, HES5, TNFRSF14, MMEL1 11 5, 7, 10, 13, 15, 16, 20, 21, 27, 33, 34 
1 4058258 4071424 13166 Loss 1p36.32 0 -  11 5, 10, 13, 15, 16, 20, 21, 23, 27, 33, 34 
1 7688809 7769768 80959 Loss 1p36.23 3 CAMTA1, VAMP3, PER3 11 1, 5, 10, 13, 15, 16, 20, 21, 27, 33, 34 
1 8353401 8432517 79116 Loss 1p36.23 1 RERE 10 5, 10, 13, 15, 16, 20, 21, 27, 33, 34 
1 18449498 18476791 27293 Loss 1p36.13 1 IGSF21 7 10, 15, 16, 20, 21, 27, 31 
1 155604487 159964392 4359905 Gain 1q23.1 - 1q23.3 >50 CD1, NHLH1 7 6, 7, 10, 13, 16, 22, 27 
2 60841274 62878002 2036728 Gain 2p16.1 - 2p15 13 REL 7 5, 10, 15, 16, 18, 22, 30 
6 4345108 28648043 24302935 Gain 6p25.1 - 6p22.1 >100 DEK, JARID2, ID4, SOX4  8 6, 15, 16, 17, 21, 22, 23, 27 
6 68316017 87472057 19156040 Loss 6q12 - 6q14.3 50 IBTK, TTK 8 7, 15, 20, 22, 23, 27, 33, 34 
6 95662927 95709520 46593 Loss 6q16.1 0 - 8 4, 13, 15, 20, 22, 23, 27, 33 
6 137342963 137728730 385767 Loss 6q23.3 3 IFNGR1, IL20RA, IL22RA2 9 4, 13, 15, 16, 20, 22, 23, 27, 33 
6 138023953 138459950 435997 Loss 6q23.3 2 PERP, TNFAIP3 9 4, 13, 15, 16, 20, 22, 23, 27, 33 
6 142365293 142454020 88727 Loss 6q24.1 1 NMBR 9 4, 5, 13, 15, 20, 22, 23, 27, 33 
7 24327356 38203836 13876480 Gain 7p15.3 - 7p14.1 68 CREB5 11 1, 5, 6, 8, 10, 15, 17, 19, 22, 27, 32 
7 139605151 148810234 9205083 Gain 7q34 - 7q36.1 67 BRAF, EZH2, (TRB) 10 1, 5, 6, 10, 15, 17, 19, 22, 27, 32 
7 150603168 150622306 19138 Gain 7q36.1 1 SMARCD3 10 1, 5, 6, 10, 15, 17, 19, 22, 27, 31 
8 123643836 146264219 22620383 Gain 8q24.13 - 8q24.3 >100 MYC, PTK2, MAPK15, NFKBIL2 7 1, 4, 5, 10, 11, 22, 31 
9 21891747 22197146 305399 Loss 9p21.3 3 CDKN2A, CDKN2B, MTAP 7 2, 8, 11, 18, 26, 28, 31 
12 20125482 20129995 4513 Gain 12p12.2 0 - 7 1, 5, 13, 15, 18, 22, 32 
12 31760458 32007644 247186 Gain 12p11.21 1 AMN1 7 1, 5, 10, 15, 18, 22, 32 
12 37536490 37970109 433619 Gain 12q12 2 CPNE8, KIF21A 8 1, 5, 10, 12, 15, 18, 22, 32 
12 41955589 47430170 5474581 Gain 12q12 - 12q13.12 32 ARID2, HDAC7 9 1, 5, 10, 12, 15, 18, 20, 22, 32 
18 148226 12395119 12246893 Gain 18p11.32 - 18p11.21 42 USP14, YES1 10 4, 6, 9, 12, 16, 19, 25, 26, 28, 31 
18 49444874 58857002 9412128 Gain 18q21.2 - 18q21.33 31 TNFRSF11A, MALT1 11 4, 6, 8, 9, 12, 16, 25, 26, 28, 30, 31 
X 2713391 58319642 55606251 Gain Xp22.33 - Xp11.1 >100 UTX, JARID1C 9 6, 13, 15, 18, 22, 25, 26, 27, 32 
X 137893124 154578240 16685116 Gain Xq27.1 - Xq28 >100 IKBKG,IRAK1 8 12, 13, 15, 18, 20, 25, 27, 32 
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Table 4.3  Minimum common regions of CN gain or loss in t-FL 
 
 
The table layout is as indicated for Table 4.2. 
 
Chr Start End Length Type Cyto-band No. Genes  Candidate genes Cases Case numbers involved 
1 1406566 6202339 4795773 Loss 1p36.32 - 1p36.31 37 CDC2L2, TNFRSF14, TP73 11 5, 10, 11, 13, 15, 16, 19, 20, 26, 27, 34 
1 7688809 7982611 293802 Loss 1p36.23 6 CAMTA1, VAMP3, PER3, UTS1, TNFRSF9, PARK7 11 1, 5, 10, 13, 15, 16, 19, 20, 26, 27, 34 
1 163839348 164031598 192250 Gain 1q24.1 3 MGST3, ALDH9A1, TMCO1 9 1,10, 13, 16, 17, 21, 22, 26, 27 
2 60899425 61552674 653249 Gain 2p15 5 REL, PUS10, PEX13, AHSA2, USP34 11 1, 4, 5, 10, 15, 16, 17, 18, 21, 25, 30 
6 87472057 91385530 3913473 Loss 6q14.3 - 6q15 24 CASP8AP2, MAP3K7 7 1, 13, 17, 20, 21, 24, 34 
6 137018030 138821596 1803566 Loss 6q23.3 12 IFNGR1, IL20RA, IL22RA2, PERP, TNFAIP3 7 1, 4, 8, 13, 20, 24, 25 
7 138342 6660808 6522466 Gain 7p22.3 - 7p22.1 59 CARD11, FAM 7 1, 5, 10, 15, 17, 19, 27 
7 18357112 101876473 83519361 Gain 7p21.1-7q22.1 >100 HDAC9, CREB5, IGFBP1/3, EGFR 7 1, 5, 10, 15, 17, 19, 27 
7 150603168 150622306 19138 Gain 7q36.1 1 SMARCD3 8 1, 5, 10, 15, 17, 19, 27, 31 
9 21813210 22146338 333128 Loss 9p21.3 3 CDKN2A, CDKN2B, MTAP 7 7, 10, 18, 26, 27, 28, 31 
12 23344385 24396333 1051948 Gain 12p12.1 1 SOX5 7 1, 5, 6, 10, 15, 18, 32 
12 37536490 37970109 433619 Gain 12q12 2 CPNE8, KIF21A 8 1, 5, 6, 10, 12, 15, 18, 32 
12 44391098 45110683 719585 Gain 12q12 -  12q13.11 4 ARID2, SFRS2IP, SLC38A1, SLC38A2 10 1, 5, 6, 10, 12, 15, 18, 20, 22, 32 
12 51714508 51844412 129904 Gain 12q13.13 6 CSAD, EIF4B, IGFBP6, SOAT2, SPRYD3, TENC1 10 1, 5, 6, 7, 12, 18, 20, 21, 22, 32 
12 55116404 56037731 921327 Gain 12q13.2 - 12q13.3 26 STAT6 10 1, 5, 6, 7, 12, 15, 18, 20, 22, 32 
17 1874025 7888604 6014579 Loss 17p13.3 - 17p13.1 >100 TP53, CD68, JMJD3, TNFSF12 10 4, 6, 8, 9, 13, 15, 17, 20, 21, 24 
17 10881798 17567464 6685666 Loss 17p13.1 - 17p11.2 40 TNFRSF13B (TACI), RASD1 9 4, 6, 8, 9, 13, 15, 20, 21, 24 
18 1543 1567856 1566313 Gain 18p11.32 9 USP14, YES1 13 4, 8, 9, 12, 15, 16, 17, 19, 24, 25, 26, 28, 31 
18 23335186 28890957 5555771 Gain 18q12.1 16 MEP1B 14 6, 8, 9, 12, 13, 15, 16, 17, 24, 25, 26, 28, 30, 31 
18 48387638 48415217 27579 Gain 18q21.2 1 DCC 15 6, 8, 9, 10, 12, 13, 15, 16, 17, 22, 24, 26, 28, 30, 31 
21 13266376 18159067 4892691 Gain 21p11.1 - 21q21.1 10 USP25 8 1, 12, 13, 16, 17, 18, 30, 34 
21 23133880 44590433 21456553 Gain 21q21.2 - 21q22.3 >100 ERG, ETS2, DYRK1A 7 1, 12, 13, 16, 17, 18, 30 
X 2713391 63173777 60460386 Gain Xp22.33 - Xq11.1 >100 UTX, JARID1C 8 1, 6, 12, 13, 15, 18, 27, 32 
X 104841149 113186400 8345251 Gain Xq22.3 - Xq23 42 IRS4, MYCL2 10 1, 6, 12, 13, 15, 18, 21, 27, 28, 32 
X 135045986 138303981 3257995 Gain Xq26.3 - Xq27.1 12 CD40LG, FGF13 10 6, 12, 13, 15, 18, 20, 21, 27, 28, 32 
X 142106349 142197820 91471 Gain Xq27.3 0 - 11 1, 4, 6, 12, 13, 15, 18, 20, 21, 27, 32 
X 152485294 154292605 1807311 Gain Xq28 61 FUNDC2 12 1, 6, 12, 13, 15, 18, 20, 21, 24, 27, 28, 32 
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Figure 4.6  Gain 2p16.1-15 predicts OS from survival in FL that transforms 
 
Top, the minimum common region of gain at chromosome 2p16.1-15 (marked by the vertical dashed 
lines and extending from 60.8 to 62.8 Mb) in 7 / 31 FL cases is indicated by the blue arrow. The 
horizontal blue bars represent regions of CN gain in different cases (with one case having two regions 
of separate gain). Chromosome cytobands and genomic positions are indicated. Bottom, Kaplan-
Meier plots for the seven cases with gain at 2p16.1-15 (in blue) and the remaining cases (n = 24) all 
with normal copy number at this location (in black); the log rank test statistic and hazard ratio (HR) 
are given on the right.  
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oncogenes in NHL (Satterwhite et al. 2001) and, specifically, FL (Lu et al. 1991; 
Goff et al. 2000). No associations were observed with TTT or survival from 
transformation for gain 2p15-16 in FL or t-FL, respectively. 
No other associations were observed between CNAs and the survival outcomes, 
although all cases with gains of either 8q24.13-q24.3 (n = 7) or 18q21.2-q21.33 (n = 
11) in the initial FL sample or loss 9p21.3 in the initial FL sample (n = 7) or t-FL 
sample (n = 7) had died. 
4.4.5 CNAs emerging at t-FL 
Disruption of genes by CNAs occurring at t-FL might contribute to the 
transformation process and determining which MCRs of loss or gain are enriched at 
t-FL may help identify these potential driver events. Eight such MCRs were 
identified by comparing the t-FL and FL CNA sets on a chromosome-by-
chromosome basis (Table 4.4), four of these contained multiple genes (≥37) over a 
minimum 1.7Mb size and one was a micro-CNA (<30kb) but contained no known 
coding regions. The remaining three MCRs (Figure 4.7), which ranged from 0.3 to 
1.4 Mb in size and contained less than ten genes (suggesting these sites might be 
preferentially targeted in transformation), are detailed as follows:  
i. loss 11q24.2 which includes two putative tumour suppressors: EI24 (coding a 
protein which has a role in TP53 mediated apoptosis (Gu et al. 2000), binds 
Bcl-2 (Zhao et al. 2005) and when subject to loss may confer therapy 
resistance (Mork et al. 2007)) and CHEK1 (protein product of which inhibits 
CDC25 by phosphorylation leading to CDK-cyclin complex phosphorylation 
and cell cycle arrest (Sorensen et al. 2003)). Although only 4 cases were 
affected by this loss, they showed shorter OS from FL with no cases 
surviving more than 2.5 years after transformation (Appendix 5 Figure 1);  
ii. gain 13q31.3 containing two genes: GPC5 (coding a cell surface 
proteoglycan which may have a role in cell division and control of growth 
and which is over-expressed in lymphoma cell lines (Yu et al. 2003) and 
solid tumours (Williamson et al. 2007)) and MIRHG1 (a potential oncogene 
(He et al. 2005; Olive et al. 2010)) encompassing the miR17-92 cluster,  
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Table 4.4  MCRs of loss or gain enriched in t-FL compared to FL 
 
Chr Start End Length Type Cyto-band No. genes Candidate genes
§
 t-FL cases involved t-FL (FL) samples 
2 36982238 44981413 7999175 Loss 2p22.2-p21 41 SOS1, CEBPZ, 1, 15, 21 3 (0) 
3 3621942 3650872 28930 Loss 3p26.2 0 - 1, 4, 15, 17, 21 5 (1) 
3 48089538 49873624 1784086 Loss 3p21.31 52 TRAIP, CDC25A 4, 17, 20, 21 4 (0) 
4 86320359 96154196 9833837 Loss 4q21.23 - q22.3 37 MAPK10 4, 7, 9, 15, 21 5 (0) 
11 99607925 120648330 21040405 Gain 11q22.1 - q23.3 >100 MLL, ATM, IL10RA, CBL, POU2AF1 (BOB1), BCL9L 4, 6, 21, 22, 24 5 (0) 
11 124517442 125193868 676426 Loss 11q24.2 8 EI24, CHEK1 4, 6, 10, 22 4 (0) 
13 90007394 91500384 1492990 Gain 13q31.3 2 GPC5, MIRHG1# 6, 8, 10, 18, 21, 22 6 (1) 
16 27077108 27413252 336144 Gain 16p12.1 5 IL4-R, IL21-R , NSMCE1, GTF3C1, JMJD5 1, 7, 15, 17, 18 5 (1) 
 
The table layout is as described for Table 4.2. Included here are minimum common regions (MCRs) of gain / loss that occur in at least 3 additional t-FL samples compared to 
the preceding FL sample and are either absent from FL or present in only one FL sample. 
§Candidate genes were determined for each region based on their known (or predicted) function + / - their known association with other cancers. 
#This region encompasses a cluster of micro-RNAs (also termed miR17-92) which includes mirR-17, mirR-18a, mirR-19a, mirR-19b-1, mirR-20a, mirR-92a-1.  
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Figure 4.7  MCRs enriched in t-FL and loss ETS1 
 
Examples of minimum common regions (MCRs) of copy number aberrations enriched at transformation including: A, loss chromosome 11q; B, gain chromosome 13q; and 
C, gain chromosome 16p. Candidate genes in the MCRs are indicated. Also shown (A) is a recurrent region of loss affecting the ETS1 locus. The figure layout is as described 
for Figure 4.6 (top) with the addition that losses are indicated by horizontal red bars. 
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encoding at least 6 microRNAs, a locus frequently amplified in de novo 
DLBCL (Ota et al. 2004) and follicular lymphoma (Neat et al. 2001); and  
iii. gain 16p12.1 that harbours IL4-R, a potentially relevant locus in view of the 
recently described elevated IL4 expression in the micro-environment in 
primary FL samples (Calvo et al. 2008) and increased expression of IL4Rα 
previously observed in FL cells versus normal GC B cells (Husson et al. 
2002). 
4.4.6 CNAs affecting single genes 
CNAs that disrupt single genes may specifically represent events that contribute to 
disease. MCRs including only one gene (detailed in Table 4.2 and Table 4.3) 
occurred for five genes in FL: RERE (loss 1p36.23), IGSF21 (Loss 1p36.13), NMBR 
(Loss 6q24.1), SMARCD3 (Gain 7q36.1) and AMN1 (Gain 12p11.21); and three 
genes in t-FL: SMARCD3 (Gain 7q36.1), SOX5 (Gain 12p12.1) and DCC (Gain 
18q21.2), with the differences between the two tumour types reflecting the 
heterogeneity of CNAs present in FL and t-FL. Furthermore, to date none of these 
genes have been associated with FL or its transformation.  
Expanding the examination to all CNAs revealed additional single gene events 
including a loss that includes the entirety of ETS1 on chromosome 11q24.3 in FL (n 
= 3) and t-FL (n = 4 cases) in an MCR that is < 500 kb, as highlighted in Figure 4.7. 
Single cases demonstrated CNAs disrupting single genes, with a loss including 30 / 
31 exons (with only the 3’ exon unaffected) from CREBBP on chromosome 16p13.3 
occurring in both FL and t-FL samples (Figure 4.8) from case 26; a 10kb loss 
occurred in ALK (Case 33; both FL and t-FL);  MSI2 (which regulates RNA 
expression) was disrupted by loss 17q22 in case 16 (FL);  both SLCO3A1 (15q26.1) 
and NDUFV3 (21q22.3) were deleted in case 23 (FL) and EBF1 (coding a 
transcription factor with a role in B-cell lineage commitment) was included in a 125 
kb deletion at 5q33.3 in both FL and t-FL from case 26. Although not a single gene 
deletion, a 123 kb MCR of loss targeted the CDKN2A / CDKN2B locus in both FL 
and t-FL for 7 cases; a region known to be disrupted in FL as described in Chapter 1. 
  
Chapter 4 
148 
 
 
 
 
Figure 4.8  CN loss of CREBBP 
The plots represent the estimated CN of each tumour sample for Case 26 for a ~3.5Mb section of 
chromosome 16p (obtained by comparison to germline signal intensities and expressed as log2ratios) 
for t-FL (top) and FL (bottom). Each black dot represents the log2ratio for an individual probe: the 
horizontal white line represents a ratio = 0 (the majority of probes cluster around this line indicating 
the same signal intensity in germline and tumour identifying that tumour is 2n for the majority of the 
section of 16p illustrated here); the two thin horizontal black lines above and below represent 
log2ratios of 1 and -1 respectively (a ratio of -1 indicates the relative CN in the tumour is half of that 
in germline and so here is 1n). The red bar highlights a small loss which disrupts CREBBP. Scales 
underneath each plot indicate genomic location. 
Mb indicates megabase; and kb, kilobase. 
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The identification of loss targeting CREBBP is particularly relevant as this gene lies 
in a region of chromosome 16p that is subject to recurrent aUPD in FL (O'Shea et al. 
2009) and predicts worse PFS. The gene product has a role in co-activation of 
transcription factors and cellular growth control as well as co-activation of p53 
(Avantaggiati et al. 1997; Gu et al. 1997; Lill et al. 1997). As dominant negative 
CREBBP mutants suppress p53-dependent CDKN1A expression (Scolnick et al. 
1997) this indicates these variants could attenuate the tumour suppressor activity of 
p53, a mechanism contributing to many malignancies (as discussed in Chapter 1). 
Furthermore, the following clinical associations suggest a role for disruption of 
CREBBP in cancer, including FL: 
loss or mutation of CREBBP is associated with the Rubinstein-Taybi 
syndrome (Petrij et al. 1995) which includes a propensity to malignancy;  
translocations involving CREBBP occur in AML (Borrow et al. 1996; Giles 
et al. 1997) and secondary malignancy (Rowley et al. 1997); and  
the CREBBP locus was involved in a t(16;18)(p13;q21.3) described in one 
case of FL (Mahmoodi et al. 2004).  
To investigate whether the loss of CREBBP observed in case 26 identifies a target 
that is disrupted in FL, mutational analysis was performed. As CREBBP is a large, 
gene consisting of 31 exons which would require at least 39 PCR amplicons to 
enable conventional sequencing of the full coding region, a search was performed for 
existing mutations in the Sanger Institute Catalogue Of Somatic Mutations In Cancer 
web site, http://www.sanger.ac.uk/cosmic (Forbes et al. 2008). This recorded three 
mutations in the coding regions of CREBBP in a search done on 23 February 2010 
(as of January 2011 the record has been expanded to 10 missense substitution or 
deletion mutations across ovarian, lung and skin cancers). 
 These included two missense single base substitutions at position 248 (A>C; N83T) 
and 2809 (C>T; P937S) and a single synonymous replacement at position 5271 
(C>T; G1757G) in exons 2, 14 and 31 respectively. As mutations in other genes can 
cluster in “hotspots” (for example those found in TP53 cluster to exons 5 to 8 
(Petitjean et al. 2007)), the three corresponding exons were selected for mutational 
analysis in a cohort (n = 19) of the LLMPP DNA samples known to have LOH 
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(which may render mutations homozygous thereby aiding their detection) at the 
CREBBP locus on chromosome 16p13.1. These were used to rationalise use of 
limited DNA in the sequential FL / t-FL set, and were sourced from a previous study 
performed in our institution (O'Shea et al. 2009).  However, mutations were not 
detected in any of the 60 amplicons.  
4.4.7 Gain chromosome 7 and EZH2 mutation  
The finding of CN gains affecting chromosome 7 in FL (n ≥ 10; Table 4.2) and t-FL 
(n ≥ 7; Table 4.3) supports previous studies which have identified gain 7 occurring 
in at least 18% of FL cases (Bloomfield et al. 1983; Avet-Loiseau et al. 1997; 
Horsman et al. 2001; Mohamed et al. 2001). Indeed this was the most frequent 
chromosomal gain (20%) in a large series (n = 336) of FL in a report which also 
suggested this was an early event in disease evolution (Hoglund et al. 2004). 
Moreover, gain 7 may have a role in subsequent disease progression / transformation 
(Bernell et al. 1998; Horsman et al. 2001; Boonstra et al. 2003). However, until 
recently, it was not clear which genes affected by chromosome 7 gain might be 
relevant in FL.  
In a report first presented at the American Society of Hematology annual meeting, 
New Orleans 2009, Morin and colleagues (Morin et al. 2009) identified that EZH2 
may be one such target. This is a histone methyltransferase gene, the protein product 
of which forms part of the polycomb repressive complex 2 (PRC2) which functions 
to trimethylate histone H3 at lysine 27 creating a repressive mark (H3K27me3) 
associated with transcriptionally silent chromatin (Cao et al. 2002; Kuzmichev et al. 
2002; Kirmizis et al. 2004). The study identified that recurrent, non-synonymous 
single nucleotide substitution mutations affecting codon 641 in the catalytic domain 
of EZH2 occurred in germinal centre lymphomas including 7.2% of FL cases (Morin 
et al. 2010a).  
To investigate these mutations in transformation and whether they might be under 
selective pressure through amplification of the EZH2 locus at chromosome 7q36.1, 
mutational analysis was performed. In total, 9 / 31 (29%) of the sequential cases 
demonstrated mutations in codon 641 of EZH2. These were all non-synonymous 
single nucleotide substitution mutations (Figure 4.9) which, in six cases, were   
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Figure 4.9  EZH2 mutation 
Illustrated is an example of one single nucleotide substitution mutation (red star) affecting codon 641 
(black bar) of EZH2. The electropherogram shows double the level of mutated allele as compared to 
normal and is consistent with amplification of chromosome 7 in this case (Patient 1; Table 4.5) 
involving the mutated allele. 
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present in both FL and t-FL samples (for one case this included four FL samples); 
two cases showed mutations in t-FL that could not be detected in FL and one case 
showed a mutation only in FL and not the subsequent t-FL (Table 4.5). In six cases 
(67%), the mutations were accompanied by CN gains that included the EZH2 locus; 
for four of these cases both mutation and CN gain were present in FL and t-FL 
samples, for one (case 17) the CN gain was present in both samples but the mutation 
was only detected in t-FL whereas in case 33 the mutation was present in all FL and 
t-FL samples but CN gain only affected the initial FL sample. None of the mutations 
were accompanied by CN loss of the EZH2 locus. Five of the mutated cases had 
germline samples available which confirmed that the mutations were somatically 
acquired. 
In t-FL and FL, 8 (26%) and 7 (23%) of the 31 cases, respectively, were mutated 
which suggests that the rate might be higher (in this population selected on the basis 
of transformation) than that determined for a large series of FL (n = 251) in the 
report described above (Morin et al. 2010a). To examine these mutations in an 
independent, non-selected FL cohort a series of diagnostic samples (n = 56) from our 
institution were screened. In 6 cases (10.7%), EZH2 codon 641 single base 
substitution mutations were detected that similarly encoded amino acid replacements: 
asparagine (n = 3), phenylalanine (n = 2) and histidine (n = 1) with the mutation 
frequency no different to that identified by Morin and colleagues (Fisher’s exact test, 
P = 0.41).  
The doubling of mutation rate in FL from the 31 sequential cases (23%) is not 
significantly different to that in the 56 samples in diagnostic series (10.7%), P = 
0.12, which might, in part, reflect sample size limitations. Furthermore, in the 
diagnostic set of 56 samples, transformation developed in 2 / 6 (33%) mutated and 18 
/ 50 (36%) un-mutated cases; and this as well as OS and TTT comparisons between 
these groups were not significantly different. However, as the FL samples in the 
sequential cases are predominantly from disease episodes occurring after the initial 
diagnosis, and mutations can develop with transformation (Cases 17 and 20) 
indicating they can be acquired later in the course of disease, it is possible that such 
disruption of EZH2 may contribute to progression / transformation.  
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Table 4.5  EZH2 mutations in FL / t-FL 
Patient^ Sample Mutation
$
 Codon 641 change* Germline
#
 Variant amino acid 
Chr 7 copy number change including EZH2 locus  
Loss Gain  
1 FL1 + 
TA/TC n.a. Phe 
- +  
 
t-FL + - +  
5 FL1 + 
TA/TC n.a. Phe 
- +  
 
t-FL + - +  
7 FL1 + 
TA/CC n.a. Ser 
- -  
 
t-FL - - -  
12 FL1 + 
T/CAC n.a. His 
- -  
 
t-FL + - -  
15 FL1 + 
TA/TC Normal Phe 
- +  
 
t-FL + - +  
17 FL1 - 
T/AAC Normal Asp 
- +  
 
t-FL + - +  
19 FL1 + 
TA/TC Normal Phe 
- +  
 
t-FL + - +  
20 FL1 - 
TA/TC Normal Phe 
- -  
 
t-FL + - -  
32 FL1 + 
TA/TC Normal Phe 
- +  
 
FL2 + - -  
 
FL3 + - -  
 
FL4 + - -  
 
t-FL + - -  
 
^Patient number in italics = only FL or bold = only t-FL sample mutated. $For each patient the same mutation was found in all affected samples.  *All mutations identified 
within EZH2 codon 641 were non-synonymous single base substitutions. Mutations are indicated by an underline with the left-hand replaced by the right-hand base.  
#Germline DNA was analysed where available.  +indicates present; -, absent; n.a., not available; Phe, phenylalanine; Ser, serine; His, histidine; and Asp, asparagine. 
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4.4.8 Candidate genes identified by loss of chromosome 1p36  
Loss of the telomeric aspect of chromosome 1p occurs in a variety of cancers 
(Ragnarsson et al. 1999) and its loss has been reported in FL (Horsman et al. 2001; 
Hoglund et al. 2004; Zhang et al. 2004). Ross and colleagues have since identified 
that LOH of chromosome 1p36 through allelic loss or aUPD occurs in up to 50% of 
FL (Ross et al. 2007). Subsequently, aUPD 1p36 has been shown to predict OS in FL 
(O'Shea et al. 2009) and an array-CGH determined 11.4 Mb loss at 1p36 found to 
predict both OS and risk of transformation (Cheung et al. 2009b). This strongly 
suggests that 1p36 contains a genetic locus which, when disrupted, contributes to FL 
outcome.  
4.4.9 CDC2L2: a candidate tumour suppressor gene on 1p36 
In the current study, loss of 1p36 that affected genes was present in four MCRs 
found in FL samples and two found in t-FL. The MCRs ranged from 27 to 81kb and 
293 kb to 4.8 Mb in size, in FL or t-FL respectively, and occurred in up to 11 / 31 
cases (35%). To address this further the Wellcome Trust Sanger Institute Cancer 
Genome Project (CGP) website, http://www.sanger.ac.uk/cgi-bin/genetics/CGP was 
examined. This includes over 800 cell lines that have been assayed for LOH and 
CNAs; of these 127 are haematological with 15 sourced from B-NHL cases, four of 
these contain t(14;18) and one, WSU-NHL (derived from the pleural effusion of a 
progressive, refractory nodular histiocytic B-NHL which may have transformed), has 
an apparent homozygous loss of chromosome 1 at around 1 to 2 Mb (within 1p36).  
A small, homozygous region of loss extending from 1.60 to 1.66 Mbps was 
identified within chromosome 1p36.33 in DNA from WSU-NHL (Figure 4.10) and 
this was confirmed by PCR (Figure 4.11). This 60 kb region was included within 
losses affecting both the FL (n = 10) and t-FL (n = 11) samples and contained two 
genes. One of these, CDC2L2 (CDK11A), has a role in the negative regulation of 
normal cell cycle progression and may function as a tumour suppressor gene as it is 
deleted or altered frequently in neuroblastoma (Lahti et al. 1994) and its single allele 
loss facilitates skin carcinogenesis in mice (Chandramouli et al. 2007). Furthermore, 
its protein product down-regulates BCL2 (Yun et al. 2007) and enhances apoptosis  
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Figure 4.10  Chromosome 1p loss in WSU-NHL cell line 
Illustration of homozygous loss within a larger area of hemizygous loss on chromosome 1p in WSU-
NHL. Top, copy number plot with each dot representing one probe (from the Affymetrix 
GenomeWide SNP6.0 array) and its signal intensity for the WSU-NHL cell line relative to that of a 
germline pool of non-malignant human DNA plotted as log2ratio, as described in Figure 4.8. Middle, 
the majority of the plot shows copy number of 1 highlighted by the interrupted purple line; the small 
red line highlights a region of homozygous loss extending from 1.60 to 1.66 Mbps. Bottom, the two 
known genes located within this region are indicated: CDC2L2 (CDK11a) has a role in cell cycle 
control and SLC35E2 is a predicted solute transporter gene.  
Mbps indicates megabase pairs 
  
Chapter 4 
156 
 
 
 
 
Figure 4.11  Confirming CDC2L2 homozygous loss 
Illustration of the approach taken to confirm the CDC2L2 homozygous deletion in WSU-NHL and to 
demonstrate that the loss seen on the micro-array was not an artefact due to CNVs in the germline 
baseline pool of normal DNA (analogous to the effect of CN changes in FL if t-FL were compared 
directly to FL as illustrated in Appendix 1 Figure 1). Left, schematic representation of genes (black 
boxes) within chromosome region 1p36 including CDC2L2 and two neighbouring genes (not to 
scale); the telomeric gene (SSU72) is uppermost. Right, agarose gel electrophoresis images of PCR 
products from amplification of regions of the respective genes demonstrates lack of amplification of 
CDC2L2 (illustrated here for the first and last exons) in WSU-NHL DNA confirming the microarray 
findings of a homozygous loss at this locus.  
NTC indicates no template control; MNC, pooled mononuclear cells. 
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of HCC cells (Cai et al. 2002). Consequently, FL cases (n = 12; four of which 
subsequently transformed) from the LLMPP series (O'Shea et al. 2009) were 
screened for CDC2L2 mutations. These represented a good screening cohort as, in 
each case, 1p36 was affected by aUPD which would render mutations homozygous.  
All 20 exons in CDC2L2 were amenable to sequencing as 15 amplicons. As CDC2L1 
has a high degree of homology to CDC2L2, unique primers for respective amplicons 
could not always be designed. Consequently, forward and reverse sequencing was 
performed upfront with nucleotides common to both determining a consensus 
sequence. However, no CDC2L2 mutations were detected across all exons in the FL 
cases examined. 
4.4.10 TNFRSF14 mutations occur frequently in FL and t-FL 
An elegant study, first presented at the American Society of Hematology annual 
meeting in December 2009, and recently published (Cheung et al. 2010b), identified 
that TNFRSF14 (located less than 1Mb centromeric to CDC2L2 as shown in Figure 
4.12) was mutated in 18% FL cases at diagnosis. The gene product of TNFRSF14 is 
expressed on the surface of many cell types including both B and T lymphocytes and 
can bind different ligands which may activate effector function, although it can 
function in a co-stimulatory or co-inhibitory manner and this is dependent on the 
ligand bound (Cai and Freeman 2009).  
As this gene is located within the MCR losses in FL (n = 11) and t-FL (n = 11) cases 
at sizes 190kb and 4.8Mb, respectively (Table 4.2, Table 4.3 and Figure 4.12), the 
mutation status of TNFRSF14 was determined for the FL / t-FL sample set to 
examine the relationship with transformation and loss 1p36. All coding regions of the 
eight exons were assessed and 12 mutations were detected in 10 / 31 (32.3%) cases 
across the first six exons (Table 4.6).   In half of these cases, the same mutation was 
present in all FL and t-FL samples; two cases (7 and 26) showed mutations only in t-
FL (case 7 had two distinct mutational events); case 33 had one mutation found only 
in the earliest FL and a second mutation found only in the subsequent FL2 and t-FL 
samples (indicating that ongoing acquisition of different TNFRSF14 mutations by 
different disease sub-clones can occur over the course of FL / t-FL) whereas the  
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Figure 4.12  CDC2L2 and TNFRSF14 are candidate genes within loss 1p36 
The figure layouts are similar to that detailed for Figure 4.6 (top) with the addition that red bars 
indicate region of loss. The positions of CDC2L2 (black filled arrow) and TNFRSF14 (white filled 
arrow) within the common regions of chromosome 1p loss are indicated for t-FL (A) and FL (B) 
samples. 
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Table 4.6  TNFRSF14 mutations in FL / t-FL 
Exon region Patient
ψ
 Sample Mutation Mutation type Start position
+
 Mutation effect Germline 
Chr 1 CNA inc. TNFRSF14  
gain loss  
          
 
          
 
1 7 FL1 - 
del 24 bp‡ between 297 and 299† TSS deletion n.a.^ 
- +  
  
t-FL1 + - -  
 
17 FL1 + 
G>A# 302 TSS disruption (ATG > ATA) normal 
- -  
  
t-FL1 + - -  
 
22 FL1 + 
G>A 1 bp intron 1-2 Alters splice region n.a.^^ 
- -  
  
t-FL1 - - -  
 
32 FL1 + 
T>A 2 bp intron 1-2 Alters splice region normal 
- -  
  
FL2 + - -  
  
FL3 + - -  
  
FL4 + - -  
  
t-FL1 + - -  
2 5* FL1 + 
G>A 67 Non-synonymous: Glu > Lys n.a. 
- +  
  
t-FL1 + - +  
3 33 FL1 - 
G>A 109 Non-synonymous: Cys > Tyr normal 
- +  
  
FL2 + - -  
  
t-FL1 + - -  
4 19 FL1 + 
C>A 119 Premature stop codon normal 
- -  
  
t-FL1 + - +  
 
23 FL1 + 
ins TGTGTGA 55-56 Frameshift normal 
- -  
  
FL2 + - -  
  
t-FL1 - - -  
 
33 FL1 + 
C>T 111 Non-synonymous: Arg > Cys normal 
- +  
  
FL2 - - -  
  
t-FL1 - - -  
5 26 FL1 - 
ins C between 34 and 41$ Frameshift normal 
- -  
  
t-FL1 + - +  
6 7 FL1 - 
ins A between 4 and 6§ Frameshift n.a.^ 
- +  
  
t-FL1 + - -  
 
9 FL1 + 
del G 60 or 61¥ Frameshift normal 
- -  
  
t-FL1 + - -  
  
t-FL2 + - +  
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Table 4.6  TNFRSF14 mutations in FL / t-FL (continued). 
ψPatients highlighted in bold have two mutations (affecting different exons in each case.). 
+bp position in respective exon unless indicated. 
‡due to different possible start / end combinations, there are three possible 24 bp losses from GGCATGGAGCCTCCTGGAGACTGGGG including either the left-hand two, 
the inner two or the right-hand two G bases along with the other 22 bases.  
†There are differing potential start (and end) sites of deletion reflecting runs of G bases at start and end sites. The three possible start sites to the loss are 297-8, 298-9, 299-300 
bp. 
^ mutation in t-FL only (not in FL) 
#t-FL homozygous  
^^ mutation in FL1 only (not t-FL1) 
 *The single bp substitution in exon 2 of case 5 could be a rare non-synonymous SNP variant. However, no SNP has been identified from dbSNP build 131. This is the only 
one of the twelve mutations which has potential to be a germline variation. (The other patients who lack germline have at least one tumour sample without mutation which 
shows germline sequence.) 
$ can be any of position 34-5, 35-6, 36-7, 37-8, 38-9, 39-40, 40-1 bp due to run of six Cs in germline and ins C 
§ position 5 in germline is A so ins A either between 4-5 or 5-6 bps 
¥positions 60 and 61 bp both G in germline so del single G either 60 or 61 bp 
Chr indicates chromosome;  CNA, copy number alteration; -, absent; +, present; del, deletion; ins, insertion; bp, base pair; TSS, translation start site; n.a., not available; 
Glu, glutamic acid; Lys, lysine; Cys, cysteine; Tyr, tyrosine; Arg, arginine. 
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remaining two cases (22 and 23) showed mutations only in FL samples but not the 
subsequent t-FL, giving a frequency in transformed samples of 26% (n = 8).  
The mutations included single nucleotide substitutions (n = 7), single nucleotide 
insertions (n = 2), a 7bp insertion, a single nucleotide deletion and a 24 bp deletion. 
Consistent with a role as a tumour suppressor gene, the mutations all had potential to 
disrupt translation / splicing / protein sequence through disruption of the translation 
start site / ATG initiation codon (n = 2), amino-acid substitutions (n = 3); frameshifts 
(n = 4) and direct creation of stop codon (n = 1). The two remaining mutations were 
located 1 and 2 bp in to intron 1 - 2 and had potential to disrupt exon:intron splicing. 
The mutations in the eight cases with germline DNA available were confirmed as 
acquired (examples are given in Figure 4.13) and of those remaining, three were 
present in only one of the FL or t-FL samples. The final mutation (a single nucleotide 
substitution at position 67 of exon 2 in case 5) was present in both FL and t-FL and, 
without germline DNA for comparison, a SNP could not be excluded although this is 
unlikely as such a variant has so far not been reported 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and the encoded amino acid change 
would replace glutamic acid (acidic) with lysine (basic) and is predicted to be 
potentially damaging to protein function using the PolyPhen website, 
http://coot.embl.de/PolyPhen/ (Ramensky et al. 2002). When the respective FL or t-
FL mutated versus un-mutated cases were compared, no associations were 
demonstrated regarding time to transformation or OS in FL nor survival from t-FL. 
Mutational frequency was then determined at FL presentation by screening samples 
from the diagnostic FL set (and was possible for 54 / 56 cases). A total of 17 
mutations each in separate cases (a frequency of 31%) and again affecting the first 6 
exons were detected. The majority (n = 13) constituted single nucleotide 
substitutions (three of which disrupted the ATG initiation codon); three were 
deletions including two single nucleotide losses and one 28 bp loss; and one involved 
a single nucleotide insertion. Germline DNA was available and confirmed the 
mutations for 6 cases whereas for four single nucleotide substitutions (two 
synonymous and two occurring at the exon:intron junction) the possibility that they 
represent undescribed SNPs could not be excluded (in a similar manner to case 5 
from the sequential set above). All events had the potential to disrupt initiation of  
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Figure 4.13  Acquired TNFRSF14 mutations in FL / t-FL 
Example electropherogram traces of six different TNFRSF14 mutations (red stars) in five FL / t-FL cases 
(patients 9, 17, 26, 32, 33) with available (un-mutated) germline DNA. Mutations are ordered from left to right 
by their genomic position in TNFRSF14. For Case 17, a hemizygous single nucleotide substitution in the ATG 
translation start site at FL (black bar) is rendered homozygous at transformation (this case is known to have 
aUPD in t-FL, but not FL, from a previous study (Fitzgibbon et al. 2007). For Case 32, a single substitution is 
seen in all available FL and t-FL samples whereas in Case 33 two separate mutations, one in the initial FL 
sample only, the other restricted to the second FL and the t-FL samples. For Case 26, a single base insertion, 
present only at transformation, causes frameshift (and a downstream premature stop codon) with a single 
nucleotide deletion in Case 9 having a similar effect but in all available FL and t-FL samples. The respective 
mutation sites are indicated below the case numbers and sample origin is indicated to the left of each trace (with 
numbers corresponding to disease episodes). germ indicates germline. 
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translation, protein sequence or intron splicing as, once again, confirmed mutations 
were detected at the start (within the initial 5 bp) of introns. The risk of 
transformation was no different for mutated (41%) versus un-mutated (32%) cases, P 
= 0.55, and, similarly, no significant associations were demonstrated for time to 
transformation and overall survival, contrasting with the recently published report by 
Cheung and colleagues (Cheung et al. 2010b). However, on exclusion of the four 
possible SNPs and the three early intronic events, the revised mutation rate 
(including only non-synonymous exon mutations) of 10 / 54 cases (19%) is similar to 
that study. 
4.4.11 t-FL associated mutations may occur in FL sub-clones 
Of the four TNFRSF14 mutations demonstrated only at transformation in three FL / 
t-FL cases (7, 26 and 33; Table 4.6), mutation specific forward and reverse ASO 
primers were generated for two (24 bp del in exon 1 and ins A in exon 6, both from 
Case 7). These enabled FL samples to be examined for presence of (low-level) t-FL 
clones and were applied in separate PCR reactions to the respective FL and t-FL 
samples. This confirmed the mutations were present in the t-FL samples. 
Significantly, in the preceding FL samples for which conventional sequencing had 
not detected the mutations, the targeted PCR confirmed they were indeed present but 
at lower levels than in the subsequent t-FL, as illustrated (for ins A) in Figure 4.14, 
which indicates that (in this case) the t-FL clone is present in FL almost two years 
before presenting clinically as transformation. 
4.4.12 Non-sequential mutations suggest divergent evolution in FL / t-FL  
Three cases (22, 23 and 33) contained mutations present in FL but absent from 
subsequent samples (Table 4.6); similar to the scenario observed for the EZH2 
mutation in Case 7 (section 4.4.7). In case 22, a single nucleotide substitution (G>A) 
occurred at the first position of intron 1-2 in FL only and in case 23 a 7bp insertion 
within exon 4 was identified in the two available FL samples but could not be 
detected at subsequent transformation. For case 33 (which had normal germline 
DNA available) a non-synonymous C>T substitution (coding Arg>Cys) was present 
at position 111 of exon 4 in the initial FL sample but neither the subsequent FL2 or  
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Figure 4.14  Detection of t-FL associated mutations in preceding FL 
 
Left, electropherogram traces demonstrating germline sequence (with no detectable mutation) in FL and the presence of a mutation (insertion A) in exon 6 of TNFRSF14 
causing frameshift in t-FL occurring almost two years later, as illustrated by the red star. Right, agarose gel electrophoresis of mutation specific PCR with primers designed on 
germline exon 6 sequences used (top) as a control and showing amplification in both tumour samples and the normal DNA; forward (middle) and reverse (bottom) primers 
designed on the mutation detected only in t-FL and applied to the same samples confirm its absence in normal (MNC) DNA and its presence in t-FL, as expected, but also 
reveal a low level amplification in the preceding FL (red arrow). This suggests the t-FL clone is present, in FL, almost two years before presenting clinically as disease. 
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t-FL samples. In the same case, a second mutation (the non-synonymous G>A 
substitution coding Cys>Tyr) occurred in FL2 and t-FL but was not detected in the 
initial FL. 
Consequently, these cases demonstrate that future FL / t-FL episodes may not arise 
directly from the preceding FL but, rather, a more complex evolutionary pattern 
occurs. Using case 33 as an example, a divergent model of disease development can 
be proposed in which a common origin acquires differing TNFRSF14 mutations 
present in either the initial FL or the subsequent relapse (FL2) and transformation 
(Figure 4.15). In particular, a common origin, as opposed to two independent FL 
episodes, is indicated by the presence of chromosome 10q loss (identified by the 
earlier micro-array study) in all three samples (FL, FL2 and t-FL). As over a decade 
elapses between FL and FL2, this indicates the persistence of a long-lived clone 
marking a common origin to both episodes. For case 22, the CNAs identified by the 
micro-array study also support a common origin as, in addition to those present in FL 
but absent at t-FL, and those occurring only in t-FL, other gains and losses are 
common to both FL and t-FL.  
4.4.13 Divergent evolution of FL / t-FL from a common progenitor cell 
In light of the divergent evolution suggested for four cases by the EZH2 and 
TNFRSF14 mutational analysis, the distributions of micro-array determined CN 
changes for the respective samples from each of the 31 sequential FL / t-FL cases 
were compared. This demonstrated that in 22 / 31 cases (71%) development arose by 
divergent evolution from a common origin, based on certain CNAs present in FL 
being absent from subsequent t-FL.  The remaining cases showed either sequential 
acquired CN changes in subsequent disease episodes (n = 7), indicating direct 
evolution of later disease from the initial FL, or had insufficient changes (n = 2) to 
define the evolutionary pattern (Appendix 5 Table 2).  
All samples in each case were shown to be clonally related as follows: 
 all except three cases (22, 23 and 24) had some CNAs that were present in 
each respective sample;  
Chapter 4 
166 
Figure 4.15  Non-sequential mutations suggest divergent evolution of FL / t-FL 
Illustrated for the three samples (FL, FL2 and t-FL) available for Case 33 are electropherogram traces of two TNFRSF14 mutations (indicated by the red stars). In exon 4, a 
mutation (C>T) present in FL, but absent from future FL2 and t-FL, indicates that these disease episodes did not develop directly from the FL clone. Furthermore, a second 
mutation (G>A) appears at FL2 and persists at transformation. As the earlier micro-array study indicates that loss chromosome 10q occurs in all three samples, this leads to a 
divergent model of development, illustrated on the left, in which a common origin (grey oval) that contains loss 10q acquires differing TNFRSF14 mutations present in either 
the initial FL or the subsequent relapse (FL2) and transformation.  
A time-line for disease episodes is given to the left, with an unknown (?) time elapsing between development of the common precursor, its acquisition of the exon 4 mutation 
and clinical presentation as FL. The long time course (12 years) between FL and FL2 indicates the persistence of a long-lived clone marking a common disease origin (that 
lacks the exon 4 mutation and acquires the exon 3 mutation at some point prior to FL2 presentation). The exon 4 mutation demonstrates the divergent evolution of disease 
clones and the additional exon three mutation reflects ongoing acquisition of different TNFRSF14 mutations by different disease clones over the course of FL / t-FL. 
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cases 22 and 24 were previously shown to have the same IGH-BCL2 
rearrangements in their respective FL and t-FL samples (Jenner et al. 2002); 
and 
case 23 shows the same IGH-V segment selection (demonstrated later in 
chapter 5, Table 5.2) in the FL and t-FL samples  
which indicates that no disease episodes occurring after the initial FL represent 
entirely new, spontaneously arising disease clones.  
Consequently, these data suggest that a putative common progenitor cell (CPC) that 
has acquired some genetic changes may give rise to FL or t-FL through subsequent 
non-sequential, divergent genetic evolution. As an example, in case 33, loss 10q is 
common to all cases, with loss 1p36 and the TNFRSF14 exon 4 mutation occurring 
only in FL whereas the TNFSRF14 exon 3 mutation occurs only in FL2 and t-FL; 
suggesting that a CPC has acquired loss 10q and goes on to acquire the other genetic 
changes as the respective disease episodes develop. 
Recurrent copy number changes in cases with divergent evolution might represent 
early events when present in both FL and t-FL. The CN changes in these cases are 
indicated in Appendix 5 Figure 2 and recurrent MCRs (n = 29), present in all 
samples from each case and occurring in at least 3 / 22 (>10%) cases, are 
summarised in Table 4.7. Three of these involve only one gene and, in particular, 
gain 7q36.1 includes only SMARCD3 the product of which contributes to regulation 
of gene transcription through chromatin remodelling and is part of a chromatin 
remodelling complex that regulates the self-renewal / proliferation of neuronal stem 
cells (Lessard et al. 2007). As these can give rise to diverse progeny, which at least 
in part mirrors the putative CPC, SMARCD3 represents a further candidate gene in 
FL / t-FL development.  
Finally, the CPC model of evolution not only applies to FL followed by 
transformation but can also apply to sequential t-FL samples (as illustrated for Case 9 
in Figure 4.16 and Figure 4.17) and FL that relapses after t-FL (Case 21; Figure 
4.18 and Figure 4.19), with these two scenarios reflecting variation in the hierarchy 
of progenitor development. In case 9, a less primitive sub-clone gives rise to t-FL, 
but undergoes clonal divergence in giving rise to relapse of this disease (t-FL2). In  
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Table 4.7  CPC common MCRs in all samples of 3 or more cases 
The table layout is as indicated for Table 4.2. 
Chr Start End Length Type Cytoband No. Cases No. Samples No. Genes Candidate genes Cases 
1 18449498 18476791 27293 Loss 1p36.13 4 9 1 IGSF21 10, 15, 27, 31 
1 24306170 27853506 3547336 Loss 1p36.11 4 10 60 RUNX3, CD52 10, 11, 15, 27 
1 28523347 32332437 3809090 Loss 1p35.3-35.1 4 10 33 PUM1 10, 15, 21, 27 
1 155604487 179419537 23815050 Gain 1q23.1-25.3 3 7 >100 ABL2 10, 22 ,27 
2 60646978 66775162 6128184 Gain 2p16.1-14 3 7 26 REL, MEIS1 10, 15, 18 
2 135357790 141512804 6155014 Gain 2q21.3-22.1 3 8 16 CXCR4 8, 15, 18 
2 209792047 209825550 33503 Gain 2q34 3 9 0 MAP2 <200kb downstream 8, 18, 25 
2 238257900 239413568 1155668 Gain 2q37.3 3 8 14 HES6, TRAF3IP1 8, 10, 18 
7 138342 101876473 101738131 Gain 7p22.3-q22.1 3 7 >100 CARD11, FAM, HDAC9, CREB5, IGFBP1/3, EGFR 10, 15, 27 
7 150603168 150622306 19138 Gain 7q36.1 3 8 1 SMARCD3 15, 27, 31 
8 112962509 113314553 352044 Gain 8q23.3 3 10 1 CSMD3 10, 22, 31 
8 132846688 146264219 13417531 Gain 8q24.22-q24.3 3 10 99 MAPK15, NFKBIL2, PTK2 4, 10, 31 
9 21813210 22146338 333128 Loss 9p21.3 4 8 3 CDKN2A, CDKN2B,  MTAP 18, 26, 28, 31 
12 37536490 37970109 433619 Gain 12q12 5 15 2 CPNE8, KIF21A 10, 12, 15, 18, 32 
12 44391098 45110683 719585 Gain 12q12-q13.11 6 16 4 ARID2, SFRS2IP, SLC38A1, SLC38A2 10, 12, 15, 18, 22, 32 
12 98797775 98984451 186676 Gain 12q23.1 3 10 2 ANKS1B, UHRF1BP1L 4, 19, 32 
15 18973525 19685239 711714 Loss 15q11.2 3 7 1 POTEC 10, 15, 31 
15 41134331 42863544 1729213 Loss 15q15.2-q21.1 3 7 31 TP53BP1, CCNDBP1, B2M, TRIM69 6, 10, 15 
15 59476426 59482274 5848 Loss 15q22.2 3 8 0 RORA <200kb upstream 7, 10, 15 
17 52368 7883476 7831108 Loss 17p13.3-p13.1 3 7 >100 TP53, CD68, JMJD3, TNFSF12 4, 8, 21 
17 23383257 25111724 1728467 Gain 17q11.2 3 6 40 TNFAIP1 8, 18, 31 
17 38777643 39890078 1112435 Gain 17q21.31 3 6 27 ETV4, HDAC5, GRN 8, 18, 31 
17 45304401 61464987 16160586 Gain 17q21.33-q24.1 3 6 >100 CD79B, SMARCD2, 8, 18, 31 
17 69521471 72216370 2694899 Gain 17q25.1-q25.2 3 6 76 CDK3 8, 18, 31 
18 148226 1567856 1419630 Gain 18p11.32 7 16 9 YES1 4, 9, 12, 25, 26, 28, 31 
18 16864653 28890957 12026304 Gain 18q11.1-q12.1 7 17 42 GATA6 6, 9, 12, 25, 26, 28, 31 
18 49444874 58857002 9412128 Gain 18q21.2-q21.33 6 16 31 MALT1, TNFRSF11A 6, 8, 9, 12, 26, 28 
X 6838911 58319642 51480731 Gain Xp22.31-p11.1 5 14 >100 UTX, JARID1C 6, 15, 18, 27, 32 
X 137893124 154578240 16685116 Gain Xq27.1-28 5 14 >100 IKBKG, IRAK1 12, 15, 18, 27, 32 
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Figure 4.16  Divergent evolution giving rise to relapsed t-FL 
Shown are fifteen CN plots (as described for Figure 4.8) from Case 9. There are five plots each for FL, t-FL and subsequent relapsed t-FL samples (labelled left), for five 
separate chromosome arms (indicated top) and corresponding cytobands (indicated bottom). Horizontal bars highlight the CN losses (red) and gains (blue). All cases have the 
same gain 18q and this in combination with loss 9q in FL only suggests divergent evolution of FLl and subsequent t-FL from a CPC containing gain 18q. A t-FL specific loss 
on 17p occurs but loss 4q in only the initial t-FL suggests divergence of t-FL from a precursor containing both gain 18q and loss 17p and this then acquires loss 9p at relapse 
of transformation (t-FL2). Time between samples is indicated to the right. The gain on chromosome 18 includes 18p, only gain 18q is illustrated here. 
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Figure 4.17 Model of divergent evolution of relapsed t-FL 
A model of disease evolution for Case 9 developed from the CNAs illustrated in Figure 4.16. FL then 
t-FL / relapsed t-FL (t-FL2) are illustrated as blue and red ovals respectively. Putative progenitor 
stages are illustrated as grey ovals. The CNAs occurring at each stage are shown below the ovals. The 
more primitive progenitor stage gives rise to FL and a less primitive progenitor stage by divergent 
evolution, subsequently the less primitive progenitor stage gives rise to t-FL and its clinical relapse by 
divergent evolution. The time course between clinical episodes (bottom) indicates progenitor cells can 
persist for many months before disease presents clinically.  
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Figure 4.18  Divergent evolution giving rise to relapse of FL after transformation 
The figure layout is as described for Figure 4.16 with the addition that there are six CN plots for each sample, and these correspond to FL, t-FL and FL relapse post-
transformation (FLp) from Case 21. All cases have the same loss 1p and this in combination with gain 3p in FL only suggests divergent evolution of FL and subsequent t-FL 
from a CPC containing loss 1p. CNAs specific to t-FL (gain 1q, loss and gain 3p and loss 4q) indicate FLp does not arise directly from t-FL. The gain 1p common to both FL 
and FLp suggests they share an origin less primitive than that which gives rise to transformation. The mutually exclusive loss 3q (FLp) and gain 3p (FL) indicate non-
sequential evolution of FL / FLp. 
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Figure 4.19  Model of divergent evolution of FL relapse after transformation 
The figure layout is as described for Figure 4.17, except that samples are FL, t-FL and FLp (Case 21) 
and CNAs are those from Figure 4.18. The time course between clinical disease events indicates that 
both the more primitive and less primitive progenitors can persist for months. 
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case 21, a less primitive sub-clone gives rise to initial FL (FL1) and subsequent FL 
relapse after transformation (FLp), with t-FL arising from a more primitive sub-
clone. This case raises the possibility that different (long-lived) progenitor sub-clones 
can co-exist, with temporal evolution of these progenitors not necessarily reflecting 
the temporal occurrence of clinical disease. 
4.5 Discussion 
Following the demonstration that germline variation is important in FL outcome 
(Chapter 3), the investigation described in this chapter has examined the role of 
acquired genetic changes in FL and its transformation. Using a series of sequential 
FL and t-FL samples from cases with comprehensive clinical follow-up, high 
resolution genome wide copy number profiling was performed to determine tumour 
associated CNAs. Those that either occurred recurrently or appeared enriched at 
transformation or targeted single genes were then used to determine candidate 
regions that might be relevant to disease development or progression in FL / t-FL. 
The inclusion of germline DNA was an important aspect of the study in both 
identifying disease associated CNAs and revealing somatically acquired mutations.  
4.5.1 DNA copy number changes identify candidate regions in FL / t-FL 
CNA losses and gains occurred in every sample, consistent with previous a large 
karyotyping study in which 97% FL cases harboured chromosome changes in 
addition to t(14;18) (Horsman et al. 2001). The recurrent CNAs in FL (Table 4.2) or 
t-FL (Table 4.3) occur at similar chromosome regions to those described in other 
reports in FL (using karyotyping (Johansson et al. 1995; Horsman et al. 2001; 
Hoglund et al. 2004); CGH (Bentz et al. 1996; Avet-Loiseau et al. 1997); or array-
CGH (Cheung et al. 2009b) and FL / t-FL (using array-CGH (Martinez-Climent et 
al. 2003)) that have examined chromosome imbalances in FL / t-FL, with the high 
resolution of the Affymetrix SNP 6.0 genome-wide array used in the current study 
facilitating the refinement of certain recurrent CNAs to smaller (sub-megabase) 
MCRs, for example the losses at chromosome 1p36, as well as identifying those 
targeting single genes. 
Chapter 4 
174 
Previous reports have identified gain 2p (including the proto-oncogene REL) in FL 
(Ross et al. 2007) and FL / t-FL (Goff et al. 2000) and the survival association 
shown here suggests this gain may have a clinical impact, at least in FL that is 
destined to transform. However, although none of the other CNA MCRs predicted 
outcome, this association requires examination in a larger cohort to determine 
whether this effect is independent from other, clinical, predictors. 
The focal loss of the majority of CREBBP (on chromosome 16p13.3) in Case 26 in 
combination with the association of 16p aUPD in FL and PFS (O'Shea et al. 2009) 
and the disruption of CREBBP in other malignancies (Borrow et al. 1996; Giles et al. 
1997; Rowley et al. 1997; Mahmoodi et al. 2004) led to investigation of this locus 
here. Although no mutations were identified in a rationalised study of this large gene, 
this locus does appear to be relevant in FL as, subsequently, Pasqualucci and 
colleagues have recently demonstrated using whole exome sequencing that CREBBP 
is disrupted by genomic deletions and / or somatic point mutations in 32% FL (and 
29% de novo DLBCL) (Pasqualucci et al. 2011). Furthermore, similar to findings 
from a recent report in FL (n = 25) in which both BAC array-CGH and the 
Affymetrix 500K SNP array were applied to samples to provide increased resolution 
to the genomic analysis (Cheung et al. 2010a), other single genes were also disrupted 
by CN changes in the current investigation. In addition, chromosomal breakpoints 
occurred through potentially important genes such as KDM2B (a histone 
demethylase) on chromosome 12 and PRIM2 (DNA primase polypeptide 2 which has 
a role in DNA replication) on chromosome 6p. The location of such breaks may 
either directly impact on gene function or may represent translocations with potential 
to create hybrid fusion gene products. Consequently, these and the other single gene 
events, particularly the loss disrupting ETS1, represent candidates for future study. In 
this regard, recent presentations made at the American Society of Hematology annual 
meeting, Orlando, December 2010 identify that, in up to 89% of FL cases, recurrent 
inactivating mutations affect MLL2, which codes a histone methyltransferase 
involved in the epigenetic control of transcription (Mendez-Lago et al. 2010; Morin 
et al. 2010b). Importantly, this follows recent methylation studies indicating that 
epigenetic influences have a role in FL (Martin-Subero et al. 2009a; O'Riain et al. 
2009). Moreover, MLL2 is located on chromosome 12q so the mutations offer a 
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selective basis for the recurrent 12q aUPD observed in other FL series (Fitzgibbon et 
al. 2007; O'Shea et al. 2009).  
Of CNAs potentially enriched at transformation, the MCR of gain 16p, including 
IL4-R, is of particular interest in view of the known relevance of micro-environment 
immune response in FL outcome (Dave et al. 2004). This follows the demonstration 
that expression of IL4 protein (a cytokine with roles in T cell differentiation and B 
cell activation by TH cells) is increased in the micro-environment of FL tumours 
(Calvo et al. 2008) and that the IL4-R protein is over-expressed in FL cells (Husson 
et al. 2002), raising the possibility that gain IL4-R might predispose to its increased 
protein expression which, through interaction with IL4 present in the FL micro-
environment, somehow favours transformation.   
4.5.2 EZH2 and TNFRSF14 mutations in FL / t-FL 
During the course of this study, the discovery of somatic mutations affecting EZH2 
(chromosome 7q.36.1) in GC lymphomas (including FL) was reported (Morin et al. 
2010a). As gain 7 occurred in almost one third of the sequential FL / t-FL cohort, 
EZH2 was examined in this cohort and mutations were identified in a subset of these 
cases with some restricted to transformation. Although EZH2 mutations at FL 
diagnosis do not appear to confer increased risk of developing transformation, their 
development later in the course of disease in some cases suggests they may have a 
driver role in progression / transformation. The subsequent demonstration that 
heterozygous codon 641 point mutations are gain of function and act in a dominant 
manner (Sneeringer et al. 2010; Yap et al. 2011) suggests that the 7q CN gain, 
including the EZH2 locus, observed in ⅔ of the mutated FL / t-FL cases is selecting 
for this oncogenic event (Table 4.5).  
Disruption of chromosome 1p36 by aUPD (O'Shea et al. 2009) or CN loss (Cheung 
et al. 2009b) has clinical significance in FL. CN loss occurred frequently in the 
sequential FL / t-FL series with sub-megabase MCRs identified. Two genes were 
investigated: CDC2L2 showed no mutations despite its involvement in recurring CN 
losses (subsequently a single non-synonymous mutation G>C at cDNA position 145 
in one case of lung cancer has been reported (Ding et al. 2008)) whereas TNFRSF14 
was mutated frequently. The investigation of TNFRSF14 mutations followed a 
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presentation at the American Society of Hematology Annual Conference, New 
Orleans, 2009 (Cheung et al. 2009a), subsequently reported in November 2010 
(Cheung et al. 2010b), which identified exonic, non-synonymous mutations in 
TNFRSF14. This was a large study including over 200 FL cases and identified that 
TNFRSF14 mutations at diagnosis predict OS in the era of rituximab therapy, 
although this association could not be reproduced here this is probably an effect of 
the limited population size of cases with available diagnostic FL samples (n = 56).  
It is of significance that additional mutations, occurring within the first five bases of 
introns within TNFRSF14 and confirmed by comparison to germline DNA, are 
demonstrated in the current study suggesting that the actual mutation rate of this gene 
in FL may be higher than that initially reported (Cheung et al. 2010b). All five 
intronic splice site mutations identified in this study occurred in 5’ donor splice sites 
and, using the website http://www.cbs.dtu.dk/services/NetGene2/, each mutation was 
predicted to abolish the donor splice site function and disrupt exon:intron splicing. 
Analogous point mutations in 5’ splice sites of other genes typically induce exon 
skipping and their exclusion from gene transcripts but can lead to inclusion of 
intronic regions and early termination of the transcript both of which can lead to 
truncated protein products and reduced expression (Antonarakis et al. 2002) and can 
occur in different cancers (Brose et al. 2004; Bianchi et al. 2011). Future work 
should determine the consequences of TNFRSF14 splice site mutations on 
transcription and translation and whether these associate with gain or loss of 
function. This should help further unravel the selective basis of such mutations in FL 
given the role of ligand binding by TNFRSF14 (also termed HVEM) on the cell 
surface of normal B cells and their subsequent activation but the down-regulation of 
TNFRSF14 in GC B cells (Duhen et al. 2004), the origin of FL.     
The TNFRSF14 mutations are also detected only at t-FL and this suggests they may 
have relevance as drivers in the process of transformation, whereas the lack of 
association between mutations at FL diagnosis and transformation risk suggests these 
mutations do not predispose to t-FL. However, the demonstration that apparent 
transformation specific mutations are indeed detectable, at low level, in preceding FL 
suggests they may be early events in the transformation process. Furthermore, these 
mutations might occur in long-lived disease sub-clones which exist many months 
before clinical presentation as transformation.  
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4.5.3 Evolution of FL / t-FL may occur from a common progenitor cell 
Having provided confirmation of EZH2 and TNFRSF14 mutation frequencies in FL, 
this study went on to demonstrate that acquired, disease specific mutations can occur 
non-sequentially in FL / t-FL as, for both TNFRSF14 and EZH2 mutations, there 
were specific cases in which mutations were found only in FL (being absent from 
subsequent t-FL). This suggested that t-FL may not develop directly from the 
(principal) FL disease clone and on inspection of the CNAs for each sample across 
all chromosomes, analogous modes of FL / t-FL development were determined in 
71% cases. These are consistent with reports from prior to this study (Martinez-
Climent et al. 2003; Fitzgibbon et al. 2007) and others published during the course of 
this study (d'Amore et al. 2008; Johnson et al. 2008b; Ruminy et al. 2008; Eide et al. 
2010) which identify that genetic changes present in FL can be absent from relapse 
or transformation; and helps explain the similar levels of CNAs in the initial FL 
sample set compared to the initial t-FL set. The presence of shared CNAs in such 
cases supports the existence of a common progenitor cell (CPC) that is the origin to 
different disease episodes through acquisition of genetic events that are specific to 
respective disease episodes. In certain cases, the time-course of this non-sequential 
(divergent) indirect clonal evolution of FL and its transformation indicates that the 
putative CPC is also long-lived, giving rise to different disease episodes many 
months, even years, apart. Although the CNAs provided a means by which the 
evolutionary pathway of most FL / t-FL cases could be inferred and these changes 
may harbour (or cause) genetic events that contribute to these tumours, they may also 
represent passenger events that occur secondary to the genomic instability that is a 
hall-mark of malignant cells. Consequently, it is an important finding that specific 
potential driver events, namely the focal mutations of EZH2 or TNFRSF14 that occur 
independently in case 7 or cases 22 / 23 / 33 respectively, are similarly suggestive of 
divergent evolution. 
The CNAs that occur in all samples of a case with evolution from a putative CPC, 
and occur recurrently in different cases, may represent important early events in 
development of a putative CPC. In this cohort there are four MCRs of loss or gain 
affecting only one gene (1p36.13, 7q36.1, 8q23.3, 15q11.2) and a further four MCRs 
that affect only 2 to 4 genes (9p21.3, 12q12, 12q12-13.11, 12q23.1). In particular, 
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gain 1p36.13 includes SMARCD3, the product of which has a role in chromatin 
remodelling and in regulation of neuronal stem cells and merits further study in the 
context of a putative CPC in FL / t-FL. 
Furthermore, the cases with more than just single FL and t-FL samples provide 
additional insights in to the complexity of disease evolution, as follows: 
a) a “transformation-primed” progenitor clone can persist for at least 18 
months before giving rise to t-FL relapse (Figure 4.17);  
b) less primitive progenitor clones can give rise to either FL (Figure 4.19) or 
t-FL (Figure 4.17);  
c) these clones can survive the therapy applied at initial transformation 
(Figure 4.17 and Figure 4.19); and  
d) the sequence of genomic CN change acquisition in the progenitor clones 
themselves may be divergent and not mirror the clinical course of disease 
(Figure 4.19). 
Significantly, the demonstration of divergent evolution in FL / t-FL has important 
clinical implications regarding the process of disease recurrence as it suggests this 
may arise from a potential long-lived progenitor (that is resistant to conventional 
therapies). To examine this further, the concept of the putative CPC origin was 
addressed in more detail in a subset of cases and this investigation is described in the 
following chapter. 
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Chapter 5    Evolution of FL and its transformation 
5.1 Introduction  
The conventional model of FL transformation is one of progressive acquisition of 
additional genetic events that promote expansion of an affected FL sub-clone which 
eventually presents clinically as t-FL. This is supported by the demonstration that 
sequential FL / t-FL tumours are clonally related and that t-FL may arise from a 
single FL cell (Zelenetz et al. 1991). Furthermore, as described in Chapter 1, several 
subsequent studies provide evidence supporting this model.  
However, recurrent secondary genetic changes in t(14;18) containing tumours 
suggest that this model may be an over-simplification (Horsman et al. 2001; Hoglund 
et al. 2004; de Jong 2005) with the findings from chapter 4 adding further 
complexity as, in certain cases, copy number changes or gene mutations present in 
FL are absent from subsequent t-FL. As certain changes remain common to both 
tumours and t-FL can acquire other genetic changes, this suggests that FL and t-FL 
can develop from a common precursor by acquisition of independent genetic events 
in a pattern of non-sequential divergent disease evolution.  
This follows the proposal, over a decade ago, by Matolcsy and colleagues of a 
common malignant ancestor model for the evolution of FL. This was based on a non-
sequential clonal relationship of Immunoglobulin VHDJH sequence variability, in 
which sequence changes present in a case of FL were absent from subsequent t-FL 
(Matolcsy et al. 1999). Furthermore, reports soon indicated that FL relapse might 
arise by evolution from pre-existing minor sub-clones (Aarts et al. 2000; Aarts et al. 
2001). Subsequently, support for the model has been provided by the identification 
(through genome-wide array-CGH performed on a series of samples from FL that 
relapsed or transformed) of DNA copy number losses or gains in 9 / 12 FL samples 
that were absent from the subsequent disease episodes (Martinez-Climent et al. 
2003). More recently, analogous results were provided by the demonstration that 
aUPD may occur non-sequentially in the majority (10 / 18) of FL / t-FL cases 
(Fitzgibbon et al. 2007). These data suggest that a long-lived precursor may give rise 
to temporally and genetically distinct disease episodes. Clinical support for such a 
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model is provided by the demonstration that t-FL arising 11 years post-procedure in 
the recipient of an allo-HSCT (performed for high risk AML) was derived from 
donor cells. Significantly, the tumour contained an identical BCL2-MBR re-
arrangement to that found in FL which developed in the donor 3 years post-donation 
(and which subsequently transformed). This suggests that a long-lived progenitor 
cell, which was passed from donor to recipient, gave rise to both lymphomas (Hart et 
al. 2007). These data support a model, as illustrated in Chapter 4, indicating that FL / 
t-FL may arise from common progenitor cells (CPCs) that can survive for months or 
even years in patients with FL. 
To examine such evolution of FL / t-FL, it is important to have genetic markers that 
can distinguish differing disease clones including potential progenitor cells. As 
described in Chapter 1, FL originates from lymphoid germinal centres where SHM 
occurs in B cells. Furthermore, malignant clonal expansion in FL occurs after the 
initiation of SHM (Zelenetz et al. 1992) and ongoing SHM occurs within the tumour 
(Zelenetz et al. 1992; Ottensmeier et al. 1998). Consequently, SHM patterns can be 
utilised as markers of FL / t-FL clones (after sites of SHM have been established 
from tumour derived IGH-V sequences). Comparison of the SHM patterns in 
sequential FL / t-FL samples should then determine a pattern of the clonal evolution 
of disease progression and transformation. Furthermore, unique sites of SHM could 
be used to generate allele specific oligonucleotides enabling interrogation of FL 
tumours for the presence of t-FL clones and potential progenitor clones. By using a 
series of sequential FL / t-FL sample sets, this approach could provide important new 
insights in to the evolution of FL and its transformation.   
5.2 Aims and Objectives 
The suggestion that t-FL may not develop directly from preceding FL, and the 
possibility of examining sub-clones of these diseases using IGH-V SHM patterns, led 
to this study exploring the evolution FL transformation. 
Study objectives included determination of IGH-V usage in sequential FL and t-FL 
samples, mapping the SHM patterns at the respective VH loci, interrogating FL 
samples with t-FL clone specific primers / probes to determine whether t-FL could be 
detected in preceding FL samples and (in cases showing divergent evolution) 
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identifying the SHM sequence of putative common precursor cells then confirming 
its presence in the respective FL and t-FL sample pairs. 
5.3 Materials and Methods 
5.3.1 Patients and samples  
The same cases with sequential FL and t-FL samples that had been investigated in 
Chapter 4 were included in this study. Due to limitations of DNA availability, only a 
subset consisting of 18 cases could be examined. In parallel, samples from a father 
and son allo-HSCT donor / recipient pair who each subsequently developed FL / t-
FL, (provided by Drs Jason Hart and Raymond Lai from the Departments of 
Medicine and Pathology, University of Alberta and Cross Cancer Institute, 
Edmonton, AB, Canada) were examined. 
5.3.2 DNA preparation 
DNA was extracted and stored as previously described (section 2.4.1). 
5.3.3 PCR detection of IGH-VH segment usage and SHM sites  
The BIOMED consortium’s VH segment consensus primers, as described in Chapter 
1 and detailed in Appendix 6 Table 1, were used to determine clonality of samples. 
Amplification was performed with either Amplitaq
®
 Gold (Applied Biosystems), 
Platinum Taq
®
 (Invitrogen) or AccuPrime™ Pfx (Invitrogen) DNA Polymerases 
(1.25units) in a final volume of 50μl containing the respective proprietary buffers 
(final concentration 1), dNTPs (500μM), MgCl2 (1.5mM), primers (400nM) and 
100ng of DNA as further described in section 2.4.3. To confirm sites of SHM and 
exclude single base changes generated by DNA polymerase template reading errors, 
PCR reactions were performed initially with Amplitaq
®
 Gold then repeated with a 
second enzyme.  
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5.3.4 Homo-hetero-duplex analysis 
Homo-hetero-duplex (HH) analysis and gel extraction of the IGH-VH PCR products, 
performed as described in sections 2.4.9 and 2.4.10. The homo-duplex bands, 
representing the major tumour clones, were used to: 
1. Identify VH segment usage by the tumour clone  
2. Determine SHM patterns of the major clones from sequential FL / t-FL 
samples by PCR re-amplification of the extracted homo-duplex band using 
the appropriate VH primer and then sequencing (as in section 5.3.5).   
3. Design allele specific oligonucleotides on SHM sites specific to t-FL (as 
indicated in section 2.4.4) 
5.3.5 Determining SHM sites in tumour sub-clones 
To map the evolution of SHM patterns within FL and t-FL sub-clones, PCR products 
from IGH-VH reactions were cloned using the TOPO TA Cloning
®
 system and 
separate colonies were selected as templates for PCR amplification as described in 
section 2.4.11. 
5.3.6 Sequencing 
Purified PCR products following cloning or HH analysis were directly sequenced 
using BigDye
®
 Terminator chemistry as described in section 2.4.12.  
5.3.7 SHM sequences 
The IGH-VH region sequences obtained from homo-duplexes and single colonies 
were then compared to germline sequence through the IMGT/V-QUEST programme 
available at http://www.imgt.org (Brochet et al. 2008) to determine SHM sites. The 
sites of SHM for each homo-duplex product were compared for each set of FL / t-FL 
sequential samples to determine the pattern of evolution. SHM sites from multiple 
clones from each tumour sample were also compared. This enabled the construction 
of genealogical trees. These chart the acquisition of SHM sites by different sub-
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clones present within respective tumours and present them as an evolutionary 
hierarchy (examples are presented later in section 5.4.3). Moreover, after excluding 
SHM sites unique to either FL or t-FL, the remaining SHM sites (present in both 
tumour samples) provided a mark that might help detect a putative common 
progenitor cell (CPC). 
5.3.8 qPCR 
To investigate the time-course of transformation, FL samples were examined for 
presence of t-FL clones. qPCR was performed using ASO primers and probes as 
described in section 2.4.7.  
5.4 Results 
5.4.1 Patient samples 
A total of 43 lymph node biopsy samples from 20 patients were analysed. They 
included FL and t-FL samples for each of the 18 cases with sequential samples, with 
an additional FL sample available for each of 5 cases, and one sample each from the 
HSCT donor / recipient pair.  
Patient and sample characteristics for the series of cases with sequential sample sets 
are summarised in Table 5.1. The median age at FL diagnosis was 44 years (range 
22 to 70) with 10 cases (56%) male. Available FL tumour grades at diagnosis (17 / 
18 cases) were 1 (n = 12) or 2 (n = 5). One case had no detectable IGH-BCL2 
translocation, 12 cases had rearrangements involving the IGH MBR region and the 
remaining 5 involved IGH mcr or atypical regions, a distribution similar to previous 
studies (Tsujimoto et al. 1985a; Cleary et al. 1986a; Ngan et al. 1989; Buchonnet et 
al. 2002). FL samples were taken prior to treatment in 7 cases (3 available from 
diagnosis, 4 at progression after initial “watch and wait” expectant management), at 
first or second relapse in 9 cases and at later stages of disease for the remaining 2 
cases. There was a median of 4 treatment courses (range 0 to 13) prior to t-FL and 
the median time to transformation from FL diagnosis for this cohort was 45.9 months 
(range 12.1 to 174.9), similar to that observed in two recent large series of FL 
patients (Montoto et al. 2007b; Al-Tourah et al. 2008).  
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Table 5.1  Characteristics of the cases (n = 18) with sequential FL / t-FL samples 
Case* Gender Age Grade 
Sample 
TTT (months) 
Tx prior 
to t-FL 
FL
§
 t-FL
#
 
1 F 41 2 Rel1 1 40.2 3 
2 F 70 2 Prog 1 27.5 0 
4 F 43 1 Rel1 1 120.0 4 
5 M 45 2 Rel2 1 44.9 7 
6 M 53 1 Prog 1 12.1 2 
7 M 22 1 Rel2 1 114.5 5 
8 M 67 2 Prog 1 35.7 1 
9 F 47 1 Prog 1 94.5 7 
11 M 46 1 Rel1 1 46.8 4 
12 F 30 1 Rel7 1 174.9 13 
15 M 30 1 Rel1 2 82.4 5 
16 M 61 2 Rel2 1 22.8 3 
20 F 26 1 Diag 1 12.1 1 
21 F 32 NA Rel2 1 72.9 4 
23 F 42 1 Diag 1 39.3 0 
25 M 45 1 Diag 1 18.2 2 
26 M 40 1 Rel1 1 49.2 7 
27 M 60 1 Rel2 1 104.0 4 
  
*For five cases (indicated in bold)  second FL samples were included in the study: in cases 26 and 27 
the second FL sample was obtained from FL relapse prior to t-FL whereas in cases 2, 5 and 21 the 
sample was obtained at FL relapse after t-FL. Of the 18 cases, 15 have died and the median follow-up 
of the 3 remaining cases is 20.2 years (range 13.0 to 25.4). 
§Earliest FL sample in the study. 
#For t-FL samples, 1 indicates the first episode of transformation and 2 the second. 
TTT indicates time to transformation from diagnosis of FL; Tx, a separate course of treatment 
(radiotherapy / chemotherapy / immunotherapy or combinations of these together); F, female; M, 
male; Rel, relapse; Prog, progression; Diag, diagnosis; and NA, not available. 
 
 
 
Chapter 5 
185 
5.4.2 IGH-V usage indicates common origin of FL and t-FL samples 
The IGH-V segment (VH) usage for each of the 18 paired cases, as determined by 
IGH-V PCR then direct sequencing of homo-duplex products, is detailed in Table 
5.2 with examples of homo-duplex bands and the subsequent PCR products obtained 
after amplification of DNA from the extracted bands provided in Figure 5.1 and 
Figure 5.2, respectively. A homo-duplex band (major clone) was obtained for all 
samples, with FL and t-FL samples from respective cases showing the same VH 
segment usage which indicated they were clonally related. The majority of cases (n = 
13) showed VH3 usage, 4 used VH4 and, in a single case, the VH5 segment had been 
selected. This pattern of VH segment usage is in keeping with those described in 
previous reports for normal B cells (Schroeder et al. 1987; Mortuza et al. 2001) and 
malignant B cells (Pritsch et al. 1999; Camacho et al. 2003) including FL cells 
(Hummel et al. 1994). In the majority of FL / t-FL cases (n=17) the IGH-V sequences 
contained no stop codons nor insertions / deletions with accompanying frame-shifts 
and were potentially functional; in the remaining instance (case 11) the selected VH5 
segment was partially deleted in both FL and t-FL samples.  
5.4.3 SHM in major (HH) clones indicates divergent evolution can occur 
Comparison of SHM sites in the homo-duplex sequences from paired FL / t-FL 
samples indicated that in the majority of cases (n = 12) sequential additive 
acquisition of SHM sites in the progression from FL to t-FL (indicating direct 
evolution as illustrated in Appendix 6 Figure 1) did not occur. Rather, indirect 
evolution (Figure 5.3) could be demonstrated with common SHM sites found in both 
FL and t-FL but additional SHM sites found in FL that were absent from t-FL. This 
indicated that t-FL arose by divergent evolution from an earlier clone, which 
contained fewer SHM sites than occurred in FL, representing a putative common 
progenitor cell (CPC) origin for both tumours. In these 12 cases the median number 
of tumour specific SHMs acquired by the major clones of the FL and t-FL samples 
were 4 (range 1 to 9) and 3 (range 0 to 22), respectively, with a median homology of 
the CPC sequence to germline of 89.78 % (range 83.47 [Case 6] to 94.49 [Case 12]). 
The evolution patterns determined from the homo-duplex sequence results for all 18  
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Table 5.2  FL / t-FL IGH-V segment usage and evolution on HH analysis  
Case 
number* 
IGH-V allele
#
 
 Evolution pattern  Tumour specific SHMs
$
 
CPC homology 
to germline (%) 
 SHM  CN   FL t-FL 
1 IGH-V4-34*01/*02  CPC CPC  5 12 87.35 
2 IGH-V3-11*01  DIRECT DIRECT  - - - 
4 IGH-V3-48*03  CPC CPC  4 3 90.73 
5 IGH-V3-48*03  DIRECT np  - - - 
6 IGH-V3-21*01  CPC CPC  4 3 83.47 
7 IGH-V4-61*01  CPC CPC  9 22 94.42 
8 IGH-V4-59*01  CPC CPC  9 0 93.51 
9 
IGH-V3-
23*01/*03/*04/*05 
 DIRECT CPC  - - - 
11 IGH-V5-51*01  DIRECT CPC  - - - 
12 IGH-V3-15*01/*02  CPC CPC  4 3 94.49 
15 IGH-V4-61*02  CPC CPC  4 12 89.24 
16 IGH-V3-23*01/*02/*04  CPC CPC  1 3 87.10 
20 IGH-V3-23*01/*04  DIRECT DIRECT  - - - 
21 IGH-V3-53*01  DIRECT CPC  - - - 
23 IGH-V3-48*01  CPC CPC  4 1 90.73 
25 IGH-V3-30*01/-03*01  CPC CPC  4 7 90.32 
26 IGH-V3-11*01  CPC
§
 CPC  6 4 87.90 
27 IGH-V3-23*01/04  CPC CPC  3 0 85.89 
 
The IGH-V segment usage for the FL and t-FL samples from each respective case was the same.  The 
evolution pattern of FL to t-FL suggested by copy-number (CN) changes (from chapter 4) is shown 
for comparison to that determined by SHM analysis.  
For all cases (n = 12) with indirect (CPC) evolution by SHM analysis, this pattern was confirmed by 
CN analysis. 
In three cases (9, 11 and 21) with apparent direct evolution according to SHM analysis (underlined), 
the copy number analysis provided additional evidence that indicated evolution had occurred 
divergently from a putative CPC.  
*Cases with second FL samples analysed are highlighted in bold (as detailed in Table 5.1). For the 
copy number analysis performed in chapter 4, the second FL samples from cases 2, 5 and 26 had not 
been available. 
#IGH-V allele used by the major tumour clones. Nomenclature as per the IGMT database (Brochet et 
al. 2008).  
$For the twelve CPC cases, the number of SHMs acquired by the CPC in subsequent FL and t-FL 
major clones are indicated. 
§In case 26, the SHM analysis revealed that FL showed divergent evolution as compared to both 
relapsed FL and subsequent t-FL but t-FL showed direct evolution from FL relapse (Appendix 6 
Figure 2). 
IGH-V: immunoglobulin heavy chain variable region; SHM, somatic hypermutation; CN, DNA copy 
number; CPC: common progenitor cell; and np, not possible to determine whether DIRECT or CPC.  
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Figure 5.1  Homo-hetero-duplex analysis 
DNA from paired FL and t-FL samples from two cases (6 and 16) is shown. Following PCR specific 
to the IGH-V region usage (VH3 for both cases in this example) the PCR products were subject to 
homo-hetero-duplex formation. The products of this are observed here following electrophoresis at 
20mA for 16 hours on a polyacrylamide gel. The image is inverted to maximise the visualisation of 
bands. Prominent homo-duplex bands are clearly visible for each sample at around 400bp in size. 
More slowly migrating hetero-duplex bands are seen as fainter bands occurring earlier in the gel (*). 
The prominent bands represent the major (most highly represented) SHM sequence pattern of the 
IGH-V region present in the tumour DNA samples.  
 
 
 
 
Figure 5.2  PCR of homo-duplex products  
Four of the follicular lymphoma samples which were subject to hetero-duplex analysis are illustrated. 
All four cases involve VH3 segment usage. The homoduplex bands were then amplified by PCR and 
the products sequenced. Only 10ng of MNC DNA were used in the MNC DNA control lane. MNC 
pools contain DNA from multiple differing B cell sub-clones: those with VH3 segment usage generate 
the band seen here for the MNC DNA used as a control. 
MNC: mononuclear cell; NTC: no template control. 
  
* 
* 
* 
* * 
* 
* * 
* 
* 
La
d
d
er
 
Case 16 
FL t-FL 
Case 6 
FL t-FL 
506 bp 
396 bp 
344 bp 
1018 bp 
P
t 
2
 
P
t 
4
 
P
t 
5
 
P
t 
6
 
M
N
C
  D
N
A
 
N
TC
 
 
298 bp 
Chapter 5 
188 
  
 
   
Figure 5.3  Homo-duplex derived SHM sequences from sequential FL / t-FL 
Schematic summary of SHM analysis on homo-duplex major clones from the FL and t-FL samples of 
one patient (Case 25) illustrating the acquisition of SHMs from germline through CPC on to FL and t-
FL. The numbers beside arrows indicate the amount of SHM sites acquired between each successive 
step in the ontogeny. The numbers for FL (4) and t-FL (6) arrows represent mutually exclusive, 
tumour specific SHMs. The percentage homology of tumour IGH-V sequences to the germline IGH-V 
sequence (circle filled with black) is provided for both FL (circle filled with grey) and t-FL sequences 
(unfilled circle). The sites of SHM common to both samples (n = 24) provide a common IGH-V 
sequence (represented by the circle filled with hatching), which has higher homology to germline and 
so represents a sequence that is intermediate between germline and tumour. This then acquires 
mutually exclusive additional sites of SHM found in either FL (n = 4) or t-FL (n = 6), which mark 
divergence of the two separate tumour clones from this intermediary. 
Carlotti et al. 2009 
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cases and the tumour specific SHMs and germline homology for the CPC cases are 
provided in Table 5.2.  
For the father and son cases, one FL and one t-FL sample were available 
respectively. The IGH-V segment usage in the homo-duplex bands of both samples 
was the same (IGHV3-48*03), indicating these samples were clonally related. On 
determination of SHM sites from the homo-duplex bands, 23 common to both the FL 
sample (father) and t-FL sample (son) were identified with additional tumour specific 
SHM sites present in the FL (n = 28) and t-FL (n = 47) samples (Figure 5.4). This 
suggested that the tumours present in father and son had undergone divergent 
evolution (in an analogous manner to the 12 sequential cases) from a common origin 
marked by the 23 shared SHM sites (and the common BCL2-IGH fusion site 
previously identified (Hart et al. 2007)) giving a 91.1% homology of the IGH-V 
sequence in the CPC to germline.  
5.4.4 Cloning confirms divergent evolution can occur 
To further investigate the CPC model of tumour development, six of the twelve 
sequential cases identified through HH analysis as having patterns compatible with 
divergent acquisition of tumour specific SHM in FL and t-FL (as shown in Table 
5.2) were selected, based on DNA availability, for examination by cloning. An 
additional sequential case showing direct evolution and the father / son set were also 
included in this study. 
Following re-amplification by PCR (Figure 5.5), the IGH-V sequences derived from 
multiple colonies from the cloning assay of each sample were compared to enable 
mapping of SHM in FL and t-FL through generation of genealogical trees specific to 
each case. An example is given in Figure 5.6 for the same case illustrated in Figure 
5.3. The results for all six putative CPC cases (and the additional case showing 
direct, sequential SHM acquisition from FL to t-FL) are shown in Table 5.3. A 
similar number of SHM sites were detected by cloning as compared to HH analysis 
across both tumour types for all seven cases. 
A median of 15 (range 9 to 25) and 9 (3 to 18) unique IGH-V sequences were 
identified by comparison of SHM patterns from a median of 28 (range 17 to 47) and  
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Figure 5.4  Homo-duplex derived SHM sequences from father and son tumours 
Schematic summary of SHM analysis on homo-duplex major clones from the father (FL) and son (t-
FL) tumour samples. The symbols and labelling are as described for Figure 5.3 and, similar to that 
example, an intermediate IGH-V sequence can be defined (containing 23 common SHM sites) which 
undergoes divergent acquisition of tumour specific SHM sites in FL (n = 28) and t-FL (n = 47). 
 
   
 
 
Carlotti et al. 2009 
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Figure 5.5  PCR of cloning products  
An example of the bands generated by PCR applied to the products of cloning from the pCR®2.1-
TOPO® kit. The unmodified vector has no DNA insert. Each clone has a larger PCR product which 
indicates incorporation of a DNA insert (each of similar size as they are derived from the same VH 
segment).  
Clones indicates PCR products of individual white colonies (the pCR®2.1-TOPO® vector with 
incorporated IGH-V product) obtained by cloning; NTC, no template control (H20); and unmodified 
vector, PCR product of a single blue colony (the naive pCR®2.1-TOPO® vector without IGVH PCR 
product incorporation) obtained by cloning.  
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Figure 5.6  Cloning IGH-V sequences indicates FL / t-FL evolves from a CPC 
Illustrated are genealogical trees summarising cloning results from the same case (25) illustrated for HH analysis in Figure 5.3. A: FL, B: t-FL, and C: combined summary of 
FL and t-FL analysis. The circles represent the same as indicated in Figure 5.3 with the addition that for A and B each grey, white or hatch filled circle represents a unique 
IGH-V sequence (clone) with acquired SHM. Digits in the circles represent the number of each respective clone identified. Numbers beside arrows represent the number of 
SHM sites acquired between successive stages in the hierarchy. The major clones identified by HH analysis are indicated. I, II and III indicate levels in the hierarchy with 
comparison of sequences in II (FL) and III (t-FL) enabling prediction of a common SHM pattern present in the putative CPC (I).  
Carlotti et al. 2009 
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Table 5.3  Comparison of HH and cloning in evolution determination 
Case 
 FL  t-FL  
Evolution pattern 
 
 Clones  SHM  Clones  SHM   
 Total§ Distinct#  Cloning range* (rate) HH  Total§ Distinct#  Cloning range* (rate) HH  Cloning HH  
 
 
 
  
 
     
 
  
  
 
1^  34 9  36-37 (0.11-0.11) 36  35 10  41-45 (0.12-0.14) 43  CPC CPC  
 
 
 
  
 
     
 
  
  
 
2  26 15  39-48 (0.13-0.15) 44  36 10  48-53 (0.15-0.17) 48  Direct Direct  
 
 
 
  
 
     
 
  
  
 
6  28 25  45-51 (0.14-0.16) 46  38 7  45-46 (0.14-0.15) 45  CPC CPC  
 
 
 
  
 
     
 
  
  
 
12  47 19  20-24 (0.06-0.07) 22  35 18  19-22 (0.06-0.07) 21  CPC CPC  
 
 
 
  
 
     
 
  
  
 
15  20 12  29-41 (0.09-0.12) 31  24 9  39-41 (0.12-0.12) 39  Direct CPC  
 
 
 
  
 
     
 
  
  
 
25  20 15  28-32 (0.08-0.10) 28  23 6  30-33 (0.09-0.10) 30  CPC CPC  
 
 
 
  
 
     
 
  
  
 
27  17 14  39-43 (0.12-0.13) 42  18 3  39-43 (0.12-0.13) 39  CPC CPC  
 
 
 
  
 
     
 
  
  
 
 
Shown are summaries of SHM analysis performed by the cloning analysis for FL and t-FL. The number of SHM sites and the evolution pattern in the major (homo-duplex) 
clones are indicated in italics for comparison. All HH results lie within the range determined by the cloning analysis. Only case 15 showed discordance in the evolution 
pattern determined by the two approaches, however, the presence of an earlier common precursor could not be excluded by the cloning analysis.  
§The total number individual colonies sampled from which clone sequences were generated.  
#The number of distinct clone sequences identified from all the clones sampled. 
*The range of SHM sites per clone in the distinct clone sequences; rate indicates number of SHM sites per bp of PCR product [calculated as SHM sites identified in a PCR 
product / product length (bp)]. HH indicates homo-hetero-duplex analysis. 
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35 (18 to 38) single colony derived tumour sub-clones from the FL and t-FL samples, 
respectively (Table 5.3). Using the Wilcoxon matched pair signed rank test, a 
significant difference, P = .04, was demonstrated between the levels of clones 
identified in the FL and t-FL samples. 
In 6 / 7 sequential cases the mode of SHM acquisition concurred with the HH 
analysis. In a single instance (Case 15), cloning indicated sequential acquisition of 
SHM by t-FL from FL in contrast to the divergent model suggested by HH analysis. 
However, the data for this case did not exclude the presence of a common 
intermediate (with few SHM sites) that was not detected by cloning but which could 
support divergence of SHM patterns for this case.  
In the father and son HSCT donor / recipient pair, cloning supported the HH 
evidence for a divergent pattern of evolution from a CPC. From 36 colonies, the 
father’s tumour showed 18 distinct clone sequences (SHM range 51 to 53) with 32 
colonies obtained from the son’s tumour sample revealing fewer distinct clones (8) 
but a higher rate of SHM (range 70 to 73). The total number of HH identified SHMs 
for the father (51) and son (70) (Figure 5.4) tumour samples lie within the respective 
cloning ranges.  
In summary, the genealogical trees generated here from the cloning data are 
consistent with previous reports of ongoing SHM in FL (Zelenetz et al. 1992; 
Ottensmeier et al. 1998) and confirm that divergent evolution of tumour clones from 
a putative CPC can occur across multiple cases. 
5.4.5 t-FL clones are detectable in preceding FL tumours 
In chapter 4, for a single case, the t-FL clone could be detected (at low level) in the 
preceding FL sample many months prior to clinical transformation. This indicates 
that a long-lived transformation primed sub-clone can co-exist with the (major) FL 
clone. As the putative CPC might give rise to both FL and t-FL, determining whether 
the tumour clones co-exist would provide insights in to their temporal evolution. This 
is important as long-lived transformation primed clones may survive prior therapies 
and treatment resistance is a significant factor complicating disease management. 
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By using SHM sites unique to major t-FL clone IGH-V sequences, as illustrated in 
Figure 5.7 (A), ASO primers and probes specific to the t-FL sequence could be 
designed (Figure 5.8) so that FL samples could be examined for the presence of t-FL 
clones. In contrast to the acquired gene mutations in chapter 4 that occur only in a 
subset of cases, SHMs affecting IGH-V are common in FL / t-FL so a more 
comprehensive screen could be performed. In view of the DNA quantity required for 
the assays, eight cases could be included in this study which consisted of the seven 
sequential cases used in cloning and case 26. Ten FL samples were analysed as cases 
26 and 27 each had a second FL sample available which preceded t-FL. Each qPCR 
assay of the FL samples was performed in duplicate using two different t-FL specific 
primer / probe combinations and these produced similar results for all ten assays 
(Table 5.4).  
Importantly, the t-FL clone was detected in 5 / 10 FL samples (as illustrated for case 
12 in Figure 5.9) at levels ranging from 10
-1
/10
-2
 to 10
-4
 relative to the quantity of 
the clone in t-FL samples (Table 5.4). Moreover, the t-FL clone could be detected in 
FL up to 2¼ years before clinical transformation occurred. In case 26, the t-FL clone 
was detected only in the more recent of two FL samples suggesting either it was 
below the detection threshold in the earlier FL sample or it had developed at some 
point between the two episodes of FL. Divergent evolution from a putative CPC had 
been suggested for four of these cases but the fifth (case 2) had shown a direct 
pattern of evolution (Table 5.2). The eight months between FL and t-FL samples in 
this case indicates that t-FL primed clones that arise directly from FL (as opposed to 
a CPC) may also co-exist with FL for some time prior to clinical presentation as 
transformation. 
5.4.6 Detection of a CPC in both FL and t-FL samples 
Following the demonstration that t-FL clones can be detected in FL, this experiment 
sought to determine whether the putative CPC could be detected in tumour samples 
and so provide a direct link between divergent FL / t-FL clones. ASO primers 
specific to the imputed IGH-V sequence of the CPC were designed as illustrated in 
Figure 5.7 (B). This sequence contained only SHM sites present in both FL and t-FL 
samples but not the tumour specific sites. The ASOs were applied in nested (4   
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Figure 5.7  Allele specific oligonucleotide design and (hemi-) nested PCR 
Schematic representations of the IGH-V region with sites of SHM indicated by vertical bars. A: examples of SHM patterns in t-FL and FL IGV-H sequences with t-FL 
specific primers (red arrows) and probe (blue arrow) designed on SHM sites unique to t-FL. B: example of imputed SHM sites in CPC IGH-V sequence; forward and reverse 
primers specific to the CPC sequence (black and grey arrows) are designed to overlap both common SHM sites (incorporated in the primer) and FL / t-FL specific SHM sites 
(germline sequence used in the primer) thereby ensuring specificity to only the CPC IGH-V sequence. C: examples of the two rounds of PCR followed by sequencing of 
reaction products for, left, nested PCR of CPC sequence using four CPC specific primers; and right, hemi-nested PCR using three CPC specific primers. 
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Figure 5.8  Optimisation of t-FL major clone specific primers 
An example agarose gel visualisation of the PCR products obtained using two sets of t-FL IGH-V 
sequence specific primers (giving different amplicon sizes) for the t-FL sample of one case. 
Specificity of the primers for t-FL is indicated by the lack of amplification when MNC DNA is used 
as a reaction template. 
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Table 5.4  Identification of t-FL clones in preceding FL by qPCR 
 
Patient Sample
¥
 
 Primer site
†
  
Primers / 
sample* 
Sensitivity
#
 
Time from FL 
sample to t-FL 
(months) 
Amplification 
Level
§
 
 Forward Reverse  
1 FL  CDR1-FR2 CDR2-FR3  4 10-4 26.8 10-2 / 10-3 
 FL  CDR1 FR3   10-4  10-2 / 10-3 
2 FL  FR2-CDR2 FR3  3 10-4 8.4 ~10-3 
 FL  FR2-CDR2 FR3   10-4  ~10-3 
6 FL  FR1-CDR1 FR3  4 10-4 5.5 ~10-4 
 FL  FR1-CDR1 FR3   10-4  ~10-4 
12 FL  FR2-CDR2 FR3-CDR3  4 10-4 76.8 No amp 
 FL  FR2-CDR2 FR3-CDR3   10-4  No amp 
15$ FL  CDR1-FR2 FR3  3 10-4 72.0 No amp 
 FL  CDR1-FR2 FR3   10-4  No amp 
25 FL  FR2-CDR2 FR3  3 10-4 18.2 No amp 
 FL  FR2-CDR2 CDR3   10-4  No amp 
 FL2  FR2-CDR2 FR3  3 10-4 8.5 No amp 
 FL2  FR2-CDR2 FR3   10-4  No amp 
26 FL  FR1-CDR1 FR3  3 10-4 33.8 No amp 
 FL  FR1-CDR1 FR3   10-4  No amp 
 FL2  FR1-CDR1 FR3  3 10-4 19.8 10-1 / 10-2 
 FL2  FR1-CDR1 FR3   10-4  10-1 / 10-2 
27 FL  FR2-CDR2 CDR3  4 10-4 25.4 10-1 / 10-2 
 FL  FR2-CDR2 CDR3   10-4  10-1 / 10-2 
 
Results are given in duplicate for each patient sample as two qPCRs using different 
primers and probe combinations were used for each sample. All duplicates showed 
concordant results. 
¥Cases 25 and 26 had second FL samples (FL2) available from subsequent disease 
episodes prior to transformation. 
†IGH-V region where the t-FL clone specific primer was designed  
*Total number of primers applied to each sample in the two qPCRs.  
#Maximal sensitivity detected for each primers + probe combination.  
§Relative amplification level of the major t-FL clone within FL sample compared to t-FL 
sample. 
$For case 15, two different probes were used, one in each qPCR.  
CDR and FR indicate cluster determination region and framework region respectively 
as described in Chapter 1; and No amp indicates no amplification detected.  
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B  
 
 
 
Figure 5.9  qPCR of t-FL clone in preceding FL  
Two qPCR plots (for case 1) demonstrating amplification of (A) the t-FL clone in FL and (B) β2M. 
Shown in blue are dilutions of a 100ng/μl preparation of t-FL DNA (from left to right: A, 10-1 to 10-4 
and B, 10-1 to 10-5). To preserve t-FL DNA, the 100ng/l working solution was not run. In red is the 
FL sample DNA (at 100ng/μl) with a no template control (H20) in purple and germline DNA (MNC 
DNA at 100ng/μl) in green. Reactions were performed in triplicate but for clarity single reactions are 
illustrated. The relative level of t-FL clone in the FL sample shown (between 10-2 and 10-3) indicates 
that it constitutes <1% of the FL tumour. The similarity of amplification between t-FL clone and β2M 
assays for the t-FL tenfold dilutions indicates that the t-FL clone constitutes virtually the entirety of 
the t-FL tumour sample. (β2M amplification confirms similar total DNA levels in the FL, t-FL and 
MNC DNA samples.) 
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primers) or hemi-nested (3 primers) PCR, Figure 5.7 (C), to FL / t-FL samples that 
had shown divergent evolution. This approach provided a means of:  
i. minimising contamination of the second PCR product by products of 
unintended primer binding;  
ii. amplifying low levels of template  
and was possible in 6 / 7 putative CPC cases examined by qPCR in the previous 
section. For (hemi-) nested PCR products providing a single band on agarose gel 
electrophoresis, the product was then cloned (as described in section 2.4.11) and 
sequenced. 
Significantly, sequencing confirmed detection of the predicted CPC IGH-V sequence 
for cases 12 and 26. In a further patient (Case 1), a common sequence containing 
fewer SHM sites (representing an earlier common intermediate clone) was detected 
(Table 5.5). Consequently, these data demonstrate that CPC clones can be detected 
in tumours by using SHM profiles as specific markers and they can co-exist with 
both FL and t-FL. Moreover, the detection of the CPC in samples obtained over six 
years apart (Case 12) provides important evidence for its considerable longevity. 
5.5 Discussion 
This study demonstrates that evolution of t-FL from FL may occur by non-sequential 
(“indirect”) clonal evolution from a putative common origin (a common progenitor 
cell; CPC), as illustrated in Appendix 6 Figure 3. In 12 / 18 (67%) cases with 
sequential FL and t-FL samples, and in the donor / recipient pair, divergent evolution 
of tumours was identified by comparison of SHMs at their respective IGH-V 
segments. To examine further the clonal development in these cases, precursor IGH-
V sequences were defined by the presence of only those SHMs common to both 
tumours. These sequences had between 83.5% and 94.5% homology with the 
respective VH segment germline sequence and served as genetic markers for the 
putative CPC enabling its detection in both FL and t-FL. Similarly, transformation 
specific SHMs enabled detection of t-FL clones in preceding FL. 
Considerable longevity could be attributed to the CPC clones, as they were detected 
in sequential FL and t-FL samples taken up to 6½ years apart. Furthermore, indirect  
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Table 5.5  Identification of CPC sequence in FL and t-FL samples. 
Case Sample 
 Primers  
Clones 
screened
¥
 
CPC 
detected 
 
Number
$
 
 Forward  Reverse  
  Region
†
 SHM
§
  Region
†
 SHM
§
  
             
1 FL  4  FR1-CDR1 2  FR3 3  31 earlier** 
 t-FL          - - 
             
6 FL  4  FR2-CDR2 6  CDR3-N1-N2 N1, N2  11 no 
 t-FL          11 no 
             
12 FL  3  CDR2-FR3 2  CDR3-N1 5  18 YES (16)* 
 t-FL          39 YES (3)* 
             
15 FL  3  FR2-CDR2 4  N2 N2  22 no 
 t-FL          - - 
             
25^ FL  3  FR3 7  FR3 3  7 no 
 t-FL          7 no 
             
25^ FL  4  FR3 7  N2 N2  7 no 
 t-FL          7 no 
             
26 FL  3  CDR1-FR2 5  N1 N1  11 YES (5)* 
 t-FL          11 YES (4)* 
             
 
Summarised is the approach for the detection of CPC clones in FL and t-FL using clone-specific 
primers designed on unique IGH-V sequences identified through SHM analysis of homo-duplex 
products. In cases 1 and 15, nested and hemi-nested PCR on the respective t-FL samples was not 
successful so cloning results are not available. In two cases, 12 and 26, the CPC clone was successfully 
detected in both FL and t-FL samples. 
$The number of primers used across the two reactions of nested (n = 4) or hemi-nested (n = 3) PCR. 
†IGH-V region where the t-FL clone specific primer was designed. 
§Total number of SHM sites represented on the combination of forward (or reverse) primers used. 
¥The total number of individual colonies sampled from which clone sequences were generated. 
**In case 1, although the putative precursor sequence was not detected, a sequence with fewer SHM 
sites (representing an earlier precursor) was detectable in the FL sample. 
*The number of clones in which the CPC was detected is indicated in parentheses; the remainder of 
the clones screened yielded a more mature sequence attributable to non-specific priming. 
^For case 25, reverse primers on FR3 and on DH-JH (N2) regions could be designed, enabling one 
nested and one hemi-nested PCR for this case. 
N1and N2 indicate clone specific mutations by nucleotide insertion in the VH-DH and DH-JH 
junctional regions, respectively. 
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experimental support for the CPC model is provided by the demonstration here that a 
transplantable (Hart et al. 2007) long-lived lymphoma-initiating cell  can give rise to 
clonally related, but distinct, disease in separate individuals. Specifically, FL 
presenting with transformation over one decade post-HSCT in the recipient arose by 
divergent clonal evolution from a long-lived CPC that was transplanted from the 
donor who themselves developed FL over three years post-procedure. 
These data support and extend the hypothesis of FL development proposed by 
Matolcsy and colleagues (Matolcsy et al. 1999), although the SHM patterns used 
then and here remain only a surrogate marker for the malignant clone. However, 
validation for the concept of a common cell of origin in FL comes from three recent 
reports which identified that divergence of acquired cytogenetic aberrations occurs in 
sequential FL samples (d'Amore et al. 2008) and that, in 40 to 60% of cases, 
subsequent biopsies lack alterations found in the original FL karyotype (Johnson et 
al. 2008b; Eide et al. 2010). A further study that assessed mutations of the IGH 
S(mu) region, which precede (but do not necessarily lead to) class switch 
recombination, provided evidence that FL relapse could arise through the evolution 
of pre-existing
 
minor sub-clones and that these could have fewer mutations and 
represent earlier sub-populations of disease (Ruminy et al. 2008).  
The use of a second technique (cloning) provided similar rates of SHM, and 
discrimination of FL / t-FL evolution, compared to the initial HH analysis supporting 
the applicability of HH in mapping disease evolution. It also provided further 
evidence for the known oligoclonality of FL (Zhu et al. 1994; Ottensmeier et al. 
1998; Bognar et al. 2005). Of course, HH only yields the most prevalent (major) 
tumour clone and so cannot directly address any other sub-clones (up to 25 and 18 in 
FL and t-FL, respectively) nevertheless, it could be used to impute CPC clones which 
were subsequently detected in tumour samples. 
Similar levels of subsequent SHMs were acquired by the CPC in the sequential FL / 
t-FL samples (with medians of 4 and 3 respectively) but considerably more were 
acquired by the tumours in the donor / recipient pair (28 and 47 in the major clones 
respectively). This variation may reflect contrasting development of the CPC in the 
two scenarios as, in the donor / recipient pair, the CPC has migrated to the BM 
whereas in the sequential cases the CPC may never have left the germinal centre. 
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Furthermore, the length of time (>10 years) between transplant and development of 
tumour in the recipient may have contributed to the high number of SHMs in this 
sample. 
A lower degree of oligoclonality observed by cloning in t-FL as compared to FL (P = 
.04) is likely to reflect the prominent outgrowth of a single disease clone.  The 
detection of t-FL clones within earlier FL samples obtained over 2 years prior to 
transformation is not contradictory to this scenario, but reflects a sub-clone which 
has a specific SHM pattern that (at some future time-point) acquires changes 
conferring aggressive phenotype. This then becomes by far the dominant clone in 
contrast to FL where less rapidly proliferating sub-clones may develop a more 
diverse spectrum of SHM sub-clones.  
Although the SHM patterns provide tumour genetic markers (valuable in quantitating 
t-FL and CPC clones), these reflect the activity of a normal B-cell process occurring 
in malignant cells. Consequently, the SHMs may not completely map all tumour sub-
clones. This was evident for cases 9, 11 and 21 where SHM determination suggested 
direct evolution of t-FL from FL whereas the pattern of acquired CN changes 
(determined in chapter 4) indicated that evolution was in fact divergent from an 
inferred CPC. It is possible in these cases that, firstly, additional tumour specific 
SHMs were not detected in FL and t-FL clones or, alternatively, a CPC containing a 
certain level of SHM then acquired divergent CN changes, perhaps driving either FL 
or t-FL disease evolution, with subsequent SHMs in the t-FL clone creating a pattern 
of direct evolution by SHM but indirect evolution by CN changes. 
What contributes to selection of t-FL clones is not clear, although specific genetic 
changes which predispose to transformation are present at FL diagnosis and certain 
genetic events or expression profiles mark transformation, as described in Chapter 1. 
Here, clones with the same SHM pattern as t-FL are present in FL samples from 
patients managed in a variety of ways: an expectant “watch and wait” policy (case 2), 
local radiotherapy (case 26) or chemotherapy (cases 1, 6 and 27). This suggests that 
selective pressures leading to further outgrowth of these t-FL clones, detectable far 
before clinical transformation, can include mechanisms other than the development 
of drug resistance (a factor potentially relevant to the increased risk of transformation 
observed in FL that has required multiple treatments (Al-Tourah et al. 2008)). 
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Another important factor in FL is the role of the microenvironment immune response 
which has a significant impact on disease outcome (Dave et al. 2004). A mechanism 
for interaction between FL cells and the microenvironment is mediated by the SHM 
process which introduces novel glycosylation motifs at the IGH-V locus in the 
majority of FL (Zhu et al. 2002; McCann et al. 2008). These are tumour specific and 
can result in oligomannosylation of surface immunoglobulin molecules on FL cells 
(McCann et al. 2008) which may bind lectins within the surrounding 
microenvironment (Coelho et al. 2010), a process which potentially supports the 
tumour cell. In view of this, IGH-V sequences in the sequential FL / t-FL sample 
cohort were assessed for novel glycosylation sites. These were demonstrated in the 
majority of cases (n = 14) with 13 / 14 being conserved in both FL and t-FL 
(Appendix 6 Table 2) and their presence in 9 CPC sequences suggests they may play 
an early role in disease development while differences between t-FL and FL (as 
observed in one case) might reflect a more specific role in transformation. 
The precise origin and role of CPCs in FL / t-FL remains uncertain but the presence 
of specific SHM signatures suggests they are derived from germinal centre B cells (a 
conclusion supported by recent gene-expression data indicating the precursor to t-FL 
derives from a germinal centre B-cell (Gentles et al. 2009)). Subsequent 
development of tumour may occur in different contexts: firstly, as t-FL clones are 
detectable in FL and the CPC clone is detectable in both tumours, the CPC, FL and t-
FL clones may co-exist within lymph nodes; alternatively, the CPC may reside in a 
pre-lymphoma (normal) follicle and give rise to FL and t-FL clones respectively 
which then form independent tumours (in which the CPC is, therefore, not 
detectable). Moreover, as in the donor / recipient pair, the CPC may migrate from its 
lymph node of origin to the bone marrow where it is supported until migrating to a 
secondary lymphoid site where it can initiate disease. The donor / recipient model 
also provides direct evidence that the CPC can give rise to tumour following 
transplantation in to a different host indicating the CPC has innate tumour initiating 
properties. Analogous xenograft repopulating models have been used to examine 
other cancer-initiating cells with their existence first demonstrated over a decade ago 
in acute myeloid leukaemia (Lapidot et al. 1994; Bonnet and Dick 1997). Since then 
cancer-initiating cells have been demonstrated in a variety of other cancers including 
both solid tumours (Al-Hajj et al. 2003; Singh et al. 2004; O'Brien et al. 2007; Ricci-
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Vitiani et al. 2007; Schatton et al. 2008) and other haematological malignancies 
(Cobaleda et al. 2000; Bhatia et al. 2003; Jamieson et al. 2004; Matsui et al. 2008). 
Although their precise origin and nature may differ; a recurrent feature shared 
between different cancer initiating cells is a stem cell-like phenotype including the 
ability for self-renewal (Reya et al. 2001; Visvader 2011).  
In this regard, the report by Gentles and colleagues cited above (Gentles et al. 2009) 
also demonstrates that a gene transcription signature (based on functional modules) 
predicts transformation and provides evidence for a stem cell-like contribution to t-
FL that is compatible with both the direct and indirect routes of FL / t-FL evolution. 
This model suggests that the expression of an embryonic stem cell-like gene 
expression program in certain germinal centre FL or FL-progenitor clones may prime 
these cells to subsequently transform. Furthermore, the indirect model of recurrence 
can be applied to other B-cell malignancies with one report indicating that divergent 
evolution of a long-lived progenitor cell may give rise to relapse of childhood B-cell 
acute lymphoblastic leukaemia (Mullighan et al. 2008), an aggressive tumour, and so 
parallels the findings here in t-FL.  
In summary, the demonstration of a long-lived CPC, that may undergo divergent 
evolution to either FL or t-FL, builds on previous models of FL by revealing 
heterogeneous routes (direct or indirect) of t-FL development and explains reports 
demonstrating acquired chromosomal changes present at diagnosis can be lost at 
disease recurrence (Martinez-Climent et al. 2003; Fitzgibbon et al. 2007; d'Amore et 
al. 2008; Johnson et al. 2008b; Eide et al. 2010). Such a model can also help explain 
the observation that the total number of SHMs in FL cases can be similar at 
progression when compared to prior disease episodes (Aarts et al. 2001; 
Halldorsdottir et al. 2008) (as demonstrated here for sequential FL and t-FL in  
Table 5.3) despite the known ongoing SHM process within FL (Zhu et al. 1994; 
Ottensmeier et al. 1998; Bognar et al. 2005), because subsequent episodes arise from 
the same precursor. In addition, the inclusion of additional (FL2) samples 
demonstrates that the conventional model of direct evolution to t-FL, through 
outgrowth of an FL clone, can co-exist with that of the CPC in individual cases. An 
example of this occurs in case 26, where t-FL evolves directly from FL2 but this and 
the initial FL arise by divergence from a CPC (Appendix 6 Figure 2). Furthermore, 
FL2 occurring after t-FL by direct evolution from the FL clone (in case 2) is 
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evidence that, despite eradication of t-FL, the original FL clone can persist and 
subsequently present clinically as relapse post transformation. 
Consequently, the clinical pattern of FL as a progression of multiple relapses and 
transformation is not always reflected by sequential acquisition of molecular hits but 
instead may occur by divergent evolution from a CPC. This model provides new 
insights in FL / t-FL and efforts are now needed to fully characterise CPCs as these 
could represent attractive targets for therapy. Furthermore, an important aspect of 
future studies addressing the complexity of disease development will be to determine 
the relationship between the CPC and the long-lived t(14;18) containing atypical B 
cells, found in healthy individuals (Limpens et al. 1995; Summers et al. 2001; 
Schuler et al. 2009), which undergo population expansion in GCs as FL-like clones 
(Roulland et al. 2006).  
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Chapter 6    Discussion 
Follicular lymphoma (FL) is the most common form of indolent non-Hodgkin 
lymphoma. Although its incidence is far less than that of the most common solid 
cancers (namely lung, breast, colon and prostate), the prolonged relapsing / remitting 
course of the disease over a median survival of around one decade confers a 
significant population disease burden. Recent improvements in survival are, 
however, encouraging (Fisher et al. 2005; Swenson et al. 2005; Liu et al. 2006) and 
these probably reflect a combination of better supportive care and advances in the 
therapeutic options available to clinicians, particularly the addition of rituximab 
immunotherapy to combination chemotherapy (as discussed in Chapter 1). 
However, it is not clear whether these impact on aggressive transformation, an event 
which confers a worse prognosis (Montoto et al. 2007b; Al-Tourah et al. 2008) and 
has a persistent risk throughout the course of FL (Al-Tourah et al. 2008). 
Furthermore, the management of t-FL is difficult as it cannot be reliably predicted 
and is often complicated by previous therapies, advanced age and patient co-
morbidities. An important aspect of addressing this significant clinical challenge is 
understanding the mechanisms of disease transformation, as this should ultimately 
help improve both t-FL prediction and management.  Consequently, the current study 
set out to identify novel genetic events in transformation. 
The genetic aspects of FL / t-FL are complex as although t(14;18) is present in 
around 85% of cases (and is important as it leads to up-regulation of the anti-
apoptotic BCL2 protein) it is insufficient in isolation to cause disease, is typically 
accompanied by other genetic changes and cases lacking this translocation may even 
form a distinct clinico-pathological subtype of this disease (Katzenberger et al. 
2009). Moreover, reports identifying familial FL cases (Marco et al. 1999; Last et al. 
2000) and increased risk of FL in first degree relatives of cases (Goldin et al. 2009) 
suggest that inherited factors have a role. This has been confirmed in numerous 
studies assessing germline predisposition to FL development most notably in the first 
genome-wide association study (GWAS) in FL (Skibola et al. 2009; Conde et al. 
2010) but few reports have addressed the influence of germline genetic variation on 
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FL outcome (Weng and Levy 2003; Jardin et al. 2005; Cerhan et al. 2007b; Hohaus 
et al. 2007; Racila et al. 2008; Han et al. 2010).  
Importantly, the current study addressed this for two SNPs (rs10484561 and 
rs6457327) and confirmed their association with FL risk, with rs6457327 also 
predicting both risk of and time to transformation (as indicated in Chapter 3). This is 
an important finding as the effect was independent of other (clinical) variables which 
are known to associate with transformation. The influence of rs6457327 genotype 
was investigated by examining the expression of C6orf15, the only coding region in 
high linkage disequilibrium with this SNP. However, this was not a promising 
candidate as the transcript was not detected in any of a series of FL and t-FL samples 
and C6orf15 was not mutated in FL at diagnosis. As the protein product of the 
murine homologue of C6orf15, termed emprin, has recently been identified as a 
component of the extra-cellular matrix (ECM) (Manabe et al. 2008) and C6orf15 is 
expressed in skin (Oka et al. 1999; Sanchez et al. 2004), this raises the possibility 
that the expression detected in tonsils might be a consequence of either the extensive 
connective or epithelial tissue contained within their structure (as opposed to 
expression by infiltrating lymphocytes). This might then help explain the lack of 
expression detected in other lymphoid material included in the current study.  
As rs6457327 is found within the HLA region and immune response profiles 
associate with FL outcome (Dave et al. 2004), germline variation at this SNP might 
influence the immune response to FL. Furthermore, as part of an ongoing 
departmental study in to the role of the micro-environment in FL, 56 of the study 
cases have already been included in FL tissue micro-arrays. Immuno-histochemical 
staining of the tumour samples has been performed for CD4, CD8, FOXP3 and 
CD68 / CD163 representing infiltrating TH1, TH2, Treg lymphocytes and 
macrophages, respectively. Interestingly, the number of FOXP3 positive cells with 
an intra-follicular location was significantly increased (P = .02; two-tailed unpaired t 
test) in FL tumour samples from the rs6457327 AA+AC cases (n = 32) compared to 
the rs6457327 CC cases (n = 21), with 3/56 cases lacking data. This follows a report 
(Farinha et al. 2010) in which a “follicular” distribution (characterized by an 
intrafollicular and perifollicular predominance) of FOXP3 positive cells in FL biopsy 
samples, as opposed to a "diffuse" pattern (in which the cells were diffusely 
distributed with no clear relationship to the
 
follicles) was associated with 
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transformation risk in a multivariate analysis (P = .004, HR = 3.9). Consequently, 
investigation of rs6457327 has now been incorporated in to the ongoing micro-
environment study in this department. 
It might be expected that SNPs which confer increased cancer risk also confer a 
worse clinical outcome and this has been demonstrated in other cancers (Grochola et 
al. 2009; Cizmarikova et al. 2010). However, in the current study, the minor (A) 
allele of rs6457327 associates with reduced risk of developing FL but in established 
cases confers an increase in risk of transformation (a deleterious clinical outcome). 
This is reminiscent of a recent study in colorectal cancer which demonstrates that the 
variant (G) allele of SNP rs1799977 in MLH1 confers increased risk of this disease 
but associates with better clinical outcome (lower risk of vascular invasion, distant 
metastases and recurrence) (Nejda et al. 2009). Potential explanations for these 
scenarios include i) differing alleles of the same SNP being contained within 
different risk and outcome inherited genetic haplotypes or ii) that risk and outcome 
determinants occur together within a haplotype containing one SNP allele but the 
influence of associated determinants is exerted at different times.  
In addition to marking risk alleles, SNPs may have direct functional consequences 
(Thomas et al. 1999; Bond et al. 2004). Therefore, it is noteworthy that the 
Encyclopedia of DNA elements consortium’s website, http://genome.ucsc.edu/cgi-
bin/hgGateway?org=human ("The ENCODE Project"  2004; Rosenbloom et al. 
2010) reveals both rs10484561 and rs6457327 are located near or within putative 
regulatory regions. A genomic site particularly sensitive to DNase I activity (a 
feature associated with regulatory regions) is found around 3kb telomeric to 
rs10484561 whereas rs6457327 is found within a potential DNase I hypersensitivity 
region. The latter is associated with modification of H3K4Me1, an enhancer and 
promoter associated histone mark, providing further evidence that this region has a 
regulatory function. rs6457327 is also located less than 5kb centromeric from a 
potential enhancer region (as well as being less than 5kb telomeric from the C6orf15 
coding locus). Consequently, both SNPs might be implicated in control of gene 
transcription through modulation of these putative regulatory regions.  
The prolonged clinical follow-up of the cases within the germline investigation is an 
important aspect of this study. From the cohort (n = 130) used in determining clinical 
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outcome associations for rs6457327, the 67 surviving patients were followed up for a 
median of 9.3 years (range 1.6 – 30.5) with 94% seen for >5 years and 48% for >10 
years and such prolonged follow-up is important as FL typically has a long disease 
course. This provides robust clinical outcome data with a transformation frequency 
of 35% (45 / 130 cases) similar to that reported in large series of biopsy proven and 
clinically determined transformation (Al-Tourah et al. 2008) or biopsy proven 
transformation (Montoto et al. 2007b). Furthermore, it enabled identification of two 
cases in which transformation presented in the third decade after FL diagnosis 
(Figure 3.3), supporting the ongoing risk of transformation demonstrated in a recent 
report (Al-Tourah et al. 2008) and extends it to over 20 years. 
The significant relationship between transformation and overall survival reported for 
the two recent large FL series above (Montoto et al. 2007b; Al-Tourah et al. 2008) 
was maintained in this cohort, P = .0004 (Wrench et al. 2011). However, the 
rs6457327 genotype association with transformation did not translate to prediction of 
survival, P = .97 (Table 3.8). This may reflect the contribution of several different 
factors to the transformation and survival of FL as, firstly, this SNP is one of a large 
number of heterogeneous factors linked with transformation (Bernstein and Burack 
2009) and, secondly, there is emerging data (Davies et al. 2007; Gentles et al. 2009) 
suggesting there are potentially different early and late mechanisms contributing to 
transformation. It may be that the degree of influence for each individual factor 
towards transformation or survival differs, and this could account for the seemingly 
discrepant rs6457327 result (as well as that for a marker previously reported to 
predict transformation but not OS (Jardin et al. 2005)).  
Two well described SNPs influencing the MDM2-p53 axis, MDM2 SNP 309 and 
TP53 Arg72Pro, were also examined but they showed no associations with either 
clinical outcome or risk of FL. Although such correlations do occur for both SNPs in 
other cancers, these effects are often not consistent and at times are contradictory 
(Wilkening et al. 2007; Gryshchenko et al. 2008; Zenz et al. 2008; Chua et al. 2010).  
However, these SNPs might have future relevance in FL by affecting responses to 
novel therapies such as the nutlins, small molecule inhibitors which disrupt MDM2 
binding to p53 (Vassilev et al. 2004). These might relieve p53 inhibition in cancer 
where the MDM2-p53 axis is disrupted thereby limiting malignant cell proliferation. 
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Significantly, these compounds show activity in a range of B-NHL including MCL 
(Tabe et al. 2009), primary effusion lymphoma (Sarek et al. 2007) and Burkitt 
lymphoma (Renouf et al. 2009) as well as CLL (Coll-Mulet et al. 2006; Kojima et al. 
2006). A structurally similar molecule, MI-319, has recently shown activity against a 
t(14;18) containing NHL cell line in vitro and in murine models (Mohammad et al. 
2009). Should experimental molecules such as these become part of the treatment 
armament for FL in future, disease responses may be affected by polymorphic 
variation affecting MDM2 and its expression in FL cells, such as that at MDM2 SNP 
309. 
The germline investigations followed a targeted approach in which the SNPs 
examined were selected based on their known characteristics or disease associations. 
However, new methods are opening up the entire genome to simultaneous 
investigation. In particular, the development of genome-wide micro-array based 
techniques represents a significant advance in the ability to examine genetic variation 
in both normal and disease states. They provide high resolution combined with the 
ability to examine multiple samples in parallel. In studies of the human genome they 
are revealing novel information on germline genomic variants including SNPs 
(McCarroll et al. 2008) and copy number polymorphisms (Iafrate et al. 2004; Redon 
et al. 2006; McCarroll et al. 2008). Furthermore, SNPs can be used as genomic tags 
in large GWAS, which have assessed how such variation may predispose to disease 
such as cancer, including FL (Skibola et al. 2009; Conde et al. 2010).  
The most recent tools can determine copy numbers and genotypes for both SNP and 
non-SNP loci providing information on CNAs and LOH over a large number of 
genomic loci at a high resolution: every ~700 bp for the array used in this study. 
Consequently, regions of genomic change that are beyond the resolution of earlier 
techniques such as conventional karyotyping, CGH, and array-CGH, could be 
detected down to around 7 kb in size (using segments with at least 10 consecutive 
probes) which was evident in detection of CN loss affecting CREBBP (150 kb) and 
CDC2L2 (60kb) or gain affecting SMARCD3 (16 kb), as detailed in Chapter 5. 
During the course of the study both array-CGH and SNP-array platforms with even 
higher resolution have been developed and these represent important developments 
that should help identify the critical genetic events in cancers.  
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A particular important advance has been the development of genome-wide 
sequencing. This has enabled the identification of novel gene mutations in whole 
exome sequencing of malignancies including AML (Ley et al. 2008; Mardis et al. 
2009) and subsequently solid cancers including melanoma and lung cancer (Lee et 
al. 2010). The application of this technique to FL samples is similarly revealing 
novel mutations which include those reported in EZH2 (Morin et al. 2010a) and 
recently described events affecting MLL2, MEF2B and CREBBP (Mendez-Lago et 
al. 2010; Morin et al. 2010b; Pasqualucci et al. 2011) as discussed in Chapter 4. This 
technique can also identify a variety of other genomic aberrations including 
breakpoints, micro-insertions and deletions, cryptic translocations and inversions as 
well as disease subclones and so it represents a powerful tool for the discovery of 
driver events as well as determinants of treatment resistance and disease progression. 
Moreover, as this technique can now establish the human genome sequence in a 
matter of hours it may ultimately enable the production of personalised cancer 
genetic signatures that could be applied as a routine clinical adjunct to enhance 
disease management by facilitating individual, tailored treatment regimes. 
The identification by such sequencing of EZH2 mutations in FL (Morin et al. 2010a) 
which, as suggested in Chapter 4, may be enriched in t-FL is of particular interest as 
the EZH2 protein product forms part of the polycomb repressor complex 2 (PRC2). 
This complex also includes the SUZ12, EED and RbAp46 proteins and functions as a 
histone methylase facilitating the trimethylation of histone H3 Lysine 27 
(H3K27me3) (Cao et al. 2002; Kuzmichev et al. 2002; Kirmizis et al. 2004). The 
EZH2 mutations are now known to confer gain of function specific for the di- to 
trimethylation step (Sneeringer et al. 2010; Yap et al. 2011) which is important as 
H3K27me3 creates a transcriptionally repressive histone mark and is associated with 
gene methylation in cancer (Schlesinger et al. 2007). Moreover, recent studies, 
performed by our group for FL / t-FL (O'Riain et al. 2009) and elsewhere for 
DLBCL (Martin-Subero et al. 2009b), have identified that the gene set targeted for 
transcriptional repression by methylation is enriched for genes previously shown to 
be targets of PRC2 mediated repression in embryonic stem cells (Lee et al. 2006b). 
This suggests that a stem cell profile might be important in FL development (and 
could be influenced by somatically acquired mutations such as those in EZH2). It is 
therefore significant that a gene transcription signature, based on functional modules 
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and which predicts transformation of FL, also provides evidence for a stem cell-like 
origin to t-FL (Gentles et al. 2009). Overall, these data provide a tentative model in 
which disruption of PRC2 mediated chromatin remodelling, that targets genes 
specifically regulated in stem cells, may represent an early event in FL. 
Although cancer initiating cells have now been described in several malignancies, 
including a lymphoid tumour (B-ALL) (Cox et al. 2004; Notta et al. 2011), these are 
yet to be described in FL. However, the data from chapters 4 and 5 indicates that FL / 
t-FL may arise by divergent evolution of a common progenitor cell (CPC) and 
supports earlier (Matolcsy et al. 1999; Martinez-Climent et al. 2003; Fitzgibbon et 
al. 2007) and more recent (Ruminy et al. 2008; Eide et al. 2010) reports detailing 
non-sequential patterns of clonal evolution in sequential FL samples. As the CPC has 
undergone somatic hyper-mutation of the IGH-V gene this suggests that, like its 
progeny, it arises from the germinal centre, a concept also proposed in the report by 
Gentles and colleagues (Gentles et al. 2009). Furthermore, the evolution of FL and 
then t-FL from a CPC by non-sequential, indirect evolution many months or even 
years apart indicates the attributes of CPCs include longevity, chemotherapy 
resistance and the ability to generate distinct episodes of divergent disease (either FL 
or DLBCL / t-FL). Indeed, this may help explain the related clinical scenarios of 
discordant, composite and downgrade lymphoma as well as the relapse of FL after t-
FL. Importantly, the CPC attributes are reflected in normal haematopoietic stem cells 
which can give rise to differing cell types, can repopulate the bone marrow after 
high-dose chemotherapy and, through self-renewal, are long-lived. Consequently, 
determining whether stem cell-like molecular profiles contribute to the CPC, as 
recently proposed by Martinez-Climent and colleagues (Martinez-Climent et al. 
2010), could provide valuable insights in to the processes that drive evolution of FL / 
t-FL.   
The relative importance of inherited genomic variation, host micro-environment 
immune response and tumour genetic or epigenetic events to FL is unclear. However, 
molecular outcome predictors have been derived from acquired tumour genetic 
events (O'Shea et al. 2008; Cheung et al. 2009b; O'Shea et al. 2009; Cheung et al. 
2010b) and host microenvironment immune profiles (Dave et al. 2004). Indeed, 
correlation between these processes has been reported (O'Shea et al. 2008) and this 
supports a dynamic interplay between tumour cells and the microenvironment in FL. 
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In this regard, the mutations of TNFRSF14 examined in Chapter 4 are particularly 
relevant as its gene product has a role in signalling between B cells and other 
immune cells (Cai and Freeman 2009) and mutations are known to disrupt its ligand 
binding (Compaan et al. 2005). Similarly, gain affecting the IL4-R locus in t-FL 
(detailed in the same chapter) provides another potential bridge between tumour 
genetics and the microenvironment and follows studies in FL showing over-
expression of IL4-R (Calvo et al. 2008) and IL4 (Husson et al. 2002) in tumour and 
immune cells, respectively. Furthermore, SHMs that create novel glycosylation 
motifs in the Ig genes of FL cells lead to Ig molecules on the cell surface that bind 
lectins in the surrounding microenvironment (Coelho et al. 2010), and these are 
interactions which might support tumour cells. Consequently these, and the 
association of rs6457327 genotype with FOXP3 positive tumour T cells detailed in 
chapter 3, represent good candidates for further study as the pathways underlying 
genetic-microenvironment correlations in FL may be targets for therapeutic 
disruption. 
This study has identified germline and acquired genetic disease outcome predictors 
with regard to FL and its transformation. Together with the recently described 
acquired predictors (O'Shea et al. 2008; Cheung et al. 2009b; O'Shea et al. 2009; 
Cheung et al. 2010b), these represent a growing pool of molecular markers in FL.  
Moreover, although the use of micro-array profiling has provided valuable insights in 
to FL and t-FL (Lossos et al. 2002; Dave et al. 2004; Glas et al. 2005; Davies et al. 
2007; Glas et al. 2007), including prognostic signatures (Dave et al. 2004), it 
requires complex research techniques currently beyond the remit of most clinical 
centres. Nevertheless, progress has been made through the validation of microarray 
derived RNA expression profiles using RT-PCR (Sakhinia et al. 2007; Byers et al. 
2008) and this represents a step towards routine application of molecular profiling. 
However, to achieve these aims, such research tools should be adapted into 
approaches amenable for use on formalin fixed paraffin embedded material, the 
current standard preparation of tissue biopsies. Moreover, integration of both 
germline and acquired molecular determinants in such profiling should be considered 
in view of the robust correlation shown here between SNP rs6453727 and t-FL.  
In a similar way to the FLIPI clinical prognostic tools (Solal-Celigny et al. 2004; 
Federico et al. 2009), molecular markers are yet to routinely influence patient 
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management and determining whether this can be achieved requires their validation 
in prospective clinical studies. This would pave the way for assembly of clinical-
molecular prognostic algorithms as well as predictors of treatment response and 
transformation that might aid rationalised, targeted therapy; a credible goal given the 
plethora of available and emerging treatments and the grave outcome of 
transformation.  
The recent therapeutic advances and improvements in outcome provide important 
developments in FL. Whether these herald a change in the natural history of 
transformation, which remains a persistent clinical challenge more than eighty years 
since the first description of FL (Brill et al. 1925; Symmers 1927) is unclear. 
However, the demonstration here that a CPC can give rise to distinct disease 
episodes by divergent clonal evolution indicates that the clinical pattern of FL, as a 
progression of multiple relapses and transformation, is not always reflected by 
sequential acquisition of molecular hits. Furthermore, this model augurs well for the 
formal identification of an FL progenitor cell and the subsequent eradication of a 
lymphoma initiating cell pool, enabling better treatment of this disease.  
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Appendix 1 
 
Appendix 1 Figure 1  Determining copy number changes in FL / t-FL 
Shown are schematics of copy number (CN) plots for FL and t-FL. Dashed lines indicate signal intensities over 
a section of one chromosome with red indicating t-FL, blue FL and black germline. Solid lines represent the CN 
plots produced by comparison of sample of interest (top dashed line) to reference sample (bottom dashed line) 
with black indicating t-FL against FL, red t-FL against germline and blue FL against germline. The necessity for 
generating CN plots for FL and t-FL against germline is indicated as for a gain in t-FL against normal FL (A, 
top) and normal t-FL against a loss in FL (B, top) the CN plots produced are the same. However, by instead 
generating CN plots for the same tumour samples against germline and then comparing the two CN plots the 
gain in t-FL (A, bottom) can be distinguished from the loss in FL (B, bottom). 
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Appendix 2 Table 1  Oligonucleotide primers and probes 
 
 Locus#  Oligonucleotide§ 5’ to 3’ sequence 
Chapter 3     
 MDM2 SNP 309  F CGGGAGTTCAGGGTAAAGGT 
   R GCGCAGCGTTCACACTAG 
   Allele probe 1 VIC-CTCCCGCGCCGAAG 
   Allele probe 2 FAM-TCCCGCGCCGCAG 
     
 TP53 Arg72Pro  F GCGCAGCGTTCACACTAG 
   R CCAGATGAAGCTCCCAG 
   Allele probe 1 VIC-TCCCCGCGTGGCC 
   Allele probe 2 FAM-CTCCCCCCGTGGCC 
     
 SNP rs6457327  F TGAAGGCTGGTGACAGATGT 
   R TCTGTCCCTCCTTTCTCTGA 
     
 SNP rs10484561  F GCCATTTGAGTTCTTCTGTGA 
   R AGAAGCCAGGTGAGAACTTG 
     
 C6orf15 exon 1 +  2 (proximal) F GAATGAGGGTGGAATGTGGA 
   R CACTGGAGAGGTAAGAGAGT 
     
  exon 2 (distal) F ATCCTTGGCAGATGATGGCT 
   R TCAGCTTATGCCCAGACTCA 
     
 C6orf15 cDNA exon 1* F GGCCGCGTGGCAGGGAG 
  exon 2* R AGTGGAGGAAGGTTGTCCGAGCTG 
     
  splice site F GTCTTCATCTCCCAGGCC 
  exon 2 R CCAGTGGAGGAAGGTTGTC 
     
  exon 2 F ATCCTTGGCAGATGATGGCT 
  exon 2 R CCAGATTCCCTCAGGGTGT 
     
Chapter 4     
 CREBBP exon 2 F TGGCAGTTGGAGAGCTGTA 
   R CTGGCTGCCTGTTTAGGCA 
     
  exon 14 F ACTCAGCCATCAACTCCTGT 
   R TGCTGGAGACGAGGTCTCA 
     
  exon 31 F TACGACCTCTGCATCAACTG 
   R AGTGCTTGGCGTGGTAGCA 
     
 EZH2 exon F GTGTGCCCAATTACTGCCTT 
   R AGCATGCAAATCCACAAAC 
     
 SSU72 exon 2 F GTGTCTTAGTGTGACTGTGAT 
   R ACCAGGAATAGAAACCAAGCT 
     
 GNB1 exon 3 F TTTACTTTTCTCACCTGCTTCA 
   R AACAAGTCATCCTGTAAACCAT 
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 Locus  Oligonucleotide§ 5’ to 3’ sequence 
Chapter 4     
 GNB1 exon 11 F GGCACACAGGTGAGATCGA 
   R CTAGAAACCGTTAATGACAACT 
     
 CDC2L2 exon 1 F TTTGGAGTCCTGGACCTGA 
   R TTCCGTGCGGGATGAGACT 
     
  exon 2 F TGTGTCCTGATGTAGGCTGA 
   R CTTCACCGAAGAAGCGTTGT 
     
  exon 3 F TTTGGGATGTTGCCCAGGTT 
   R GCACACAGTTGTCACAGTGA 
     
  exon 4 F TTCTCAAGCATGACGCAGT 
   R CACACTTGAACATGATGTCA 
     
  exon 5 F TGAAGTGAGGTTTCTTTGCA 
   R TCTTCTTCATTGCTGTGACA 
     
  exon 6 F GAATTACGTAGAAAGCCAGCT 
   R AAAGCAAGCACCGGAACCAA 
     
  exon 7 F AGGAAGGCAGTGCTGCTAGT 
   R TTCAGCCAGCACATCTCTCA 
     
  exons 8 + 9 F CGTCTGTGGATGAGCTGGTT 
   R TAGTGAAGTCACAACACCTCA 
     
  exon 10 F TTCTTGGGAACACTTGTTGCT 
   R GACCGGCTGTCTTAGGAGA 
     
  exon 11 F AGGAGGAGGTTCATGATCCT 
   R TGGTAACTCCGACTGCCAAT 
     
  exon 12 F AAAGAACTGAGCTGCTCCCA 
   R CCAGTAGCTGCTCAGGTGAA 
     
  exon 13 + 14 F CCGTGACTTTGAGAATGCCT 
   R CACTTGTACGCAGACAGGA 
     
  exons 15 + 16 F GTCCTGTCTGCGTACAAGT 
   R GGAGTATTCCTAAGACGCCA 
     
  exon 17 + 18 F GCACTGGCCTTCCTGAACA 
   R GACTGGGAAGTCACCGCTA 
     
  exons 19 + 20 F TGGAGCACACGAGCACCT 
   R GAGGAGTTCCGAGTCTCAT 
     
 TNFRSF14 exon 1 F AGTGGACTGGAATGGTGCA 
   R TGGACGGAGTGGTGAGTG 
     
  exon  2 F CTGTCCTCTCTACCAGGCA 
   R TTCATCACACCCATGGCTGT 
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Appendix 2 Table 1 (continued) 
 
 Locus  Oligonucleotide§ 5’ to 3’ sequence 
Chapter 4     
  exon  2 F CTGTCCTCTCTACCAGGCA 
   R TTCATCACACCCATGGCTGT 
     
  exon  3 F TAGCTGGTGTCTCCCTGCT 
   R AAGTGAGAGGTGAGACAGAG 
     
  exon 4 F TCCATGCTGGGTACCTCTG 
   R CCAAGGTTCTGTCTCACCA 
     
  exon 5 F GAAGCTCACAGACAAGCAGT 
   R CTTCAAGCCTTTCTGCTGGA 
     
  exon 6 F TCCCTGGGACCTGTCTTCA 
   R GGTGACAGAGCTCCAAGAG 
     
  exon 7 F GGGAGAAGCAGGAGTTGTG 
   R GACTCAGGACCCTCAGAGA 
     
  exon 8 F TAGCTCAGGAAAGAACCCAC 
   R AGGTGGACAGCCTCTTTC 
 
#Primers for SSU72 and GNB1 were used as positive controls to confirm DNA amplification either side of the 
chromosome 1p36 deletion observed in the WSU-NHL cell line. 
§Forward and reverse oligonucleotide primers are all designed on intronic sequences to give full exon coverage 
except for those used to sequence SNP MDM2 SNP 309 (intronic) and TP53 Arg72Pro (designed in exon so as 
near to the SNP as possible); SNP rs6457327, SNP rs10484561 which are not in genes; and for examination of 
C6orf15 expression using cDNA. Oligonucleotide probes are indicated for AD-PCR determination of MDM2 
SNP 309 and TP53 Arg72Pro genotypes. For rs6457327 and rs10484561 commercial prepared AD-PCR 
genotyping assays were used as detailed in 3.3.4. 
*These primers were utilised from the report by Skibola and colleagues (Skibola et al. 2009). 
F indicates forward; and R reverse. 
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Appendix 3 Figure 1  AD-PCR plots for TP53 Arg72Pro and MDM2 SNP 309 
  
Illustrated are AD-PCR result plots with assigned genotypes (GG, GC, CC for TP53 Arg72Pro; TT, TG, GG for 
MDM2 SNP 309) indicated on the right. Those samples marked with a cross required subsequent inspection of 
the real-time PCR curves produced in the AD-PCR reaction for genotype assignment. Each axis corresponds to 
the signal intensity of the respective allele’s oligonucleotide probe with those incorporating the FAM 
fluorescent reporter dye on the y axis and those incorporating the VIC fluorescent reporter dye on the x axis. 
Top, example of plot for one run of TP53 Arg72Pro AD-PCR; bottom, example of plot for one run of MDM2 
SNP 309 AD-PCR. Units for each axis = normalized RFU (relative fluorescence units). 
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Appendix 3 Table 1  Cross-tabulation of all MDM2 / TP53 SNP genotypes 
 
MDM2 SNP 309 
genotype 
TP53 Arg72Pro genotype 
Total 
GG GC CC 
     
TT 45 (20) 46 (20) 8 (4) 99 
TG 50 (22) 40 (18) 8 (4) 98 
GG 10 (4) 19 (8) 0 (0) 29 
Total 105 105 16 226 
     
 
 
Appendix 3 Table 2  Cross-tabulation of restricted MDM2 / TP53 SNP genotypes 
 
MDM2 SNP 309 
genotype* 
TP53 Arg72Pro genotype* 
Total 
GG GC / CC 
    
TT 45 (20) 54 (24) 99 
TG / GG 60 (26) 67 (30) 127 
Total 105 121 226 
    
 
Percentages are included within parentheses. 
*Genotypes are restricted to homozygosity for major allele and presence of minor allele. 
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Appendix 3 Table 3  Median age at diagnosis for MDM2 SNP 309 and TP53 Arg72Pro 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Genotype 
Median age at FL 
diagnosis (range) 
P 
MDM2 SNP 309 
TT 46 (21 - 84)  
TG 47 (22 - 85) 0.91 
GG 47 (33 - 69)  
    
TP53 Arg72Pro 
GG 47 (21 - 84)  
GC 46 (30 - 79) 0.60 
CC 46 (30 - 74)  
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Appendix 4 Figure 1  Linkage between rs6457327 and nearby SNPs and genes 
The plot was generated using the SNP Annotation and Proxy (SNAP) search (Johnson et al. 2008a) version 2.2, 
available at http://www.broadinstitute.org/mpg/snap/ldplot.php. Diamonds represent individual SNPs from the 
HapMap ("The International HapMap Project" 2003) and 1000 genome (Durbin et al. 2010) projects, with the 
largest diamond representing the SNP of interest. R-squared represents the degree of pair-wise linkage between 
SNPs and values > 0.8 represent high LD with limits indicated by the black bar. (Also illustrated is the 
recombination rate represented by the spikes in the plot.) Genes are indicated at the foot of the plot with 
C6orf15 located at the centromeric aspect of the region of high LD indicated by the black oval. The study by 
Skibola and colleagues (Skibola et al. 2009) localized the region of high LD around rs6457327 to a smaller, 26 
kb, region that still contained C6orf15.  
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Appendix 4 Figure 2  Linkage between rs10484561 and nearby SNPs  
The layout and abbreviations are as indicated in Appendix 4 Figure 1. rs10484561 is located 30kb centromeric 
to HLA-DQB1 and 43kb telomeric to HLA-DQA2. Conde and colleagues (Conde et al. 2010) further localized 
the high LD surrounding rs10484561 to a 100 kb region.  
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Appendix 4 Figure 3 AD-PCR plots of rs6457327 and rs10484561 genotyping results 
Illustrated are the plots obtained from interpretation of the fluorescence signals at the end of AD-PCR reactions 
for a cohort of samples typed for top, rs6457327 and bottom, rs10484561. For rs6457327 one sample in 
triplicate is “undetermined” (in addition to the negative control). The position of the three samples suggests CC 
genotype and this was confirmed by examination of the real-time qPCR curves generated during the AD-PCR 
reaction. For rs10484561, one sample in triplicate is undetermined with no signal (similar to the negative 
control). This was due to suboptimal quantity and quality of the dilution made from the stock DNA. When a 
new DNA dilution was reassessed, genotyping by AD-PCR was successful. For both plots the legend to the 
right indicates the genotypes of the respective SNP which correspond to the plot points. Units for each axis = 
normalized RFU (relative fluorescence units). 
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Appendix 4 Table 1 rs6457327 and rs10484561 genotypes and age at FL onset 
 
  
  
SNP genotype n Median age in years (range) Association 
  
  
  
  
  
  
rs6457327 
 
  
AA+AC 74 51 (26 – 87) 
P = 0.73 
CC 65 52 (31 – 78) 
          Total           130   
  
  
rs10484561 
 
  
GG+GT 59 51 (35 – 84) 
P = 0.59 
TT 71 53 (26 – 87) 
          Total          130   
    
 
 
 
 
 
Appendix 4 Table 2 rs6457327 allele distributions in 130 and 88 case sets 
 
 
 
 
 
 
 
The “130” case set was used to determine clinical outcome associations and was drawn from the full cohort (n = 
218). The “88” case set represents the remainder. 
 
Case set 
Number of alleles 
P 
A C Total 
“130” 83 177 260 0.84 
“88” 58 118 176  
   Total    141    295    436  
Appendices 
273 
Appendix 5 
Appendix 5 Table 1  Micro-array quality control 
   
 
Sample Call rate (%) CQC MAPD 
   
 
   
 
1_F 99.01981 1.54 0.2930170 
1_T 99.15756 2.15 0.2643848 
2_G 99.31840 2.09 0.3020828 
2_F 99.04686 2.64 0.2924905 
2_T 99.34577 1.87 0.2876506 
4_F 98.94682 1.43 0.3025794 
4_T 98.24619 2.03 0.2746587 
5_F 99.31224 2.24 0.2273867 
5_T 98.70496 2.22 0.2546665 
6_G 97.92727 1.13 0.3279828 
6_F 98.29391 0.81 0.2904454 
6_T 97.68443 1.13 0.3165253 
7_F 99.49660 2.73 0.2632862 
7_T 99.45483 2.15 0.2596367 
8_G 98.55467 1.07 0.3157633 
8_F 97.35989 0.58 0.3652553 
8_T 96.58660 0.77 0.3472361 
9_G 98.49553 2.22 0.3240928 
9_F 99.18449 1.76 0.2928613 
9_T1 99.05664 1.34 0.2831904 
9_T2 97.93233 1.05 0.2918422 
10_F 99.41042 2.59 0.2510170 
10_T 97.62737 1.51 0.2674138 
10_Fp 98.68066 2.24 0.2479891 
11_F1 99.49221 2.62 0.3017525 
11_F2 99.27992 2.00 0.2810147 
11_T 99.07423 2.68 0.2768654 
12_F 98.46838 1.76 0.2939214 
12_T 98.26125 2.18 0.2981420 
13_G 98.46661 1.73 0.3036524 
13_F 98.37053 2.41 0.2512861 
13_T 99.18559 2.29 0.2520840 
15_G 99.17614 1.33 0.3125776 
15_F 99.33269 1.62 0.2483445 
15_T 97.07845 1.30 0.3108491 
16_G 99.45263 3.18 0.3115786 
16_F 97.92518 2.32 0.3272201 
16_T 97.62990 2.03 0.3756202 
17_G 98.11108 1.40 0.2789112 
17_F 97.94717 1.54 0.3352565 
17_T 96.66763 1.05 0.2838591 
18_F 99.13789 1.19 0.2932741 
18_T 99.31543 1.94 0.2720354 
19_G 99.45944 1.95 0.2774876 
19_F 96.83561 1.28 0.3585160 
19_T 98.78543 0.85 0.3040063 
 
 
 
 
 
  
   
 
Sample Call rate (%) CQC MAPD 
   
 
   
 
20_G 99.56377 1.86 0.2901816 
20_F 98.72914 2.16 0.2813541 
20_T 98.49289 2.07 0.3115596 
21_F 99.20252 2.16 0.3030906 
21_T 98.34921 1.65 0.2881464 
21_Fp 98.71936 1.58 0.2836809 
22_F 97.16190 1.34 0.3092867 
22_T 96.96171 0.94 0.3415176 
23_G 99.61105 2.52 0.2806892 
23_F1 99.04884 2.00 0.3153980 
23_F2 99.33852 2.25 0.3068451 
23_T 99.53278 2.61 0.2691558 
24_G 99.58653 2.22 0.2653824 
24_F 99.20451 2.18 0.3202963 
24_T 98.12999 1.37 0.2984878 
25_F 99.39700 2.09 0.2731955 
25_T 99.20341 1.53 0.2669889 
26_G 99.00794 1.84 0.2918555 
26_F 99.31367 1.96 0.3031302 
26_T 99.25903 1.53 0.2854231 
27_F 99.05950 2.23 0.2697315 
27_T 98.54588 1.76 0.2700410 
28_G 99.06422 2.02 0.3252032 
28_F 99.45923 2.67 0.2555414 
28_T 99.42954 2.22 0.2393161 
30_G 99.42316 2.25 0.2761419 
30_F 98.88152 2.16 0.2905606 
30_T 98.38889 2.23 0.2740566 
31_G 96.71732 1.05 0.4027874 
31_F 98.94242 2.30 0.2967747 
31_T 98.86656 1.73 0.2877406 
32_G 99.56180 2.37 0.2856510 
32_F1 99.30344 1.94 0.3169082 
32_F2 99.26112 2.21 0.2723175 
32_F3 98.98606 1.71 0.2963441 
32_F4 98.98299 1.96 0.2965111 
32_T 99.14492 1.64 0.2838159 
33_G 98.89185 1.16 0.2876970 
33_F1 98.89097 1.48 0.2745235 
33_F2 97.91837 1.63 0.3411722 
33_T 97.42432 1.28 0.3606412 
34_G 98.87656 0.97 0.3289226 
34_F 99.54047 2.19 0.2629440 
34_T 99.59258 2.21 0.2690359 
Sample is the unique sample identifier consisting of the patient study number followed by either G (germline 
sample); F (FL sample); F1 / F2 / F3 / F4 (representing the first, second, third or fourth sample respectively in cases 
with more than one pre-transformation FL sample); T (t-FL sample); T2 (second t-FL sample); or Fp (FL sample 
from relapse after t-FL). CQC indicates contrast quality control; and MAPD median absolute pairwise difference. 
Sample (31_G) had a MAPD score just over the recommended screening threshold of 0.4 but was included as call 
rate, CQC and subsequent CN plots for case 31 were satisfactory. The calculation of Call rate, CQC and MAPD are 
as described in the main text.  
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Appendix 5 Figure 1 Survival from FL or t-FL and EI24 / CHEK1 loss 
Kaplan-Meier curves comparing cases with EI24 / CHEK1 locus loss on chromosome 11q (red line) against 
cases without loss (black line). Left, although not present in initial FL samples, loss EI24 / CHEK1 associates 
with worse OS from FL diagnosis (although only 4 cases affected and a small patient cohort; n = 31). Right, no 
cases with loss EI24 / CHEK1 at transformation survive more than 2.5 years from this event (which, although P 
= ns, may be a factor contributing to the difference in OS). 
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Appendix 5 Table 2  Determining the evolutionary route of FL / t-FL  
Case Evolution Chromosome 
  
                          1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y
1 CPC     
   
      
  
        
      
      
 2 Direct 
      
      
    
    
  
  
   
  
  4 CPC       
 
  
  
 
   
  
 
   
      5 Either     
  
  
 
   
 
 
 
 
 
 
          6 CPC      
 
        
 
       
 
  
    
  
7 CPC 
   
 
 
  
 
    
  
  
   
 
 
   
 
  
 
  
8 CPC    
 
    
 
        
  
   
    
 
 9 CPC   
 
   
 
               
   
      
 
   
 10 CPC                 
 
      
 
      
 
  
 
    
 11 CPC         
   
    
  
       
      
    
 12 CPC 
   
  
       
  
     
 
  
   
  13 Direct   
  
      
    
 
  
     
   
 
 15 CPC 
 
    
 
  
  
  
 
 
 
  
 
    
   
    
16 CPC      
  
  
       
  
   
  
  
 
   17 Direct       
 
    
  
 
 
 
   
      
 
  
 18 CPC 
 
  
  
  
   
 
  
   
  
    
  
   
 
   
19 Either    
  
  
 
 
      
 
   
 
   
 
 
  
20 Direct   
 
 
 
   
    
   
 
   
       21 CPC         
 
  
 
        
  
        
 
          
 22 CPC     
  
      
  
      
  
   
   
     
23 CPC 
    
    
   
   
 
  
      
 
  
  
 24 Direct 
   
       
 
    
  
 
  
  
 
  
  
  
 25 CPC 
 
 
     
   
        
  
    
  
 26 CPC    
      
  
  
 
 
 
   
  
   
   
 27 CPC     
  
   
 
   
     
 
 
  
   
  
  28 CPC 
 
   
 
  
   
  
  
 
   
     
    
 
 30 Direct 
 
    
 
  
 
 
         
    
  
 
   31 CPC 
 
            
   
   
 
    
   
  
 32 CPC 
 
  
 
  
  
    
   
     
       
    
 33 CPC 
                        34 Direct 
                         
 
For the 31 study cases, the evolution mode is given based on summaries of the CN changes given for all chromosomes. Coloured boxes indicate CNAs are present on that 
chromosome in at least one sample from the respective case. Yellow indicates only the same chromosome CNAs are present across all available samples for the respective 
case; red indicates that (with or without common changes) sequentially acquired CNAs are present in later FL/ t-FL samples for the respective chromosome and case; and 
blue indicates that there is at least one non-sequential CNA for the respective chromosome and case. Consequently, presence of blue supports a CPC origin to disease 
evolution. 
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Appendix 5 Figure 2 Recurring CNAs in CPC cases 
The plot layout is as described for Figure 4.4. 
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Appendix 6 Table 1  IGH-V subgroup family primers 
 Forward primer  Reverse primer  
 Name Sequence (5’ to 3’)  Name Sequence (5’ to 3’)  
 VH1 GGCCTCAGTGAAGGTCTCCTGCAAG  
JH 
consensus 
CTTACCTGAGGAGACGGTGACC 
 
 VH2 GTCTGGTCCTACGCTGGTGAAACCC   
 VH3 CTGGGGGGTCCCTGAGACTCTCCTG   
 VH4 CTTCGGAGACCCTGTCCCTCACCTG   
 VH5 CGGGGAGTCTCTGAAGATCTCCTGT   
 VH6 TCGCAGACCCTCTCACTCACCTGTG   
 
The BIOMED consortium designed primers on the three FR regions in VH segments. For FR1 there 
are six VH families which can be distinguished whereas for FR2 and FR3 there are seven. The six 
FR1 primers are used here as FR1 is situated farthest from the reverse primer in a consensus region of 
the J region common to all segments and this provides the largest PCR products so maximises the 
sensitivity for detecting SHM sites in the FL / t-FL samples. 
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Appendix 6 Figure 1  Direct evolution of t-FL from FL 
Shown are summaries of the SHM analysis for case 2. Symbols are as detailed in Figure 5.3. Left, 
genealogical tree constructed from cloning results shows that t-FL development is mirrored by 
sequential acquisition of SHM sites from FL to t-FL. Top right, HH major clones indicate that both 
FL2 and t-FL arise by direct evolution from FL. In combination with the time line of the three disease 
episodes, bottom right, this indicates that the FL clone persists after t-FL and gives rise to the FL2 
clone (left hand vertical bar represents FL diagnosis and right hand vertical bar represents patient 
death). 
 
 
 
 
 
Carlotti et al. 2009 
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Appendix 6 Figure 2  Direct and indirect evolution may both occur in FL / t-FL 
Summary of IGH-V sequences and SHM sites determined for the major disease clone of case 26 by 
HH analysis. Symbols are as detailed in Figure 5.3 and Appendix 6 Figure 1. Top, divergent 
(indirect) evolution from a CPC gives rise to FL and FL relapse (FL2) whereas transformation arises 
by direct evolution from FL2. Bottom, time-line of the three disease episodes indicates the CPC is 
present for at least 18 months before FL2 presents. 
 
 
 
 
 
Carlotti et al. 2009 
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Appendix 6 Figure 3  Models of direct and indirect evolution  
A summary of the two routes of FL / t-FL evolution identified by SHM analysis. LIC indicates 
lymphoma initiating cell (such as an early t(14;18) containing cell).  
For direct evolution, the sequential acquisition of different SHMs over time is represented by a, b and 
c accompanied by parallel evolution from the potential precursor to FL and on to t-FL.  
In the case of indirect evolution, the non-sequential pattern of acquired genetic events is illustrated by 
a, b, c and d. A common event, a, is followed by b in FL. However, subsequent t-FL does not arise 
from FL but from an earlier clone which acquires c and d (but not b) in progression to transformation. 
For this model, the LIC represents a common progenitor cell (CPC) which gives rise to FL and t-FL 
by divergent evolution. 
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Appendix 6 Table 2  Novel glycosylation sites in CPC / FL / t-FL 
Case Clone
#
 
 Glycosylation sites  
 Number
§
 Region(s) αα number αα motif*  
1 FL  3 CDR2 / FR3 / CDR3 58 / 67 / 109 NHS / NYS / NNS  
 
t-FL       
 
CPC       
2 FL  1 CDR1 30 NFS  
 
t-FL       
 
FL2       
4 FL  1 CDR2 56 NIS  
 
t-FL       
 
CPC       
5 FL  1 CDR3 108 NLS  
 
t-FL       
 
FL2       
6 FL  1 CDR3 108 NLS  
 
t-FL       
 
CPC       
7 FL  2 FR2 / FR3 39 / 69 NWT / NSS  
 
t-FL  3 FR1 / FR2 / FR3 25 / 39 / 69 NVS / NWT / NSS  
 
CPC  1 FR3 69 NSS  
8 FL  0 - - -  
 
t-FL       
 
CPC       
9 FL  0 - - -  
 
t-FL       
12 FL  1 CDR2 59 NKT  
 
t-FL       
 
CPC       
15 FL  0 - - -  
 
t-FL       
 
CPC       
16 FL  4 CDR1 / CDR2 / CDR2 / CDR3 30 / 56 / 62 / 116 NIT / NIS / NKT / NCT  
 
t-FL       
 
CPC       
20 FL  1 FR2 55 NIS  
 
t-FL       
21 FL  1 FR2 39 NMT  
 
t-FL       
 
FL2       
23 FL  1 CDR2 56 NIT  
 
t-FL       
 
CPC       
25^ FL  1 CDR3 108 NFS  
 
t-FL       
 
CPC       
26 FL  4 CDR1 / FR2 / CDR2 / FR3 30 / 39 / 56 / 85 NFS / NMS / NIS / NNS  
 
t-FL       
 
FL2       
 
CPC       
27 FL  3 FR3 / CDR3 / CDR3 83 / 108 / 112 NST / NQT / NKS  
 
t-FL       
 
CPC       
Father FL  1 CDR2 58 NQS  
Son t-FL  0 - - -  
 
CPC  0 - - -  
 
Glycosylation sites introduced by SHMs are indicated for samples from 17 / 18 sequential cases and 
the father / son pair. Case 11 is excluded as its DH-JH region is deleted. Protein region of the 
glycosylation site and amino acid (αα) position (number) of the predicted change are indicated.  The 
sites consist of a three αα motif (N-x-S/T, where x is any αα except proline / aspartic acid / glutamic 
acid (Co et al. 1993; Coloma et al. 1999)) and are detailed. Sites were identified in 11 / 12 CPC 
sequences for the sequential cases. The remaining case (15) showed no sites in any samples. In the 
father / son pair a single site occurred only in the father’s tumour. Case 7 was the sole case to show 
differing acquisition of additional glycosylation sites in FL and t-FL samples.  
#The major clones identified by HH analysis. 
§If one number that applies to all samples for the case. 
*C indicates cysteine; F, phenylalanine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, 
methionine; N, asparagine; Q, glutamine; S, serine; T, threonine; V, valine; and Y, tyrosine. 
